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10 | Chapter 1. General Introduction
1.1 The Golgi Apparatus
The human body is one of the most complicated systems in nature. On the larger scale, each
organ has its separate function but it also works in concert with the other organs. Descending
a level, organs and tissues are built up from cells. To function normally, cells need to commu-
nicate with each other, through physical contact with one another but also via the secretion
of soluble molecules such as cytokines, growth factors and hormones. Cells can be considered
bona fide specialized ‘factories’ within the human body, with distinct tasks: for instance, neu-
rons produce and secrete neurotransmitters for optimal brain function, while immune cells
produce and secrete cytokines and antibodies to protect the body from threats from outside.
Aswithman-built factories, the cellular ‘factory’ needs ‘machines’ to process the rawmateri-
als and prepare the products for secretion. In cells, the main responsible ‘machine’ (organelle),
is the Golgi apparatus, also known as the Golgi. Central to secretion, the Golgi is part of the en-
domembrane system in the cytoplasmand canbe observed by light and electronmicroscopy as
a compact, but large, network-like structure. In 1898, the Italian physician Camillo Golgi discov-
ered the Golgi while investigating the nervous system, initially calling the structure apparato
reticolare interno (internal reticular apparatus) 1,2. At first, Golgi’s observationwas believed to be
an artifact caused by the staining he used, but with the invention of the electron microscope
in the twentieth century, the existence of the Golgi was confirmed 3. For their work on the struc-
ture of the nervous system, Camillo Golgi and Santiago Ramón y Cajal were jointly awarded the
Nobel Prize in Physiology or Medicine in 1906 4.
The Golgi acts as a distribution center, relaying newly synthesized proteins to their correct
destination both within and outside the cell. Proteins synthesized in the endoplasmic reticu-
lum (ER) often requirepost-translationalmodifications suchas theadditionof sugarmolecules
(glycosylation) or sulfation; these processes require the Golgi 5. Glycosylation is of particular sig-
nificance as most secreted proteins are glycosylated, which is of utmost importance for their
structure, stability, function, transit, and selective targeting 6–13.
The mammalian Golgi exists as a single large perinuclear organelle, organized in separate
compartments also known as cisternae 14–16. These compartments are named based on their
layout relative to the cell nucleus: the compartment closest to the nucleus is named cis-Golgi
while the compartments furthest from the nucleus are the trans-Golgi and trans-Golgi network
(TGN). The medial-Golgi resides in-between the cis- and trans-Golgi. Each Golgi compartment
has its distinct environment composed of not only enzymes necessary for glycosylation 17–20
but also various trafficking proteins 13,21 and ions 13,22,23.
1.2 The Secretory Pathway
In a broader, intracellular context, the Golgi forms the heart of the secretory pathway. The
secretory pathway, together with the endocytic pathway, constitutes the endomembrane sys-
tem 24,25(Figure 1.1a). The secretory pathway comprises all organelles responsible for the synthe-
sis and secretion of proteins destined for the extracellular space: the ER, Golgi apparatus, and
1
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secretory vesicles. In principle, the secretory pathway enables cells to work together and not
just on their own, as the secretion of signaling molecules and production of surface exposed
receptors enables the communication between cells. Thus, the secretory pathway is responsible
for the correct production anddelivery ofmolecules outside the cell, such as cytokines, extracel-
lular matrix proteins, and hormones.
Inhumancells, newproteins are translated fromDNA-derivedmRNAandco-translationally
inserted into the rough ER. Within the lumen of the ER, proteins are folded and an initial qual-
ity control step is performed. This ensures that only properly folded proteins can exit the ER
and continue their journey through the secretory pathway 26. Newly synthesized proteins are
then packaged and transported in vesicles to the Golgi where they can be furthermodified and
sorted to their correct destination (Figure 1.1b). Onedriver in this sortingprocess is thedecrease
of pH (acidification) of the Golgi lumen from cis (pH 6.7) to trans (pH 6.0). pH differences are
important for the acceptance and release of cargo from cargo adapters due to conformational
changes andpH-dependent binding affinity 27–30. Therefore, pH is of critical importance for the
correct maintenance of Golgi cisterna identity 13,31–33 , as well as for the optimal function of gly-
cosylation enzymes 34.
After the newly synthesized proteins have sufficiently been modified, they are ready to be
sorted at the TGN and exit the Golgi 35. This final sorting step sends the newly synthesized pro-
teins to their final location, including endosomes, lysosomes, the plasma membrane, and the
extracellular space.
1


















Figure 1.1: (a) Schematic overview of themammalian secretory pathway. (b)Closer view of themammalian
Golgi apparatus. ER-derived vesicles arrive at the cis-face of the Golgi, while secretory vesicles depart from
the trans-face. Cargo is exchanged between cisternae via intra-Golgi transport vesicles.
1
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1.3 Glycosylation
One of the most important functions of the Golgi apparatus is to ensure the correct glycosy-
lation of newly synthesized proteins. In vertebrates, glycosylation is a sequential process in-
volving both the addition and trimming of glycan structures by glycosyltransferases and gly-
cosidases 36. In contrast to other essential protein synthesis processes such as translation and
transcription, glycosylation is not template-based (cf., DNA serves as a template for transcrip-
tion and mRNA as a template for translation) 37. Around 700 proteins are responsible for the
full spectrum of around 7,000 unique glycan structures. Only ten different monosaccharides,
fucose (Fuc), galactose (Gal), glucose (Glc),N-acetylgalactosamine (GalNAc),N-acetylglucosamine
(GlcNAc), glucuronic acid (GlcA), mannose (Man), sialic acid (SA, also known as neuraminic acid),
xylose (Xyl), and recently identified ribitol, are thenecessary buildingblocks for glycansofmam-
malian cells 38–43. Based on which amino acid residue of the protein the glycan is attached,
O- and N-linked glycosylation can be distinguished. O-linked glycosylation occurs on the side
chain hydroxyl oxygen of either serine or threonine residues, while N-linked glycosylation oc-
curs on asparagine residues. As the work in this thesis is mainly focused on N-linked glycosyla-
tion, below I will shortly summarize the basic mechanism of N-linked glycosylation.
N-linked glycosylation begins in the ER where a precursor glycan consisting of 14monosac-
charides is transferred from the carrier lipid dolichol to the newly synthesized protein. Concur-
rentwith translation, theprecursor glycan is removed fromdolichol andplacedonN-linkedgly-
cosylation acceptor peptide sequons (Asn – X – (Ser/Thr)) of nascent polypeptides by oligosac-
charyltransferase (OST) 44–50. Before Golgi entry of the newly synthesized glycoproteins, distal
glucose moieties are trimmed as an important step in the control of misfolded glycoproteins
in the ER 10,51,52. Once quality control is complete, the newly synthesized glycoproteins are trans-
ported to the Golgi, where the glycan structures are further trimmed, extended, and branched
until the final form of the glycan is reached (Figure 1.2, adapted from Figure 9.4 of Essentials of
Glycobiology 53).
The non-template-driven characteristics of glycosylation imply that stringent regulation
of all glycosylation machinery is required to maintain physiological glycosylation. As such,
small abnormalities can have a large effect on the final glycan product 54 and currently already
over 100monogenic diseases have been found that are characterized by incorrect glycosylation.
Collectively, these diseases are known as congenital disorders of glycosylation (CDG) 13,31,55,56.
Therefore, the proper localization of all glycosylation machinery and other required factors is
paramount.
1














































Figure 1.2: The processing andmaturation of a biantennary, fucosylated N-glycan. The immature glycan
structure is transferred from dolichol phosphate to the nascent polypeptide in the ER. Following quality con-
trol, the folded glycoprotein is then exported to the Golgi where the final glycan structure is produced.
1
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1.4 Membrane Fusion
Crucial to all transport steps in mammalian cells is the delivery of (cargo) proteins from one
organelle, or organellar sub-compartment, to the next. Considering the compartmentalization
of the secretory pathway, the prevailing theory of protein transport in mammalian cells is via
membrane vesicles. Once a vesicle has been released and is destined for an organelle, such as
the Golgi apparatus, the vesicle must fuse its membrane with the membrane of the accepting
compartment to transfer thecargo to the intraorganellar lumen. This step ismediatedbySNARE
proteins.
SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein (SNAP) receptors)
mediate all fusion events in eukaryotic cells, except for mitochondrial fusion 57,58. The human
SNARE family consists of 36 members, which all carry one or two SNARE motifs, domains of
approximately 60-70 amino acid residues arranged in heptad repeats 59. Most SNAREs are an-
chored to themembrane andmost SNAREs contain a transmembranedomain, while others can
be anchored through lipidmodifications such as palmitoylation or prenylation.
Mammalian SNAREs can be roughly classified into two groups based on their membrane
location: the vesicular SNAREs (v-SNARE) present on cargo vesicles and target SNAREs (t-SNARE)
on the acceptor membrane. In some cases, this classification can be inconsistent, for instance
when SNAREs are involved in bidirectional (anterograde and retrograde) transport ofmolecules
or homotypic vesicle fusionwithout defineddonor or acceptor compartments. SNAREs can also
be classifiedby the central functional residue in theSNAREmotif: R-SNAREs containanarginine
residue while Q-SNAREs (these can be subdivided in Qa, Qb, Qc or, Qbc depending on their loca-
tion in the SNAREbundle) containaglutamine residue55. For successfulmembrane fusion, four
SNAREmotifs, one R-SNARE and 3 Q-SNAREs, interact together to form a tight coiled-coil bundle
that brings the vesicular and acceptor membranes together (Figure 1.3). This mechanism over-
comes the energy barrier of membrane fusion.
Considering the Golgi as the central hub of themammalian cell, it is an important location
where many membrane fusion events occur. Vesicles containing newly synthesized proteins
from the ER, vesicles going to and from the plasma membrane, and vesicles involved in intra-
Golgi trafficking all need to fuse with Golgi membranes. Two main models of Golgi apparatus
transport exist. The firstmodel is the vesicular traffickingmodel, where each cisterna is a static
sub-compartment and cargomolecules are transportedby vesicles between the cisternae 14. The
second, more widely-accepted model is cisternal maturation in which vesicles with newly syn-
thesized proteins from the ER fuse with each other to form the cis-Golgi. Each cisterna is highly
dynamic and graduallymatures into trans-Golgi through accepting lipids and glycosylation en-
zymes from later Golgi cisternae 14. At the ER – Golgi trafficking interface in the cisternal mat-
urationmodel, four distinct trafficking steps can be identified: anterograde transport from ER
to the ER – Golgi intermediate compartment (ERGIC), from ERGIC to cis-Golgi, intra-Golgi trans-
portbetweencisternaeandretrograde trafficking from cis-Golgi to theER. In these fourdifferent
trafficking steps, syntaxin-5 (Stx5) is themost importantQa-SNARE, participating in three out of
the four different SNARE complexes 21 (Figure 1.4). The formation of different SNARE complexes
with unique cognate SNAREs is beneficial to the specificity of membrane trafficking, ensuring
1
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Figure 1.3: SNARE-mediatedmembrane fusion at the ER - Golgi interface. The t-SNARE complex on the ac-
ceptor membrane (red: Qa-SNARE, green: Qb/R-SNARE) and the v-SNARE (blue: Qc-SNARE) on the vesicular
membrane come into close proximity and form a trans-SNARE complex. As this complex tightens, the two
membranes are forced closer to each other and the lipid bilayers fuse.
that the right cargo is transported to the right destination.
Taken together, the secretory pathway is the veritable heart of the eukaryotic cell, by ensur-
ing that newly synthesized proteins are delivered in the correct composition and at the correct
location. Each transport step is finely tuned for optimal performance and maximum fidelity
of the respective cargo. Unfortunately, only small abnormalities in this trafficking system can
cause large problems on both the cellular and organism level, but the molecular mechanisms
areoftenpoorlyunderstood. In this thesis, I addressed themolecularmechanismsbehindCDGs
of components involved in protein transport from ER to Golgi.
1























Figure 1.4: Schematic overview of SNARE complexes at the ER-Golgi interface inmammalian cells. Adapted
fromChapter 5, Figure 5.1.
1
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1.5 Scope of this Thesis
The principal aim of this thesis is to obtain a better understanding of the involvement of in-
tracellular trafficking proteins in ER-Golgi transport and glycosylation. To achieve this, I per-
formed cell biological and biochemical experiments to uncover the molecular mechanism of
patients with novel CDGs.
Chapter 2 provides an overview of all CDGs that are related to intracellular trafficking pro-
teins. Recentdevelopments indiagnosticmethods forCDGhaveenabled thediscoveryofnewge-
netic variants in trafficking proteins that result in glycosylationdisorders. I discuss these devel-
opments and how they help understand ER-Golgi trafficking better. In chapter 3, I demonstrate
anewly developed technique based onfluorescence lifetime imagingmicroscopy (FLIM) tomea-
sure intraorganellarpHwithhighaccuracy. I apply the techniqueonboth static organellemark-
ers and dynamic cargo proteins. This improved imaging technique is subsequently applied in
chapter4 to determine the role of V-ATPase assembly factor TMEM199 in ER-Golgi transport and
luminal acidification.
An integral component of ER-Golgi transport, syntaxin-5, is the focus of the second part of
this thesis. Chapter 5 provides a comprehensive examination of all published literature on
syntaxin-5 and disseminates the differences and similarities of syntaxin-5 and ER-Golgi traf-
ficking in both mammals and yeast. This forms the preface to chapter 6, where I present the
discovery of a new genetic variant in syntaxin-5 resulting in a CDG with a severe phenotype. I
demonstrate themolecularmechanism behind this CDG and thereby improve our understand-
ing of the role of syntaxin-5 inmammalian intracellular trafficking and glycosylation.
1
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2.1 Abstract
Glycosylation is an important post-translational modification for both intracellular and se-
creted proteins. For glycosylation to occur, cargo must be transported after synthesis through
thedifferent compartmentsof theGolgi apparatuswheredistinctmonosaccharides are sequen-
tially bound and trimmed, resulting in increasingly complex branched glycan structures. Of
utmost importance for this process is the intraorganellar environment of the Golgi. Each Golgi
compartment has a distinct pH, which is maintained by the vacuolar H+-ATPase (V-ATPase).
Moreover, tethering factors such as Golgins and the conserved oligomeric Golgi (COG) complex,
in concertwith coatomer (COPI) and solubleN-ethylmaleimide-sensitive factor attachment pro-
tein receptor (SNARE)-mediated membrane fusion, efficiently deliver glycosylation enzymes to
the right Golgi compartment. Together, these factors maintain intra-Golgi trafficking of pro-
teins involved in glycosylation and thereby enable proper glycosylation. However, pathogenic
mutations in these factors can cause defective glycosylation and lead to diseases with a wide
variety of symptoms such as liver dysfunction and skin and bone disorders. Collectively, this
group of disorders is known as congenital disorders of glycosylation (CDG). Recent technologi-
cal advanceshave enabled the robust identificationofnovel CDGs related tomembrane traffick-
ing components. In this review, we highlight differences and similarities between membrane
trafficking-related CDGs.
2
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2.2 Introduction
The conjugation of oligosaccharide structures to proteins, glycosylation, is a ubiquitous and
fundamental post-translationalmodification found in all domains of life. Glycosylation is not
only important for the structure and functionofproteins, but also for their transit and selective
targeting through the secretory pathway 6–12. Inmammals, approximately 700 proteins are nec-
essary for generating the full diversity of over 7000 glycan structures 38–42. The addition of gly-
can structures in vertebrates is a sequential process and involves both the addition ofmonosac-
charides via glycosyltransferases and the trimming of glycans by glycosidases 36. Only ten dif-
ferent monosaccharides are required to build the full glycan spectrum: fucose (Fuc), galactose
(Gal), glucose (Glc), N-acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc), glucuronic
acid (GlcA), mannose (Man), sialic acid (SA, also known as neuraminic acid), xylose (Xyl), and re-
cently identified ribitol 38,40,41,43.
In vertebrates, N-glycan synthesis is initiated in theERas a 14monosaccharideprecursor on
the carrier lipid dolichol. During translation, this glycan is transferred by oligosaccharyltrans-
ferase (OST) 44–46from dolichol to the nascent polypeptide at acceptor peptide sequons, gener-
ally consisting of an Asn-X-(Ser/Thr)motif 47–50. Distal glucosemoieties of these immature, high
glucose and mannose containing, glycan structures are subsequently trimmed before Golgi
entry; an important step in the control of misfolded glycoproteins in the ER 10,51,52. Glycopro-
teins then exit the ER via, for instance, cargo receptor ERGIC-53 60–62 and are transported to the
Golgi apparatus for further processing. In the Golgi, glycoproteins are trimmed, extended, and
branched until they reach their final glycan form. The mammalian Golgi apparatus is a sin-
gle large perinuclear organelle, organized into discrete compartments or cisternae 14–16. The
Golgi can be subdivided into cis-Golgi, closest to the ER, medial-Golgi, trans-Golgi, and the trans-
Golgi network (TGN), furthest away from the nucleus. Furthermore, mammals have a pre-Golgi
compartment known as the ER-Golgi intermediate compartment (ERGIC, previously known as
the vesicular-tubular cluster (VTC)) 63,64. Newly synthesized glycoproteins emanating from the
ER enter the Golgi apparatus at the cis-Golgi, sequentially pass throughmedial- and trans-Golgi,
and finally, exit the Golgi at the TGN. The compartmentalization of the Golgi allows for distinct
environments containing subsets of glycosylation enzymes 17–20 , enabling sequentialmodifica-
tions for the formation of completelymature glycoproteins. The organization of Golgi-resident
enzymes and the Golgi apparatus itself differs between cell types, contributing to glycoprotein
diversity 15,65–68. Two examples are the distribution ofα-mannosidases I and II, which primarily
localize to the trans-Golgi in intestinal goblet cells, but are distributed over all Golgi cisternae
in hepatocytes, the functional consequences of which are currently unknown 68.
Efficient glycosylation fully relies on the correct localization of glycosylation enzymes, as
well as on the delivery of other glycosylationmachinery, such as nucleotide sugar transporters,
and cargo proteins to be glycosylated to the correct Golgi compartment. An important factor
involved in the correct trafficking of glycosylation enzymes is the maintenance of pH within
the Golgi apparatus. In eukaryotic cells, the principal proton pump for the regulation of in-
traorganellar pH is the vacuolar H+-ATPase (V-ATPase). The membrane V0 domain anchors this
complex in the membrane, and the V1 domain is cytosolic
69. The V0 domain contains six dif-
2
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ferent subunits (a, d, e, c, c’, and c’’). This domain functions as a proton translocator across the
membrane, which not only results in a pH gradient, but also in a change in membrane poten-
tial, which is neutralized by counter ions such as K+ and Cl-. The cytosolic V1 domain contains
eight subunits (A-H), and its main function is ATP hydrolysis 69 to provide the energy needed
for the pH gradient. In mammals, the specificity of V-ATPase localization is encoded in the V0a
subunit, as four unique isoforms exist (V0a1-4). This is in contrast to Saccharomyces cerevisiae,
which has only two unique isoforms (Vph1p and Stv1p) 69–73. The diversity in V0a subunits is
likely important for specific cell type-dependent functions and differential regulation of the
pH in different organelles. Isoform V0a1 is targeted to secretory vesicles and V0a2 to the Golgi
and endosomes, and V0a3, highly expressed inmacrophages and osteoclasts
74,75 , is enriched in
late endosomes and lysosomes, while V0a4 is mainly expressed in the kidney, inner ear, and oc-
ular ciliary body 76–79. The V-ATPase ensures a constant pH in the various Golgi compartments,
which ranges from 6.7 for the cis-Golgi to 6.0 for the trans-Golgi 22. Given the pH optima of glyco-
sylation enzymes, this pH gradient could restrict the activity of glycosylation enzymes to their
target Golgi compartment 34. However, thismight not be the complete explanation considering
the broad distribution of pH optima and the small differences in absolute pH between the cis-
ternae. Instead, or additionally, the pH-sensitive binding and release to cargo adapters might
ensure correct enzyme localization to the target Golgi compartment 31–33.
Several models for the trafficking routes in the Golgi exist, but the most favorable model
of membrane traffic within the Golgi is the cisternal maturation model (Figure 2.1) 80. Cister-
nal maturation is the gradual conversion of a Golgi compartment by the delivery of proteins
and lipids frommoremature Golgi compartments concomitant with the removal of Golgi pro-
teins and lipids from previous Golgi compartments by coatomer (coat protein complex I; COPI)-
mediated retrogrademembrane trafficking 14,80. Beforemembrane fusion of these COPI vesicles,
a set ofmolecular instruments orchestrates correct vesicle targeting to andwithin the Golgi. An
important group of such trafficking factors is the Golgin family, which consist of large coiled-
coil proteins that associate with the Golgi membrane. Golgins form a tentacular web in the
cytosol that efficiently and selectively tethers cargo vesicles 81? ,82. Concurrently, Golgins can act
as scaffolding proteins for small Rab or Arf GTPases 83? –85. At the Golgi, Rab6 and Rab30 can
recruit effectors, such as the cytoskeletal motor protein myosin II, for vesicle trafficking 86–90.
Completing the ensemble is the conserved oligomeric Golgi (COG) tethering complex, a hetero-
octameric protein complex bridging the Golgi membrane and COPI vesicles 91,92. Finally, when
the Golgi membrane and the uncoated COPI vesicle are in close enough proximity, membrane
fusion occurs. Membrane fusion is performed by soluble N-ethylmaleimide-sensitive factor at-
tachment protein receptor (SNARE) proteins.
As glycosylation is such an extensive process with a multitude of different factors that op-
erate together for sequential remodeling of glycanmoieties, only slight disturbances can have
major implicationsonglycosylation. As such, over 100monogenicdiseaseshavebeen identified
characterizedbydysfunctional glycosylation, which formagroup collectively knownas congen-
ital disorders of glycosylation (CDG) 31,55,56. A large subset of these includes genetic variants in
the priormentioned trafficking proteins, but also in subunits of the vacuolarH+-ATPase and its
assembly factors. Recent technological advances in CDG diagnostics have enabled more com-
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Figure 2.1: Schematic overview of the early secretory pathway inmammalian cells. Abbreviations: ER, endo-
plasmic reticulum; ERGIC, endoplasmic reticulum-Golgi intermediate compartment; COG complex, conserved
oligomeric Golgi complex; COPI, coat protein complex I.
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prehensive analysis of glycosylation disorders. Novel mass spectrometric methods to detect
changes in glycosylation 93? together with next-generation sequencing to detect novel genomic
mutations 94,95 are a powerful combination for the interrogation ofmembrane trafficking com-
ponents in CDGs. This review serves to provide a comprehensive overview of trafficking-related
CDGs and to form a detailed understanding of how Golgi trafficking influences glycosylation.
2.3 Membrane Trafficking Components in CDG
Efficient membrane trafficking is of utmost importance for the entire secretory pathway. In
this review, we focus on disorders directly affecting Golgi function. Therefore, other disorders
affecting for instance ER to ERGIC transport will not be discussed.
2.3.1 Vacuolar H+-ATPase
For efficient delivery of glycosylation enzymes to Golgi cisternae to occur, the intraorganellar
pHmust allow the association of the glycosylation enzyme with a trafficking cargo receptor at
the donor compartment and release from the receptor at the receiving compartment. Given the
role of pH in intracellular trafficking and how stringent cisternal pH is regulated in the Golgi
apparatus (Figure 2.2) 22 , alterations in pH maintenance might be expected to lead to mislocal-
ization of glycosylation enzymes, which in turn cause glycosylation disorders. Indeed, genetic
variants in ATP6V0A2, the gene encoding the membrane-bound V0a2 subunit of the V-ATPase
localized to endosomes and TGN 78,79 , lead to glycosylation defects 77. Patients with pathogenic
variants, loss-of-function mutations leading to a truncated protein, in ATP6V0A2 present with
wrinkly skin syndrome and autosomal recessive cutis laxa type II, both connective tissue dis-
orders related to the secretion of elastin to the extracellular matrix, and neurological involve-
ment. Moreover, experiments inpatientfibroblastswith the fungalmetabolite BrefeldinA (BFA),
which inhibits the formation of COPI vesicles 96 , demonstrate that retrograde intra-Golgi traf-
ficking is impaired inpathogenicATP6V0A2 variants, likely causing themislocalizationof glyco-
syltransferases. Supporting this, neutralization of the Golgi pHwith theweak base ammonium
chloride or proton pump inhibitor Bafilomycin A1 alsomislocalizes glycosyltransferases 97. Fur-
thermore, the misregulation of Golgi pH could influence the delivery of glycosylated cargo via
the cargo receptor ERGIC53, which binds high mannose glycans in the ER in a pH-dependent
manner and transports them to the Golgi apparatus 60–62,98. Thus, in addition to the deviation
of thepHvaluesaway fromthoseoptimal for glycosyltransferaseactivity,mutations in subunits
of theV-ATPase could result inmislocalizationofbothglycosyltransferases and their substrates,
and this likely contributes to the CDG pathology. General pHmaintenance in the Golgi is imper-
ative for physiological glycosylation.
Aside fromvariants in theV-ATPase itself, assembly factors andaccessoryproteinshavealso
been implicated in CDGs. One accessory protein of the V-ATPase, Ac45 (Figure 2; also known as
ATP6AP1, the ortholog of yeast Voa1p), is ubiquitously expressed 104–107 andmainly guides the V-
ATPase into cell type-specific subcellular compartments such as neuroendocrine secretory vesi-
cles 108,109 or the ruffled border of osteoclasts 104,110,111. Missense mutations at sites coding for
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Figure 2.2: Schematic overview of themammalian V-ATPase and the putativemodel of its assembly. Lower-
case letters denote the various subunits of the V0-domain; uppercase letters denote the subunits of the V1-
domain. The assembly factors VMA21, TMEM199, and CCDC115might assemble themembrane-associated
V0-domain of the V-ATPase. VMA21 interacts with V0c’ and V0a
99–102 , TMEM199 and CCDC115 interact
with V0a
103 . Abbreviations: V-ATPase, vacuolar H+-ATPase; CDG, congenital disorder of glycosylation.
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highly conserved residues in Ac45 have been identified 112 with patients suffering from immun-
odeficiencies, hepatopathy, neurocognitive abnormalities, andabnormal protein glycosylation.
Thisnot onlydemonstrates thatAc45 is an important factor in (tissue-specific) traffickingof the
V-ATPase, but also strengthens the notion that the trafficking of the V-ATPase is imperative for
functional protein glycosylation.
Another accessory protein, ATP6AP2 (Figure 2.2), has also been implicated recently in CDG 113.
While its precise mechanistic role in V-ATPase assembly has not been determined, loss of
ATP6AP2 in murine cardiomyocytes, hepatocytes, or podocytes causes a decrease in V0a1-3 pro-
tein levels, as well as defects in autophagy 114–116. Patients withmissensemutations in ATP6AP2
presentprotein glycosylationabnormalitieswithhypogalactosylationandhyposialylationand
autophagic defects relating to aberrant lysosomal acidification 113. This phenotype demon-
strates the importance of a functional V-ATPase for both glycosylation and lysosomal function.
Similarly, recently, a novel CDG involving the putative V-ATPase assembly factor VMA21
(ortholog of yeast Vma21p) was discovered, with patients presenting with a hepatic pheno-
type with steatosis and hypercholesterolemia 117. Two mutations causing a premature stop
codon and one missense mutation in VMA21 were discovered. Mechanistically, the symptoms
of VMA21-CDG patients are the result of impaired lipophagy due to reduced lysosomal acidi-
fication, and patients present with a loss of sialic acid and galactose on glycoproteins 117. In
yeast, Vma21p interactswith V0 subunit c’ and thus promotes the assembly of the V0 proteolipid
subunits into a ring (Figure 2.2) 99,100. In mammals, VMA21 can also directly interact with sub-
unit a of the V0 domain, and this interaction is dependent on glycosylation of subunit a (Fig-
ure 2.2) 101,102. This observation has a two-pronged implication: efficient glycosylation is reliant
on the proper assembly of the V-ATPase, and the proper assembly of the V-ATPase is reliant on
efficient glycosylation. This could function as a quality control mechanism to abrogate the as-
sembly of a faulty V-ATPase. Most interestingly, in yeast strains lacking Vma21p, the ER-Golgi
SNAREBos1p (orthologofmammalianGosR2 21,118) was completely absent fromCOPII vesicles 119 ,
strengthening the importance of pH homeostasis for functional ER-Golgi trafficking.
Furthermore, missense mutations in the gene coding for putative V-ATPase assembly fac-
tors uncharacterized transmembrane protein 199 (TMEM199, the ortholog of yeast Vma12p)
and coiled-coil-domain containing protein 115 (CCDC115, the ortholog of yeast Vma22p) have
also been found in novel CDGs 120,121. CCDC115 and TMEM199 are hypothesized to assemble
the membrane-integral V0 domain of the V-ATPase through interactions with subunit a (Fig-
ure2.2) 103. In S. cerevisiae, assemblyof theV0 domainmediatedbyVma21p, Vma12p, andVma22p
occurs at the ERmembrane 122–124 , after which the V0 domain is transported to the Golgi and as-
sociates with the V1 domain to form the fully functional V-ATPase complex
69. Inmammals, the
exact mechanism of V-ATPase assembly is still unclear, but as TMEM199 and CCDC115 localize
to the ER, it is suggested that mammalian V-ATPase assembly is analogous to that in yeast 125.
Pathogenic variants in either protein mainly have a hepatic phenotype similar to VMA21-CDG,
although a neurological phenotype is observed for CCDC115-CDG patients. Abnormal glycosy-
lation, mainly the truncation of glycans through the loss of sialylation and galactosylation,
is seen for both CDGs. This observation corresponds to the mislocalization of especially trans-
Golgi-resident galactosyltransferases, which is consistentwith the concomitant acidificationof
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theGolgiapparatus. Incontrast toVMA21-CDG 117 , but in linewithATP6V0A2-CDG 77 , nodisorders
inautophagyweredescribed for TMEM199-CDGandCCDC115-CDG 120,121. One explanation is that
a potential lysosomal defect was not investigated. Another plausible explanation for this phe-
nomenon is that TMEM199 and CCDC115 participate in the assembly of a specific V-ATPase for
the Golgi apparatus, while the lysosomal V-ATPase is still assembled regularly in TMEM199-CDG
andCCDC115-CDG. This raises thepossibility thatTMEM199andCCDC115primarily interactwith
a certain V0a subunit, likely V0a2 concerning the glycosylation phenotypes in TMEM199-CDG
and CCDC115-CDG, to facilitate the assembly of a Golgi-specific V-ATPase 126–128. The severity of
the symptoms of ATP6AP1-CDG, ATP6AP2-CDG, andVMA21-CDGpatients could stem fromamore
general role of these factors in V-ATPase assembly. Incomplete assembly of the V-ATPase might
also result inmislocalization of the V0 domain, as the trafficking of the V0 domainmight be pH
dependent itself, thereby amplifying the phenotypes. Aside from their role in CDG, TMEM199
and CCDC115 have also been implicated in ironmetabolism 125 and influenza A virus infection,
most probably via a pH-dependentmechanism 129. These observations underpin howV-ATPase
assembly, glycosylation, ER-to-Golgi, and intra-Golgi trafficking are intertwined.
Finally, pathogenic variants in the uncharacterized transmembrane protein 165 (TMEM165,
also knownas TPARL) leading to CDGhave been identified 130 , one intronicmutation in the gene
coding for TMEM165 leading to the production of a truncated protein and twomissense muta-
tions at sites coding for highly conserved residues. Patients with TMEM165-CDGmainly present
with skeletal and hepatic abnormalities and an N-glycosylation defect consisting of hyposialy-
lation and hypogalactosylation. No O-glycosylation abnormalities were observed in these pa-
tients. TMEM165 is a putative proton pump, based on protein sequence homology 130 , primar-
ily localizing to the late Golgi apparatus and potentially maintaining the pH in this compart-
ment (Figure 2.2). This theory is corroborated by the similar glycosylation defects observedwith
TMEM165-CDG and V-ATPase-related CDGs discussed above. Additionally, depletion of TMEM165
usingRNA interference inHEK293 cells revealedadefect inGolgi galactosylation,whichcouldbe
rescued by supplementation withmanganese 23. As manganese is required for the proper func-
tioning of some glycosylation enzymes 131,132 , TMEM165 may also be required for manganese
homeostasis, perhaps by functioning as amanganese transporter.
2.3.2 Golgins, GRASPs, GORAB, and Rabs
Vesicle fusionwith the Golgi apparatus is initiated by specific capture of vesicles by long coiled-
coil proteins decorating the Golgi membrane: Golgins 81,82,133,134. Next to this, Golgins also act as
structural proteins to maintain Golgi architecture 135. To date, genetic variants in several Gol-
gins have been identified that affect both retrograde intra-Golgi trafficking and glycosylation.
For instance, a nonsense mutation in the gene coding for GMAP-210 (Figure 2.3, also known
as TRIP11) causes neonatal lethal skeletal dysplasia in both mice and humans 136. Similar to
GORAB (see below), the phenotypes in patients carrying loss-of-function mutations in TRIP11
are caused by defective glycosylation of extracellularmatrix proteins. GMAP-210 normally func-
tions as a tether for both ER-to-Golgi and intra-Golgi vesicles 137,138. TRIP11mutant chondrocytes
and osteoblasts isolated from mice carrying this nonsense mutation showed swollen ER and
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a disrupted Golgi architecture. Patient fibroblasts with either a heterozygous or homozygous
nonsense variant of GMAP-210 showed incomplete glycosylation of themodel secretory protein
vesicular stomatitis virus G protein (VSVG) fused to GFP, suggesting a function of GMAP-210 in
trafficking. Thesemutant cells also showed increased lectinGS-II bindingalong cell surfaces, in-
dicatingadefect inglycosylationdue toGMAP-210 loss-of-function, as lectinGS-II binds to termi-
nal non-reducing N-acetyl-D-glucosamine, which is normally not present in fully processed gly-
coproteins 136. Hypomorphic mutations, or partial loss-of-function mutations, in TRIP11 cause
a different genetic disorder called odontochondrodysplasia (ODCD) 139 , affecting skeletal and
dental development. In contrast to the loss-of-functionmutations in TRIP11, secretion is not af-
fected in ODCD. Glycans on the lysosomal glycoprotein LAMP2 and the extracellular matrix pro-
tein decorin were both abnormal, and synthesis of extracellular matrix proteins was strongly
reduced, leading to disease 139.
Other Golgins also regulate glycosylation, but have not been associated with CDGs. An in-
tronic splice donor site mutation in the gene coding for Golgin giantin (Figure 2.3, also known
as GOLGB1) produces a truncated protein, which causes cleft palate in mice, with murine em-
bryos showingan increase inGS-II lectinbinding to terminalGlcNAcmoietieswithin thepalatal
regions, which is indicative of incomplete protein glycosylation. In parallel, frontal sections
of developing palatal shelves of giantin loss-of-functionmutant mice show increased binding
of PNA lectin after desialylation with neuraminidase, showing an increase in galactosylated
O-type mucins on the cell surface 140. In addition to giantin, certain membrane tethering pro-
teins, such as giantin, GRASP55, and GRASP65 (Figure 2.3), are thought to regulate the rate of
retrograde trafficking, likely to assure efficient recycling of glycosylation enzymes to their tar-
get Golgi compartment. RNA interference-mediated depletion of giantin in HeLa cells revealed
that this causes aberrant fusion of Golgi cisternae 141. This, in turn, caused a two-fold increase
in the mobility of the glycosylation enzyme ManII as measured by fluorescence recovery after
photobleaching and accelerated the trafficking of VSVG to the plasma membrane 142. Further-
more, siRNA depletion of giantin caused overexpression of sialylated glycoproteins at the cell
surface 142. Moreover, depletion by RNA interference of GRASP55/65 accelerated the anterograde
trafficking of VSVG, independent of ER stress and unconventional protein secretion, and con-
currently decreased the complete glycosylation of VSVG 143.
More recently, several missense and nonsense mutations in GORAB have been identified in
patients (Figure 2.3). Although GORAB was previously described to be a Golgin, it is now under-
stood that it is a COPI vesicle coat scaffolding protein that likely engages in vesicle formation
and has been associated with the development of the skin and bone disorder gerodermia os-
teodysplastica (GO) 144–147. GO presents with osteoporosis and has a similar elastin deficiency
as cutis laxa 148,149. Importantly, patients have deficient glycosylation of proteoglycans includ-
ing decorin and biglycan, leading to their pathologies. GORAB is primarily functional at late
stages of intra-Golgi trafficking. GORAB promotes COPI recruitment to the trans-Golgi through
the formation of stable membrane domains. GORAB also scaffolds the catalytically inactive
protein kinase Scyl1 144. Scyl1 localizes to the ERGIC and cis-Golgi budding sites and binds to
COPI coats using a C-terminal RKLD sequence, similar to the KKXX COPI-binding motif present
in ER transmembrane proteins. The depletion of Scyl1 in HeLa cells by RNA interference dis-
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Figure 2.3: Schematic overview of COPI vesicle capture by coiled-coil tethering proteins at the Golgi. Tentac-
ular coiled-coil proteins attached to the Golgi membrane can capture COPI vesicles to direct them to the Golgi.
Abbreviations: CDG, congenital disorder of glycosylation; COG complex, conserved oligomeric Golgi complex;
COPI, coat protein complex I; SNARE, soluble N-ethylmaleimide-sensitive factor attachment protein receptor.
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rupts COPI-mediated retrograde trafficking of the KDEL receptor towards the ER 150. Several mis-
sense and nonsense mutations in SCYL1 have been described, but, in contrast to GORAB, pri-
marilyhepatological andneurological phenotypeswereobserved 151–153. Cellular investigations
of patient fibroblasts show an enlarged Golgi morphology as shown by immunofluorescence
and impaired retrograde trafficking when perturbed with BFA 151. Most interestingly, one pa-
tient demonstrated hyposialylation of both transferrin and apolipoprotein CIII as measured
by isoelectric focusing (IEF) during a liver crisis, but this returned to normal after the crisis had
passed 151. An explanation for this might be that the secretory burden of glycoproteins in this
patient was too high during the crisis, leading to abnormal glycosylation. Pathogenic variants
in GORAB either affect the binding affinity of GORAB to Scyl1 or affect the assembly of GORAB
in membrane domains, leading to the dysfunction of GORAB. Loss-of-function mutations in
GORAB inhibit the retrieval of trans-Golgi resident enzyme ST6GAL1 in a COPI-mediated man-
ner, demonstrating the necessity of GORAB for COPI-mediated intra-Golgi trafficking. Concur-
rently, GORABmutant fibroblasts from GO patients show a reduced abundance of complex ter-
minally sialylated glycans, suggestingdeficient glycosylationbydysfunctional GORAB 144. Taken
together, the observed phenotypes suggest that GORABmutations can be considered CDGs.
Once a vesicle has been captured by a Golgin, effectors such as Rab GTPases are recruited
(Figure 2.3). Rabs exists in a GDP-bound inactive state and are activated by the exchange for
GTP through guanine nucleotide exchange factors (GEFs). This nucleotide exchange results in
a conformation switch, which enables Rabs to recruit specific effectors required for vesicular
trafficking. Genetic variants within Rab proteins are associated with several neurological and
metabolic disorders, including Parkinson’s disease and Neumann–Pick’s disease 154. Certain
Rabs play an active role in retrograde Golgi trafficking, such as Rab6, which is required for bidi-
rectional transport of cargo at the Golgi 87. Furthermore, Rab2 can influence the function of
GMAP-210 in COPI vesicle tethering 138 , while Rab1, Rab2, Rab4, and Rab6 can interact withmem-
bers of theCOGcomplex and thereby tether COPI vesicles to theGolgimembrane 155. Rab1, inpar-
ticular, has also been identified to regulate the Golgi architecture and function and therefore
has an indispensable role in glycosylation 154. While genetic variants in Rabs or their regulatory
proteins have not been implicated in CDGs thus far, it is conceivable that Rab dysfunction al-
ters the identity of COPI vesicles, which results in themislocalization of glycosylation enzymes.
Thus, considering the potential effects of Rab dysfunction on glycosylation, it stands to reason
that Rab CDGs are yet to be identified.
2.3.3 Conserved oligomeric Golgi Tethering Complex
After Golgins mediate the capture of Golgi-destined vesicles from the cytosol, the COG complex
functions as a tether to anchor COPI vesicles to the Golgi membrane 156–158. COG subunits have
been described to interact directly with COPI coat components, as well as with SNAREs and Rab
GTPases involved in Golgi trafficking 91,159–164. Despite the lack of transmembrane domains in
COG subunits, they are membrane-associated proteins. The COG complex is a hetero-octameric
protein complex, consisting of eight unique subunits COG1-8 (Figure 2.4). These subunits or-
ganize themselves into two distinct lobes: lobe A consisting of COG1-4 and lobe B consisting
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of COG5-8. This in turn also dictates their localization: lobe A is primarily present on the Golgi
membrane, while lobe B localizes to COPI vesicles 164. The two lobes are bridgedby an interaction
betweenCOG1andCOG8 through the formationof alpha-helical bundles 91,159. The COG complex
is therefore required for the trafficking of glycosyltransferases and cargo proteins.
Cellularmodels of COG-subunit deficiencies show an alteration in glycosylation homeosta-
sis 165. At a cellular level, the depletion of COG subunits 2, 3, 4, 6, 7, and 8 causes the mislo-
calization of glycosylation enzymes MAN2A1, MGAT1, B4GALT1, and ST6GAL1 to COG complex-
dependent vesicles 166,167 , demonstrating their necessity in functional glycosylation 168. Studies
in HeLa cells depleted of COG4 by RNA interference also demonstrated glycosylation defects
and the mislocalization of vesicles containing COG-interacting proteins (GEARs) around the
Golgi 157,159,167. Of note, the permanent membrane targeting of COG subunits 4, 7, and 8 by fus-
ing them to the transmembrane protein TMEM115 169 disrupts the ribbon structure of the Golgi
as visualized by electronmicroscopy, causing the swelling of cisternae and an increase of spher-
ical, non-cisternal elements 170. Nevertheless, membrane-anchoring of COG4 and COG7, but not
COG8, rescued the glycosylation defects observed in their respective CRISPR/Cas9 knockout cell
models. The N-terminal attachment of membrane-anchored COG8 interfered with overall COG
structure and function, impeding the rescue of the observed glycosylation defects 170. The per-
manent Golgi anchoring of COG4 and 7maintains the polarization of cis- and trans-Golgimark-
ers, but fails to restore a highly organized Golgi structure in COG4 and 7 knockout cells. These
data demonstrate that themembrane association ofmost COG subunits is imperative for their
function, and likely assists in the correct retrieval of glycosyltransferases to earlier Golgi cister-
nae.
Genetic variants causing CDGs have been identified for all COG subunits, except for
COG3 159,168,171. Most genetic variants in COG subunits are observed in lobe A subunits COG1 and
COG4 and in lobe B subunit COG8 (Figure 4). While in most CDGs, N-glycosylation is mostly af-
fected, COG-CDGs show a broader phenotype with defects in both N- and O-glycan biosynthe-
sis 168. Clinically, patients of COG-CDGs presentwith prominent incomplete galactosylation and
sialylation 168,172 , and this is true for variants in both lobe A and B subunits. While the vari-
ants mostly consist of missense mutations or truncations for lobe A subunits and full loss-of-
function mutations in lobe B subunits, glycan profiles of patients show the same hypogalac-
tosylation and hyposialylation for both types of mutations 173,174. This raises the question of
whether mutations in one COG subunit affect the entire COG complex. Indeed, a variant in one
COGsubunit is associatedwith the instabilityofanother subunitwithin that lobe, leading to the
decrease inprotein expressionof subunits in the same lobe 175. Thishasbeen shownforCOG1 172
and COG2 171 in lobe A and COG6, COG7 176,177 , and COG8 178 for lobe B. Moreover, themutations in
COG1 are associated with a decrease in protein levels of COG8 172. Oppositely, a truncation mu-
tant of COG8 also decreases the protein levels of COG1 179. The finding that all eight subunits
are required for complete COG function is a possible explanation for the similarity in glycan
profiles of COG-CDGs (see below). However, COG1- and COG4-CDG phenotypes are relativelymild,
while COG7- and COG8-CDG aremuchmore severe. This could indicate a differential necessity of
COG lobe B over lobe A.
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Figure 2.4: Schematic overview of COG-mediated vesicle tethering and SNARE-mediated vesicle fusion at
the Golgi. COPI vesicles are tethered to the Golgi membrane through the interaction of COG lobes A and B.
Subsequently, SNARE-mediatedmembrane fusion occurs, and the vesicle cargo is released to the Golgi lumen.
Abbreviations: CDG, congenital disorder of glycosylation; COG complex, conserved oligomeric Golgi complex;
COPI, coat protein I; SNARE, soluble N-ethylmaleimide-sensitive factor attachment protein receptor.
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COG-CDGs have mainly been implicated through genetic variants of COG1 and COG4 for
lobe A. Patients with an 80 residue C-terminal truncation of COG1 present with a reduction
of galactose and sialic acid moieties on N- and O-glycans. Consistent with this, fibroblasts iso-
lated from these patients demonstrate a reduction of sialic acid incorporation on mucin-type
O-glycans 172. A different variant, an intronic mutation that results in a frameshift and a pre-
mature stop codon in exon 7, in COG1 causes skeletal defects and mental retardation, together
withhypogalactosylation andhyposialylation 180. Moreover, the BrefeldinA assay performedon
thesepatientfibroblasts revealeda retrogradeGolgi traffickingdefect. InCHOcells, depletionof
COG1 by RNA interference leads to both deficient N- and O-glycosylation 157,159. Fibroblasts from
a patient with two heterozygous missense and nonsense mutations, respectively, in COG4 also
showed hypogalactosylation and hyposialylation 181,182. Effects of these variants on other COG
subunitswerenot investigated. Moreover, a patientwith adifferentmissensemutation inCOG4
presented with a similar glycosylation defect, but the instability of the other subunits in COG
lobeAwasalsoobserved, likelydue to the inability to formCOGsubcomplexes 183. Lastly, another
amino acid substitution in COG4 was identified causing a rare form of primordial dwarfism,
but patients notably have normal glycosylation of serum proteins 184. Instead, the extracellular
matrix protein decorin is abnormally glycated in these patients, underlying their pathology.
To date, only a single mutation, an intronic mutation leading to a decrease in COG5 expres-
sion, has been identified in the gene coding for COG lobe B subunit COG5 with mostly neuro-
logical symptoms and similar hypogalactosylation and hyposialylation like in other COG de-
fects 173,185–187. Several studies have shown that a single missense mutation in COG6 leads to
severe neurological and hepatological symptoms and can lead to infant mortality 188–190. The
relative severity of COG6-CDG is likely due to the observed instability of COG lobe B, as COG6-
CDG patients also have lower protein levels of COG5 and COG7. Furthermore, decreased levels
of the trans-Golgi SNARE syntaxin-6 were detected, suggesting that stabilization of syntaxin-6
via the COG complex is necessary for its function 190. Intronic mutations affecting the mRNA
splicing and ultimately causing the decrease of protein levels of COG7 cause similar glycosyla-
tion defects, with patients presenting hyposialylation in their N- and O-linked glycan biosyn-
thesis 176,177,191. Another study observed that one specific variant in COG7, which is associated
with infantile mortality 192 , causes a loss of sialylation on serum transferrin and on cell sur-
face proteins of patient fibroblasts 193. Moreover, this variant in COG7 affects Golgi trafficking
as shownby the impaired traffickingof ST3GAL1 from the ER to the trans-Golgi in patientfibrob-
lasts. A homozygous nonsense mutation in COG8 results in the formation of a truncated COG8
subunit, lacking 76 C-terminal residues, affecting the interaction between COG8 and COG1. Pa-
tients with this variant present with mild hyposialylation 179. Similarly, a patient with a differ-
ent genetic variant resulting in the truncation of COG8 with the loss of 47 C-terminal residues
showed a similar deficiency in sialylation 178. COG8-CDG patients present with a severe neuro-
logical phenotype and display a fragmented Golgi apparatus in patient fibroblasts. Overall, the
COG defects demonstrate the importance of efficient tethering of intra-Golgi vesicles and show
that even small changes are enough to destabilize the COG complex, thereby severely affecting
glycosylation.
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2.3.4 SNAREs
The final step in the delivery of glycosylation enzymes to the Golgi is SNARE-mediated mem-
brane fusion. SNARE proteins are classified by the central residue in their SNARE motif: R-
SNAREs have a central arginine residue, while Qa-, Qb-, Qbc-, and Qc-SNAREs have a central glu-
tamine residue. A tight alpha-helical coiled-coil bundle is formed by one of each type of SNARE
motif, provided by three or four cognate SNARE proteins. These are present on both the vesic-
ular (e.g., COPI vesicle) and target membranes (e.g., cis-Golgi), and the coiled-coil formation pro-
vides enough energy to fuse the two opposing membranes 57,58. At the mammalian ER-Golgi in-
terface, four distinct SNARE complexes exist: Stx5 / GosR2 (also known as GS27 or membrin) /
Bet1 / Sec22b (also known as ERS24) for anterograde transport from ER to ERGIC, Stx5 / GosR1 /
Bet1 / Ykt6 for anterograde transport from ERGIC to cis-Golgi, Stx5 / GosR1 (also known as GS28)
/ Bet1L (also known as GS15) / Ykt6 for retrograde intra-Golgi transport, and Stx18 / Sec20 / Use1
/ Sec22b for retrograde transport from cis-Golgi to ER 21,118,194–207. While in general, R-SNAREs are
present on the vesicularmembrane in eukaryotic cells 57 , evidence suggests that the Qc-SNAREs
Bet1 and Bet1L function as the vesicular SNAREs at the ER-Golgi interface 21,204,207–210. This obser-
vation, together with the necessity of Sec1/Munc18 SM) protein Scfd1 in ER-Golgi SNARE fusion,
likely implies specificity to the fusogenic SNARE complex, by inhibiting the formation of non-
functional SNARE complexes 63,211–214.
Despite the essential role of SNAREs in Golgi trafficking 21 , there is only limited evidence for
a clinical link between glycosylation and genetic variants in SNARE proteins. This also raises
the question of whether SNARE CDGsmostly remain undetected due to a possible severity of the
disease. Contrary to plasma membrane-localized SNARE complexes, ER-Golgi-localized SNARE
complexes lack redundancy, and the loss of a single SNARE protein at this interface might re-
sult in detrimental effects for glycosylation and/or life 118. Recently, the first CDG related to a
SNARE protein was identified, namely a point mutation in STX5, the gene coding for the Qa-
SNARE syntaxin-5 207. In animals, the STX5 gene is transcribed to one mRNA, which produces
two different isoforms of Stx5 via an alternative starting codon: 39.6 kDa sized Stx5 Long (Stx5L)
and 34.1 kDa sized Stx5 Short (Stx5S) 21,215. Stx5L is characterized by a 54 residue N-terminal ex-
tensionwith anRKR (arginine-lysine-arginine) ER-retrievalmotif and localizes at ER, ERGIC, and
cis-Golgi. In contrast, Stx5S lacks this RKR ER-retrievalmotif and primarily localizes to the Golgi
(Figure 2.4). The point mutation causes the specific loss of Stx5S through the mutation of the
secondstartingmethionine residue intovaline. This lossof the intra-Golgi dominantQa-SNARE
Stx5S results in a severe disorder, characterized bymetabolic and developmental defects and in-
fantilemortality. Microscopy revealed that this is causedby themislocalizationof glycosylation
enzymes to the wrong compartment in the Golgi apparatus, leading to the reduced incorpora-
tion of galactose and sialic acid moieties in N-glycans and an overrepresentation of immature
high-mannose glycans 207.
The Qbc-SNARE SNAP29 has previously also been ascribed a role in Golgi morphology, and
its dysfunction could likely result in glycosylation defects 216. Of note, several missense and
truncating mutations in SNAP29 have been associated with cerebral dysgenesis, neuropathy,
ichthyosis, and keratoderma syndrome (CEDNIK, a disorder of brain development, facial dys-
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morphism, and skin), and Pelizaeus–Merzbacher-like disorder (PMLD, a disorder of brain devel-
opment and muscle function) 217–223. The first report of SNAP29 involvement in CEDNIK noted
that no N- and O-glycosylation defects were observed, although the authors did not describe
how the patients were screened 222. This result does not exclude that SNAP29 is involved in gly-
cosylation, as, assuming that custom IEFmethods were applied for CDG screening, it is possible
that although glycosylation of either transferrin or apolipoprotein CIII were not affected, other
glycosylated proteins were. Additionally, these methods might not have been sensitive enough
to detect an underlying glycosylation disorder, or only glycosylation in certain tissues could
have been affected. Finally, fusion-impaired forms of GosR2 result in a neurological phenotype
in patients with progressive myoclonus epilepsy, but have not been associated with glycosyla-
tion defects (Figure 2.4) 224–226. It is possible that during these studies, no diagnostics for glyco-
sylation has been performed or that through a compensatorymechanism, sufficient glycosyla-
tion wasmaintained. Along these lines, more comprehensive diagnostic screening procedures
might implicate more SNAREs in CDGs.
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2.4 Discussion and Conclusions
The glycosylation process is an essential part of the secretory pathway and is a complex logistic
system. Newly synthesized glycoproteins are shuttled from the ER to the Golgi apparatus, which
acts as a production line that sequentially builds complex branched glycan structures on the
proteins. Moreover, the Golgi can be considered a distribution center that ensures that glyco-
proteins are modified and sorted correctly to their final destinations. As with factories and
other logistic systems, having efficient infrastructure is the key to a high efficiency and fidelity
of production and delivery. Each organelle in the logistic chain needs to function optimally
to avoid bottlenecks, and therefore, efficient coordination amongst organelles is of utmost im-
portance. Here, wediscussedhowdysfunctional transport processes affect glycosylationand, in
turn, cause a wide array of symptoms including skin and bone disorders, impaired liver func-
tion, and even infantilemortality. Mechanistically, these pathologies are the result of impaired
pH homeostasis in the Golgi, incorrect tethering of Golgi-destined vesicles, and defective mem-
brane fusion at the Golgi apparatus (Table 1).
In this review, we discussed pathogenic variants in the V-ATPase and associated proteins
that affect Golgi pH homeostasis and glycosylation. Considering that glycosylation enzymes
have a broad pH optimum and that the Golgi has a narrow range in pH (pH 6.7 for cis to pH 6.0
for trans), it seems unlikely that small defects in pH homeostasis result in a pronounced loss of
catalytic activity of the glycosylation enzymes. Instead, the prevailing theory is that pH affects
the trafficking of glycosylation enzymes to their cognate Golgi compartments and that altering
the Golgi pH results in mislocalization of these enzymes to the wrong compartment 31–33. This
is corroborated by the observation that Golgi-to-ER recycling mediated by the KDEL receptor is
indeedpH-dependent 27 andby theobservation that the ER-Golgi SNAREproteinBos1p is absent
from COPII vesicles of yeast strains lacking the V-ATPase assembly factor Vma21p 119. Moreover,
it has been described that the luminal pH affects the oligomerization of certain glycosylation
enzymes and thereby also influences their localization 227–234. Another well-characterized ex-
ample of pH-mediated protein sorting is the binding of the mannose-6-phosphate receptor to
themannose-6-phosphate-labeled cargo destined for the lysosome. Proteins are bound by this
receptor in the Golgi and subsequently released in the more acidic environment of late endo-
somes 29,235,236. Finally, the pH of the TGN is also important for the correct sorting of the extracel-
lular matrix components laminin and heparan sulfate proteoglycan to the basolateral surface
of polarized epithelial cells 35,235,237. Taken together, evidence shows that homeostasis of pH is of
crucial importance for trafficking within, from, and to the Golgi apparatus, and thereby likely
a critical factor for glycosylation. This also implicates thatmislocalization of the V-ATPase and
associated proteins due to pathogenic mutations in trafficking proteins such as SNAREs, COG
subunits, or Golgins can affect glycosylation.
Interestingly, except for Stx5-CDG, all described CDGs in trafficking proteins primarily
demonstrate defects in late glycan modifications such as galactosylation and sialylation (Ta-
ble 2.1). Only in Stx5-CDG, the accumulation of an early-stage highmannose glycan is observed.
Why could defects in early glycosylation steps be underrepresented? We can consider several hy-
potheses. First, correct glycosylation is of absolute importance for development 7,10 , and despite
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the redundancy in glycosylation enzymes, defects affecting early glycosylation reactionsmight
not be conducive to further development. Therefore, potential pathogenic mutations might
remain undetected as they are non-viable. Second, as disorders of glycosylation are mostly a
secondary effect of trafficking defects, glycosylation disorders might go undiagnosed as they
simply have not been screened for in potential cases such as for GOSR2 mutations 225,226. Last,
early glycosylation defects might go undiagnosed because common biochemical techniques
to measure glycosylation in a clinical setting, such as isoelectric focusing of transferrin and
apolipoprotein CIII 238 , mostly interrogate late glycosylation reactions such as sialylation. Mod-
ern advances in clinical diagnostics have added mass spectrometry of intact transferrin ? and
glycomics on total plasma N-glycans 174. These two approaches have enabled measuring all N-
glycan structures on circulating serum proteins, thereby giving a more complete view of the
glycosylation defects. This allows clinicians and scientists to identify more complex glycosyla-
tion disorders, including those in trafficking factors. Future advances to glycosylation screen-
ing might include measuring the glycome of all different tissues in the human body or mea-
suring site-specific glycosylation on a large array of proteins. Understanding trafficking and
glycosylation in different cellular contexts will ultimately further our knowledge of glycobiol-
ogy and eventually increase therapeutic options for patients suffering fromCDGs. A subcellular
understanding of CDG can pave the road for targeted therapies through, for instance, gene re-
placement of affected genes or the development of small molecules to modulate ER-to-Golgi
and intra-Golgi transport.
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Fluorescence Lifetime Imaging of pH
along the Secretory Pathway
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3.1 Abstract
Many cellular processes are dependent on correct pH levels, and this is especially im-
portant for the secretory pathway. Defects in pH homeostasis in distinct organelles
cause a wide range of diseases, including disorders of glycosylation and lysosomal
storage diseases. Ratiometric imaging of the pH-sensitive mutant of green fluores-
cent protein (GFP), pHLuorin, has allowed for targeted pH measurements in various
organelles, but the required sequential image acquisition is intrinsically slow and
therefore the temporal resolution is unsuitable to follow the rapid transit of cargo
between organelles. We therefore applied fluorescence lifetime imaging microscopy
(FLIM) to measure intraorganellar pH with just a single excitation wavelength. We
first validated this method by confirming the pH in multiple compartments along
the secretory pathway. Then, we analyze the dynamic pH changes within cells treated
with Brefeldin A, a COPI coat inhibitor. Finally, we followed the pH changes of newly-
synthesized molecules of the inflammatory cytokine tumor necrosis factor (TNF)-α
while it was in transit from the endoplasmic reticulum via the Golgi to the plasma
membrane. The toolbox we present here can be applied to measure intracellular pH
with high spatial and temporal resolution, and can be used to assess organellar pH in
diseasemodels.
3
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3.2 Introduction
Physiological pH homeostasis is crucial for many cellular processes. Not only the cy-
tosolic pH is of importance, but defined intraorganellar pH delineates the secretory
pathway. The pHof the endoplasmic reticulum (ER) is approximately 7, while the Golgi
apparatus slightly acidifies frompH6.7 at the cis face to pH 6.0 at the trans face22,242,243.
Before secretory cargo is released at the plasma membrane and reaches the neutral
pH of the extracellular environment, the pH in secretory vesicles is about 5.222,242.
pH isnotonly crucial forproperprotein foldingandenzymeactivity through influ-
encing the charge of amino acid side chains, but its importance in secretory protein
transport is increasingly clear13. pH affects binding affinities of cargo molecules to
trafficking chaperones, and thereby pH differences facilitate intracellular transport
by both influencing the transit of cargo61,62,236,237,244–246 and the sorting of secretory
pathway resident proteins27,28,247. Moreover, the localization of glycosylation enzymes
and their substrates is determined by pH13,32,234,235,248 , and defects in this homeostasis
cause a wide range of human disease13,77,112,113,117,120,121,239. Being able to accurately de-
termine intraorganellar pH along the secretory pathway is therefore of both funda-
mental and diagnostic importance.
Fluorescent dyes that allow the measurement of intraorganellar pH exist and are
commercially available249–253 , but the inability of specific organellar targeting is a
major drawback. The pH in the lumen of the Golgi and ER in mammalian cells have
beenmeasuredusing Shiga-like toxins covalently bound tofluorescent dyes254,255 and
with the biotin-avidin system256. However, especially the development of pH-sensitive
mutants of green fluorescent protein (GFP), such as pHLuorin257,258 , which can be tar-
geted to specific organelles by fusion proteins, have enabled specificmeasurement of
intracellular compartments. Two classes of pHLuorin were developed by mutagene-
sis which altered the bimodal excitation spectrum of GFP with peaks at 395 and 475
nm257,259. First, ecliptic pHLuorin which shows a reduction of its excitation efficiency
at 475 nm at pH values lower than 6. Second, ratiometric pHLuorin which shows a
gradual increase in the ratio of excitation at 475/395 nmbetween pH 5.5 and pH 7.5257.
With ecliptic pHLuorin, intraorganellar pH can be determined by first recording an
image at 475 nm excitation, and then correlating the fluorescence intensities with a
calibration curve. The pH can be determined with ratiometric pHLuorin using a sim-
ilar approach, but now by sequentially recording images at 395 and 475 nm. A new
version of ratiometric pHLuorin, ratiometric pHLuorin2 (RpHLuorin2) was later devel-
oped with 8-fold improved fluorescence258.
Ecliptic pHLuorin is less accurate than ratiometric pHLuorin, because the fluores-
cence intensitynot onlydependson thepHbut also on the concentrationof pHLuorin.
3
50 | Chapter 3. Fluorescence Lifetime Imaging of pH along the Secretory Pathway
However, ratiometric imaging also has several drawbacks, such as sensitivity to back-
groundfluorescence leading to high variation in the ratio values and the need for two
sequential image acquisitions with two different excitation wavelengths. As the ex-
ocytic pathway is highly dynamic, the sequential imaging could potentially result in
misalignment of the emitted signal, compromising the calculation of ratio values.
In this study,weexploitfluorescence lifetime, an intrinsicpropertyoffluorophores
that is insensitive to changes in laser intensity or protein concentration260,261 but is
sensitive to pH262,263 , to accuratelymeasure intraorganellar pHwith both high spatial
and temporal resolution.
3.3 Results
3.3.1 FLIMmeasurements of recombinant ratiometric pHLuorin2
We first measured the fluorescence excitation spectra of recombinant RpHLuorin2
(Supplementary Figure 3.5) in different pH solutions with a fluorescence spectrome-
ter. As expected257 , we observed strong dependence of the excitation efficiencies on
pH, as a higher pH resulted in an increased emission brightness (at 508 nm) at an
excitation wavelength of 470 nm, whereas the fluorescence brightness was reduced
at an excitation wavelength of 405 nm (Supplementary Figure 3.5a). We then plotted
the ratios of the emission signals with 470 nm over 405 nm excitation as a function
of the pH and fitted this data with a three-parameter Michaelis-Menten function, as
the (de)protonation states of RpHLuorin2will saturate at very high and low pH values
(Supplementary Figure 3.5b). The largest changes in fluorescence of RpHLuorin2 were
observed between pH 5.5 and pH 7,making RpHLuorin2 an excellent candidate for pH
measurements in the secretory pathway.
As ratiometric determination of pH with RpHLuorin2 requires two sequential im-
age acquisitions with different excitation wavelengths, we investigated whether flu-
orescence lifetime imaging microscopy (FLIM) would be an appropriate substitute to
allow for single-scan imaging. We hypothesized that as the lifetime of fluorophores
is influenced by pH262,263 , the pH sensitivity of RpHLuorin2 would allow for accurate
pHmeasurement based on fluorescence lifetime. Therefore, we performed FLIM of re-
combinant RpHLuorin2 in different pH solutions at 488 nmexcitation (Figure 3.1). We
observed a similar dependency of the lifetime as a function of pH (Figure 3.1) as in the
ratiometric measurements (Supplementary Figure 3.5), and the fluorescence lifetime
increased upon an increasing pH. We then fused RpHLuorin2 to several intraorganel-
lar markers in the secretory pathway to perform pHmeasurements in living cells.
3

























































































































Figure 3.1: Fluorescence lifetime imagingmicroscopy (FLIM) of recombinant RpHLuorin2. (Continued on the
following page.)
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Figure 3.1: (a)Representative confocal images of 10µMrecombinant RpHLuorin2 in calibration buffers with
defined pH. The intensity image (left column) was convolutedwith the fluorescent lifetime value per pixel and
pseudo-colored (right column). (b)Representative fluorescence lifetime histograms of recombinant RpHLu-
orin2 in pH 4.87 solution (red dashed line) or pH 7.5 solution (pink dashed line). Fits withmono-exponential
decay functions (pH 4.87, solid red line; pH 7.5, solid pink line) convolutedwith the instrumental response
function (IRF, gray dotted line). Graphs are normalized to themaximum photon counts. (c)Average lifetime
histograms from the images of panel (a). 30 regions of interest were selected per pH buffer and the average
lifetime τ wasmeasured. (d) pH dependence of recombinant RpHLuorin2 in defined pH calibration buffers
from the images of panel (a).
3.3.2 pHmeasurements in the secretory pathway
In order to accurately measure intraorganellar pH of specific organelles, we targeted
RpHLuorin2 intracellularly by fusing it to proteins and targeting sequences that lo-
cate to specific subcellular locations in the secretory pathway (Figure ??a). To interro-
gate the luminal pH along the entire secretory pathway, we fused RpHLuorin2 to the
signal sequence of the ER-resident protein calreticulin and a C-terminal ER retention
signal KDEL for ER targeting, to the luminal regions of cis-/medial-Golgi protein alpha-
1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (MGAT2), to trans-
Golgi enzyme beta-1,4-galactosyltransferase 1 (GalT), to lysosome-associated mem-
brane glycoprotein 1 (LAMP1) for lysosomal targeting, and finally to a GPI anchor for
plasmamembrane (i.e. extracellular) localization. For the Golgi enzymes (MGAT2 and
GalT), we truncated each protein by removing their catalytic sites and only kept the
transmembrane region and stalk regions responsible for their localization264–266.
We then expressed the fusion constructs in HeLa cells, and recorded FLIM images.
We used the GPI-anchored RpHLuorin2 to calibrate the probe expressed in cells using
the same pH buffers as used for the calibration of purified RpHLuorin2 (Figure 3.2a-c).
We again observed a dependency of the fluorescence lifetime of RpHLuorin2 on pH, al-
though theabsolutefluorescence lifetimevalueswere lower than for the recombinant
RpHLuorin2, possibly due to crowding effects. This dependence on pH could again be
fitted by a three-parameter Michaelis-Menten function. After successfully calibrating
our system,weproceededwithpHmeasurements in the lumenof theorganelles along
of the secretory pathway (Figure 3.3). With ER-RpHLuorin2, we measured an apparent
average pH of 7.2, while with cis-/medial-Golgi marker MGAT2-RpHLuorin2 we mea-
sured an apparent average pH of 6.1, and with trans-Golgi marker GalT-RpHLuorin2
an apparent average pH of 5.9 (Figure 3.3b, c). Finally, for lysosomal marker LAMP1-
RpHLuorin2 we measured an apparent average pH of 4.7. These pH values are all con-
sistent with previous literature22,249. Taken together, our data show that the RpHLu-
orin2 FLIM system is highly suitable for intracellular pH measurements with only a
single image acquisition.
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Figure 3.2: Calibration of RpHLuorin2 by fluorescence lifetime imagingmicroscopy (FLIM) in HeLa cells ex-
pressing GPI-RpHLuorin2. (a)Representative confocal micrographs of HeLa cells expressing GPI-RpHLuorin2
in defined calibration buffers. The intensity image (left column) was convolutedwith the fluorescent lifetime
value per pixel and pseudo-colored (right column). Scalebars, 10µm. (b)Average lifetime histograms from
the images of panel (a). N = 86 (pH 4.87), 108 (pH 5.31), 90 (pH 5.67), 115 (pH 6.17), 122 (pH 6.68), 113 (pH
7.03) and 120 (pH 7.5) cells from three independent experiments. (c) pH dependence of HeLa cells expressing
GPI-RpHLuorin2 in defined pH calibration buffers from the images of panel (a).
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Figure 3.3: Steady-state pHmeasurements of secretory pathwaymarkers. (a) Schematic overview of
all RpHLuorin2 constructs used in this study. The signal sequence of LAMP1 is removed following co-
translational ER insertion and is not shown in the diagram. MW,molecular weight. RUSH, retention using
selective hooks266 . SBP, streptavidin binding protein. (b)Representative confocal micrographs of HeLa cells
expressing thementioned RpHLuorin2 fusion constructs. The intensity image (left column) was convoluted
with the fluorescent lifetime value per pixel and pseudo-colored (middle column). The intensity imagewas also
convolutedwith the calculated pH per pixel and pseudo-colored (right column). FLIM, fluorescence lifetime
imagingmicroscopy. Scalebars, 10µm. (c)Quantification of average pH values from panel (b). N = 88 (ER), 188
(MGAT2), 193 (GalT), and 134 (LAMP1) cells from 3 – 5 independent experiments.
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3.3.3 Dynamicmeasurements of pH in the secretory pathway
To evaluate whether our method would be able to measure dynamic changes in pH,
we started bymeasuring the pH of the medial-Golgi marker MGAT2-pHLuorin2 in the
presence of fungal metabolite Brefeldin A (BFA). BFA is a potent inhibitor of COPI-
mediated vesicular trafficking and causes the relocation of Golgi-resident enzymes
to the ER96,267. We therefore expected a substantial increase in pH when MGAT2-
RpHLuorin2 expressing cells were challenged with BFA. Indeed, we measured an ap-
parent average pH of 7.1 in the BFA-challenged cells compared to an apparent average
pH of 6.4 in the vehicle control cells (Figure 3.4a, b). This result means that our system
is capable of measuring dynamic alterations of pH in living cells.
Next, we employed FLIM-based measurements to monitor the changes of the pH
in real-time along the secretory pathway. To this end, we chose the secreted cytokine
tumor necrosis factor alpha (TNF-α) as a model protein that is transported through
the secretory pathway. Using the Retention Using Selective Hooks (RUSH) system266 ,
we synchronized the transit of TNF-α along the secretory pathway. RUSH uses the
expression of two separate constructs in the cell: (i) the hook construct, which is an
ER-targeting sequence fused to streptavidin, and (ii) the reporter construct which is
the protein of interest (i.e., TNF-α) fused in tandem to a streptavidin binding protein
(SBP) and a fluorescent protein (RpHLuorin2). When biotin is absent from the culture
medium, the reporter construct is held at the ER through an interaction of strepta-
vidin of the hook construct and the SBP. When biotin is added to the culture medium,
biotin outcompetes this interaction and the reporter construct is released and tran-
sits along the secretory pathway in a synchronized fashion.
In our case, we used the KDEL-motif as a targeting sequence for the ER266 , and used
a TNFα-SBP-RpHLuorin2 fusion protein (RUSH TNFα-RpHLuorin2) as the reporter con-
struct, so that we could follow the dynamic transit of TNFα from the ER to the plasma
membrane (Figure 3.4c-e). In theabsenceofbiotin in the cell culturemedium,whenall
the reporter construct was trapped within the ER, we measured an apparent average
pH of 7.58, which is comparable to our earlier determined pH in the ER. In the 25min
following the addition of biotin to the cells, RUSH TNFα-RpHLuorin2 was trafficked
through theGolgi and theapparentaveragepHgraduallydecreased toaroundpH6. At
later timepoints, thepHgradually increasedagainasmoreTNFα-RpHLuorin2reached
the plasmamembrane andwas released in the extracellular environment. Because of
the limited number of photons, we fitted the fluorescence lifetime histograms with
a single exponential decay function and report the apparent average pH per cell268.
This result demonstrates that FLIM-based pHmeasurements are a suitablemethod to
determine intraorganellar pH with high temporal resolution.
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Figure 3.4: Dynamic pHmeasurements along the secretory pathway. (a)Representative confocal micrographs
of HeLa cells expressingMGAT2-RpHLuorin2 in the absence (Ctrl, green) or presence of Brefeldin A (Brefeldin
A, orange). The intensity image (left column) was convolutedwith the fluorescent lifetime value per pixel and
pseudo-colored (middle column). The intensity imagewas also convolutedwith the calculated pH per pixel
and pseudo-colored (right column). FLIM, fluorescence lifetime imagingmicroscopy. Scalebars, 10µm. (b)
Quantification of average pH values from panel (a). N = 110 (DMSO) and 165 (Brefeldin A) cells from 2 – 3
independent experiments. (c)Representative confocal micrographs of HeLa cells expressing RUSH TNFα-
RpHLuorin2 in the absence of biotin (0min) or 20, 40 and 60minutes after biotin addition. The intensity image
(left column) was convolutedwith the fluorescent lifetime value per pixel and pseudo-colored (middle column).
The intensity imagewas also convolutedwith the calculated pH per pixel and pseudo-colored (right column).
FLIM, fluorescence lifetime imagingmicroscopy. Scalebars, 10µm. (d)Quantification of average pH values of
the cell shown in panel (c). (e)Average pHmeasured of all cells expressing RUSH TNFα-RpHLuorin2. N = 29
from 2 independent experiments.
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3.4 Discussion
In this study, wemeasured the pH in various subcellular compartments using FLIM of
the pH-sensitive fluorescent protein RpHLuorin2. Consistent with previous literature,
we observed a clear acidificationof luminal pH through the secretory pathway22,242,243.
The fusion of RpHLuorin2 is not restricted to the proteins we described here; this sys-
tem is applicable to any other intraorganellar measurement, provided RpHLuorin2
can be fused to a luminal domain of a protein residing in the target organelle. Fur-
thermore, additional applications include combining RpHLuorin2with other fluores-
cence (lifetime) based probes to measure pH and other cellular processes simultane-
ously within the same cell.
The key improvement of our study is theusage of FLIMas opposed to traditional ra-
tiometric imaging. Ratiometric imagingofpHLuorinandderivatives253,257,258 requires
the sequential recording of the fluorescent protein at both 405 and 470 nm excita-
tion wavelengths. This sequential imaging intrinsically limits the temporal resolu-
tion and consequently limits the applicability for pH determination in dynamically
moving and reshapingorganelles. FLIMmitigates this issue, as only a single recording
with a single excitationwavelength is required. Moreover, FLIMmeasurements arenot
dependent on laser intensity260,261 , while ratiometric measurements can easily be af-
fected by fluctuations in excitation laser power. FLIM measurements are thus more
comparable between experiments.
In contrast to another study which relies on equilibrating pH with the ionophore
monensin253 , we used GPI-anchored RpHLuorin2 to obtain calibration curves with de-
fined pHbuffers, becausemonensin is a known inhibitor of physiological Golgi trans-
port, thereby likely affecting the observed fluorescence lifetime values269–275.
Defects in the regulation of pH are a hallmark of a wide range of disease, in-
cluding disorders of glycosylation13,77,112,113,117,120,121 , cancer276 , neurodegenerative dis-
eases277–280 , mitochondrial disorders281 and lysosomal storagedisorders282. The tools
we presented in this study offer a method to assess intraorganellar pH, both in static
compartments and in transit between organelles with high temporal resolution.
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3.5 Methods
3.5.1 Cloning
The sequence of RpHLuorin2258 was synthesized by Genscript for both recombinant
(codon optimized for E. coli) and mammalian cell expression. Synthetic RpHLuorin2
codon optimized for E. coli for recombinant protein production was inserted in pET-
28a(+) (EMD Biosciences) with restriction sites NdeI and XhoI. The construct for cy-
tosolic expression of RpHLuorin2 was generated by replacing EGFP in pEGFP-N1 (Clon-
tech)with synthesized RpHLuorin2 using restriction sites AgeI and BsrGI. ER-targeting
of RpHLuorin2 was achieved by inserting the signal sequence of calreticulin (MLLSV-
PLLLGLLGLAVA) and flexible GGSGGS linker before RpHLuorin2 and adding a KDEL
motif for luminal ER retention after RpHLuorin2. Targeting to the MGAT2-positive
compartment was achieved by inserting synthetic truncated MGAT2 (residues 1-89 of
Uniprot Q10469, Genscript) in the vector for cytosolic expression of RpHLuorin2 with
restriction sites EcoRI and BamHI. The starting codon of RpHLuorin2 was removed
and a flexible GGSGGS linker was added between the two protein fragments. Target-
ing to the GalT-positive compartment was achieved by inserting truncated GalT (Ad-
dgene plasmid #87325) in the vector for cytosolic expression of RpHLuorin2 with re-
striction sites SmaI and BamHI. The starting codon of RpHLuorin2 was removed and
a flexible GGSGGS linker was added between the two protein fragments. Targeting
to LAMP1-positive compartments was achieved by inserting the signal sequence of
LAMP1 (LAMP1-mGFP283 , Addgene plasmid #34831) N-terminal to RpHLuorin2 with re-
striction sites HindIII and AgeI. Then, the luminal domain of LAMP1 was placed C-
terminal to RpHLuorin2 after a flexible GSGS linker with restriction sites BsrGI and
NotI. GPI-RpHLuorin2was generatedby replacingmRFP fromGPI-mRFPwith synthetic
RpHLuorin2 with restriction sites XmaI and NotI. RUSH TNFα-RpHLuorin2 was gener-
ated by replacing EGFP from Str-KDEL_TNF-SBP-EGFP (Addgene plasmid #65278) with
synthetic RpHLuorin2 (Genscript) with restriction sites SbfI and BsrGI. All sequences
were verified by Sanger sequencing prior to transfection. All generated plasmids from
this study have been deposited at Addgene.
3.5.2 Cell culture and transfection
HeLa cells (authenticated by ATCC through their human STR profiling cell authentica-
tion service) weremaintained in high glucose DMEMwith Glutamax (Gibco 31966021),
supplementedwith10%fetal calf serum (FCS, Greiner Bio-one, Kremsmünster, Austria)
and antibiotic-antimycotic solution (Gibco 15240-062). Cells were regularly tested for
mycoplasma contamination. HeLa cells were transfected with plasmid vectors using
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Fugene HD (Promega E2311), using the recommended protocol of the manufacturer.
Cells were imaged 48 hours post-transfection. Only cells expressing low to moderate
levels of the transfected plasmids, based on fluorescence intensity andmanual local-
ization scoring, were chosen for subsequentmicroscopic analyses.
3.5.3 pH calibration buffers
Buffers with defined pH for the generation of a calibration curve were prepared as
described previously253. Calibration buffers contain 125 mM KCl, 25 mM NaCl, and
25 mM N-[2-hydroxyethyl]-piperazine-N-[2-ethanesulfonic acid] (HEPES, pH 7.5 or 7.0)
or 25 mM 2-[N-morpholino] ethanesulfonic acid (MES, pH 6.5, 6.0, 5.5, 5.0 or 4.5). Each
buffer solutionwas adjusted to the appropriate final pHusing 1MNaOHor 1MHCl at
37°C.
3.5.4 Recombinant protein expression and purification
RpHLuorin2 in pET-28(a)+ vector was transformed in BL21(DE3) E. coli. Cells were
grown in 2× yeast extract - tryptone medium and induced with 250 µg/mL β-D-1-
thiogalactopyranoside (IPTG) at an OD600 of 0.8 for 2 hrs at 37°C and 200 rpm. Cells
werepelletedat 3000×gat 4°C for 30minsand subsequently lysedwithB-PER (Thermo
Scientific) supplemented with 50 U DNAseI, 1:500 lysozyme and protease inhibitor
cocktail (Roche). Lysates were then cleared by centrifugation (20,000× g at 4°C for 10
mins) and supernatants with recombinant protein were loaded onto nickel – nitrilo-
triacetic acid (Ni-NTA) bead columns. Ni-NTA beads were then washed five times with
10 mM Tris-HCl pH 7.6 and 150 mM KCl, and proteins were eluted in 10 mM Tris-HCl
pH 7.6, 150 mM KCl and 200mM imidazole. To remove the elution buffer, purified pro-
tein was dialyzed overnight against ddH2O using 2 mL Slide-A-Lyzer 10K MWCO tubes
(Thermo Scientific). Protein concentration was determined using the Micro BCA Pro-
tein Assay Kit (Thermo Scientific). Fluorescence of recombinant pHLuorin2 in each
pH calibration buffer was measured using Eppendorf semimicro Vis Cuvettes on an
LS 55 Fluorescence spectrometer (PerkinElmer). A xenon lamp was used as the excita-
tion source. Samples were excited at 405 and 470 nm, and the emission was recorded
at 508 nm.
3.5.5 Confocal microscopy
Imaging of cells took place in Leibovitz’s L-15medium, with the exception of the sam-
ples for the pH calibration curve and the recombinant protein measurements. GPI-
RpHLuorin2 and recombinant RpHLuorin2 (10 µM) measurements were performed
in the pH buffers mentioned above. For calibration with GPI-RpHLuorin2, cells were
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preincubated in pH buffer for 15 mins at 37°C to achieve sufficient pH equilibration.
Imaging was performed on a Leica SP8 SMD system at 37°C, equipped with an HC PL
APO CS2 63×/1.20 WATER objective. pHLuorin2 was excited at 488 nm with a pulsed
white light laser, operating at 80MHz. Photonswere collected for oneminute or 30 sec-
onds for time-lapse experiments with a HyD detector set at 502 – 530 nmand lifetime
histograms of the donor fluorophore were fitted with amonoexponential decay func-
tion convolutedwith themicroscope instrument response function in Leica LAS X. For
reconstructing the images, tiff fileswith τ valueswere generated using FLIMFit284 and
2 × 2 spatial binning, and then convoluted with the fluorescent intensities using a
custom-written ImageJ macro.
3.5.6 Quantification and statistical analysis
All mean values represent the average of all cells analyzed. pH calibration curves
were fittedwith the three-parameterMichaelis-Menten function as described by equa-





Where y is the fluorescence intensity or lifetime, x is the pH and c, d and e are fit
parameters.
All comparisons were first checked for similar mean and median values and ac-
ceptable (< 3x) difference in variance. Statistical analysis of three ormore groups was
performedusingaone-wayANOVA, followedbyapost-hocTukey’shonestly significant
difference test. p < 0.05was considered significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p
≤ 0.0001. All statistical analyses were performed using R statistical software. All nu-
merical datawere visualized using R package ggplot2286 , with violins representing the
overall distribution of the data andmeans ± 95% CI overlaid.
3.5.7 Data and code availability
All raw data, including R scripts and ImageJ macros, have been deposited to Zenodo.
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Figure 3.5: Fluorescence excitation spectra of recombinant RpHLuorin2. (a)Representative fluorescence
excitation spectra (emission 508 nm) of recombinant RpHLuorin2 in buffers of defined pHwere collected with
a fluorescent spectrometer. (b)Calibration curve from panel (a). The ratios of fluorescence at 405 over 470
nmwere plotted as a function of pH and fitted with a three-parameterMichaels-Menten function. Data from
four independent experiments.
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N-Glycosylation is Dependent on
TMEM199-Mediated V-ATPase Assembly
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4.1 Abstract
Themammalian vacuolarH+-ATPase (V-ATPase) is an important protonpumppresent
at themembrane of the Golgi apparatusmembrane and other organelles, where it en-
sures luminal pH suitable for Golgi processes. The molecular mechanisms of mam-
malian V-ATPase assembly are still unclear, but mutations in TMEM199, the mam-
malian homolog of yeast V-ATPase assembly factor Vma12p, cause a disorder of glyco-
sylation characterized by hyposialylation, hypogalactosylation and elevated liver en-
zymes. In this study, we generate aHeLa cellmodel lacking TMEM199withCRISPR/Cas9
to dissect themolecularmechanisms of disease. We observed that several enzymes re-
sponsible for glycosylation are mislocalized in TMEM199KO cells. Then, we applied a
novel method to determine intraorganellar pH along the secretory pathway and ob-
served that intraorganellar pH is misregulated in TMEM199KO cells. Finally, we per-
formed biochemical studies to discover that TMEM199 is involved in the specific as-
sembly of the Golgi- and endosome-localized V0a2 subunit and that TMEM199 is re-
quired for membrane association of CCDC115, the mammalian homolog of yeast V-
ATPase assembly factor Vma22p. Thus, we present the underlying molecular mecha-
nisms of glycosylation disorders caused bymutations in TMEM199.
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4.2 Introduction
The Golgi apparatus has a well-defined pH gradient22 ranging from pH 6.7 at the cis-
Golgi to 6.0 at the trans-Golgi22,242,243,254. Not only is physiological pH required for
proper folding, stability and function of proteins, at the Golgi apparatus pH is of ut-
most importance for the correct localization and activity of Golgi-localized glycosyla-
tion enzymes13,31–34. Thus, strict maintenance of the Golgi pH gradient is critical and,
inmammals, is in large part mediated by the vacuolar H+-ATPase (V-ATPase).
Themammalian V-ATPase is a largemultiprotein complex (≈900 kDa) which acidi-
fies intraorganellar luminaby translocating protons across themembrane69,70. The V-
ATPase can be subdivided into two separate domains: themembrane V0 domain, con-
sisting of six different subunits (a, d, e, c, c’, and c’’), which anchors the complex, and
the cytosolic V1 domain, consisting of eight different subunits (A-H), which hydroly-
ses ATP70. Inmammals, four isoforms of the V0a subunit exist (V0a1-4), and this likely
provides subcellular specificitywith theV0a2 subunit primarily localizing to theGolgi
apparatus and endosomes74–79. This is different from Saccharomyces cerevisiae which
only expresses two unique isoforms (Vph1p and Stv1p)69–73.
Assembly of the V0 domain in yeast is dependent on a set of ER-localized chaper-
ones: Vma12p, Vma21p and Vma22p69,100,122–124. Mammalian homologues of Vma12p
(TMEM199), Vma21p (VMA21) and Vma22p (CCDC115) have recently been identified
and genetic variants in these proteins are associated with disorders of glycosyla-
tion117,120,121. Moreover, TMEM199 and CCDC115 have been shown to interact and are
important for physiological iron homeostasis, a process that also relies on intraor-
ganellar pH125. However, their role inmammalian V-ATPase assembly is poorly under-
stood.
In this study, we dissected the role of TMEM199 in mammalian V-ATPase assem-
bly. We developed a HeLa cell line deficient of TMEM199 by CRISPR/Cas9 and, using a
novelmethod for intraorganellarpHmeasurements,measured theeffectof theknock-
out on intracellular pH. To prove that TMEM199 is indeed an assembly factor of the
mammalian V-ATPase, we performed fractionation studies and examined whether
TMEM199 can tether CCDC115 to themembrane.
4.3 Results
4.3.1 Generation of a TMEM199KOmodel
To study the role of TMEM199 in glycosylation and V-ATPase assembly, we generated
two unique partial TMEM199 knockout HeLa cell lines from the same gRNA (B1 and B2;
Figure 4.1a), with different levels of residual TMEM199 expression, using CRISPR/Cas9.
4















































Figure 4.1: TMEM199KOHeLa cell lines show defective cell surface sialylation. (a)Representative im-
munoblot for TMEM199 on cell lysates of parental HeLa cells (P, green) or TMEM199KO cells (B1 and B2,
orange). α-Tubulin, loading control. (b)Representative FACS histogram of parental HeLa cells (blue, P), or two
TMEM199KO lines (green, B1 and pink, B2), probedwith SNA-I lectin conjugated to Alexa Fluor 647. Gating
strategy in Supplementary Figure 4.6. (c)Quantification of (b). Geometric means were taken and normalized
to parental. 10,000 events analyzed per condition per experiment from 3 independent experiments.
To confirm that these knockoutmodels are suitable to study the glycosylation defects
observed in TMEM199-CDG patients121 , we performed cell surface staining with the
SNA-I lectin from Sambucus nigra, which binds terminal sialic acid moieties in an α-
2,6 linkage and to a lesser extent α-2,3 linkage of N-glycans. Compared to parental
HeLa cells, we observed an approximate 60% decrease in SNA-I labeling for both
TMEM199KO clones (Figure 4.1b, c, flow cytometry gating strategy in Supplementary
Figure 4.6). As TMEM199-CDGpatients presentwith a similar decrease in sialylation121 ,
we concluded from this experiment that our TMEM199KO clones are a suitable model
for the glycosylation defect.
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4.3.2 Loss of TMEM199 relocalizes glycosyltransferases
Given that our TMEM199KO cell models have defective cell surface glycosyla-
tion, we investigated whether there is a potential trafficking defect by prob-
ing for the localization of glycosyltransferases in the Golgi apparatus. We per-
formed immunofluorescence labeling of mannosyl (α-1,3)-glycoprotein β-1,2-N-
acetylglucosaminyltransferase (MGAT1, also known as GnT1), which catalyzes the ad-
dition of N-acetylglucosamine (GlcNAc) to the early Golgi-related glycan man-5. Com-
pared to parental HeLa cells, TMEM199KO B1 showed a slightly increased colocaliza-
tion of MGAT1 with cis-Golgi marker GM130 (Figure 4.2a, b) and trans-Golgi marker
TGN46 (Figure 4.2c, d), while TMEM199KO B2 shows a strongly decreased colocaliza-
tion of MGAT1 with GM130 and a slightly increased colocalization with TGN46. As
TMEM199-CDG patients show hypogalactosylation, we next investigated the localiza-
tion of β-1,4-galactosyltransferase 1 (B4GALT1, also known as GalT) which catalyzes
the addition of galactose toN-acetylglucosaminemoieties (Supplementary Figure 4.7).
Compared to parental HeLa cells, we observed a decrease of B4GALT1 colocalization
with cis-Golgimarker ZFPL1287 in B1 cells, but an increase in ZFPL1 colocalization in B2
cells. For TGN46 colocalization, nodifferencewasobserved for B1 cells butweobserved
a decrease in colocalization in B2 cells. Finally, N-acetylgalactosaminyltransferase 2
(GALNT2), which catalyzes the first step in mucin O-linked glycan synthesis, located
slightly more to the cis-Golgi (marker ZFPL1), and slightly less to trans-Golgi (marker
TGN46) in B2 cells (Supplementary Figure 4.8).
As a control, we investigated protein expression levels (inferred from the fluores-
cence intensity of the immunofluorescence labeling) of the markers used in the colo-
calization experiments, and did not find a correlation between expression and differ-
ences in colocalization (Supplementary Figure 4.9). We did observe a slight condensa-
tion of GM130 labeling area in B1 cells and a slight dilation in B2 cells, while we ob-
served condensation of ZFPL1 labeling area only in B2 cells. A similar condensation
phenotype was observed for TGN46 in B2 cells. These results suggest that the Golgi
morphology is differentially altered in the two TMEM199 knockout strains.
Taken together, and despite the partially opposite phenotypes in the two TMEM199
knockout strains, the (partial) loss of TMEM199 causes the aberrant localization of
glycosyltransferases to the Golgi apparatus and slight morphological differences of
the Golgi. Computational simulations have shown that disruption of Golgi structure
andmislocalization of glycosyltransferases can have a profound impact on glycosyla-
tion54.
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Figure 4.2: Relocation of glycosyltransferaseMGAT1 in TMEM199KOHeLa cells. (Continued on the follow-
ing page.)
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Figure 4.2: (a) Immunofluorescencemicroscopy ofMGAT1 (green inmerge) and GM130 (magenta) in parental
HeLa cells (green, P) or TMEM199KO cells (B1 and B2, orange). Representative confocal micrographs. Scale-
bars, 10µm. DAPI in blue. (b) Pearson’s correlation coefficients betweenMGAT1 andGM130 of panel (a).
N = 118 (P), 78 (B1), and 99 (B2) from two independent experiments. (c) Same as panel (a) but now forMGAT1
(green) and TGN46 (magenta). (d) Pearson’s correlation coefficients betweenMGAT1 and TGN46 of panel (c).
N = 75 (P), 68 (B1), and 99 (B2) from two independent experiments.
4.3.3 pHmeasurements in TMEM199KO cells
As TMEM199 is a supposed V-ATPase assembly factor and physiological pH homeosta-
sis is necessary to maintain the delicate structure of the Golgi13,31–34 , we then investi-
gated whether the aberrant localization of glycosyltransferases is caused by defective
Golgi lumen pH regulation. We applied our earlier developed method based on the
fusion of a pH-sensitive GFPmutant, ratiometric pHLuorin2257,258 , to organellarmark-
ers to measure intraorganellar pH using fluorescence lifetime imaging microscopy
(FLIM)288 (Figure 4.3). We measured an ER luminal pH of 7.4 for parental HeLa cells,
which was strongly decreased for B1 cells (pH 6.7) and even further decreased in B2
cells (pH 6.5) (Figure 4.3a, b). Golgi pH was slightly decreased as measured by MGAT2-
RpHLuorin2 (cis/medial-Golgi, P: pH 6.3, B1: pH 6.1, B2: pH 6.1; Figure 4.3c, d) and GalT-
RpHLuorin2 (trans-Golgi, P: pH 6.4, B1: pH 6.0, B2: pH 5.9; Figure 4.3e, f). Finally, we ob-
servedno significant difference betweenparental cells andB1 cells in lysosomal pHas
measuredby LAMP1-RpHLuorin2 (P: pH5.0, B1: pH4.9; Figure 4.3g, h) butwemeasureda
decrease in lysosomalpH forB2 cells (pH4.5; Figure 4.3g, h). Weexpected that adysfunc-
tional V-ATPase assembly in TMEM199KOwould result in an increased intraorganellar
pH due to defective acidification. However, our results contrast this hypothesis as we
observed stronger acidification along the entire secretory pathway.
As the observed misregulation of pH might already mislocalize the probes we ap-
plied to measure intraorganellar pH, it is possible that the localization of the probes
in the B1 and B2 cells does not reflect the same localization as in the parental cells.
Thus, we developed a different strategy for assessing V-ATPase activity by measuring
intraorganellar pH in the absence or presence of the V-ATPase inhibitor Bafilomycin
A1 (BafA1)289. We reasoned that if less V-ATPase molecules are present in organellar
membranes, the difference in luminal pH (∆pH) between BafA1-treated cells and the
DMSO control should be lower. For ER-RpHLuorin2 expressed in parental HeLa cells,
we measured a lower luminal pH when treated with only DMSO compared to our pre-
vious measurements (pH 6.4 with DMSO compared to pH 7.4; Figure 4.4a, Supplemen-
tary Figure 4.10a), likely as a result of DMSO treatment, and this increased to pH 6.5
when incubated with 200 nM BafA1. Similar results with DMSO were observed for the
B1 and B2 cells (pH 6.3 and pH 6.1 respectively), but∆pH was slightly decreased in B1
cells compared to parental HeLa, but somewhat increased in B2 cells (Figure 4.4a, b,
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Figure 4.3: Decreased luminal pH in TMEM199KOHeLa cells. (a)Representative confocal micrographs of
parental HeLa cells (P, green) or TMEM199KO cells (B1 and B2, orange) expressing ER-RpHLuorin2. The
intensity image (left column) was convolutedwith the fluorescence lifetime value (middle column) and the
calculated pH (right column) per pixel. FLIM, fluorescence lifetime imagingmicroscopy. Scalebars, 10µm. (b)
Quantification of average pH values from panel (a). N = 79 (P), 80 (B1), and 80 (B2) from 3 independent exper-
iments. (c) Same as panel (a) but now forMGAT2-RpHLuorin2. (d)Quantification of average pH values from
panel (c). N = 117 (P), 97 (B1), and 72 (B2) from 3 independent experiments. (e) Same as panel (a) but now for
GalT-RpHLuorin2. (f)Quantification of average pH values from panel (e). N = 65 (P), 72 (B1), and 52 (B2) from
3 independent experiments. (g) Same as panel (a) but now for LAMP1-RpHLuorin2. (h)Quantification of aver-
age pH values from panel (g). N = 123 (P), 111 (B1), and 147 (B2) from 3 independent experiments.
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Figure 4.4: FLIM-based pHmeasurements in TMEM199KOHeLa cells challengedwith V-ATPase inhibitor
Bafilomycin A1. (a)Representative confocal micrographs of parental HeLa cells (P, green) or TMEM199KO
cells (B1 and B2, orange), in the absence (DMSO) or presence of Bafilomycin A1 (200 nMBafA1). The intensity
image (left column) was convolutedwith the fluorescence lifetime value (middle column) and the calculated
pH (right column) per pixel. FLIM, fluorescence lifetime imagingmicroscopy. Scalebars, 10µm. (b)Quantifica-
tion of the difference in pH (∆pH) between vehicle control (DMSO) and cells challengedwith Bafilomycin
A1 from panel (a). N = 84 (P, DMSO), 62 (P, 200 nMBafA1), 41 (B1, DMSO), 46 (B1, 200 nMBafA1), 43
(B2, DMSO), and 50 (B2, 200 nMBafA1) from 2 independent experiments. (c) Same as panel (a) but now for
MGAT2-RpHLuorin2. (d)Quantification of the difference in pH (∆pH) between vehicle control (DMSO) and
cells challengedwith Bafilomycin A1 from panel (c). N = 72 (P, DMSO), 77 (P, 200 nMBafA1), 78 (B1, DMSO),
46 (B1, 200 nMBafA1), 63 (B2, DMSO), and 71 (B2, 200 nMBafA1) from 2 independent experiments.
Supplementary Figure 4.10a). We observed similar results for cis-/medial-Golgimarker
MGAT2-RpHLuorin2, where∆pHwas significantly decreased for B1 cells but slightly in-
creased for B2 cells (Figure 4.4c, d, Supplementary Figure 4.10b). Finally, we performed
the same assay for trans-Golgi marker GalT-RpHLuorin2. Here we observed a small in-
crease in∆pH for B1 cells but BafA1-sensitivitywas absent for B2 cells (Supplementary
Figure 4.10c-e). Theobserved increase in∆pH for the B2 cells inbothERandearly Golgi
compartments does not support a role of TMEM199 inV-ATPase assembly but suggests
aberrant traffickingand/orprocessingof theV-ATPaseasmoreV-ATPasemoleculesap-
pear to be present on the ERmembrane. Concurrently, less V-ATPasemight be present
on GalT-positive compartments which could indicate a disorganization of the pH gra-
dient in the secretory pathway.
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4.3.4 Biochemical investigations of the role of TMEM199 in V-ATPase assembly
Prior to V0 – V1 assembly, the V0 domain is first assembled in the ER69,101,102,290. Pre-
vious studies have shown that the stability of the V0a subunits is dependent on this
assembly of the V0 domain, resulting in degradation of the V0a subunits when the V0
domain is not assembled101,102. We investigated the stability of endogenous V0a1-3 in
the parental HeLa cells and the B1 and B2 cells when chased with ribosomal inhibitor
cycloheximide (Figure 4.5a-d). Stability of the subunits V0a1 and V0a3 was not visibly
altered between parental HeLa cells, B1 and B2 cells (Figure 4.5a, b, d). However, we
did observe lower stability of the Golgi- and endosome-localized V0a2 subunit in both
TMEM199knockout strains (Figure 4.5a, c), suggesting that TMEM199mightbe involved
in the assembly of a Golgi- and endosome-specific V0-domain.
To investigate whether these results have any implication on overall V0 – V1 as-
sembly, we fractionated parental HeLa, B1 and B2 cells into membrane and cytoso-
lic fractions following intracellular crosslinking with dithiobis(succinimidyl propi-
onate) (DSP) (Figure 4.5e, f). We then quantified the relative amounts of the V1A sub-
unit from the cytosolic V1 domain present in themembrane fraction and observed an
unsignificant trend towards more overall V0 – V1 assembly in the TMEM199KO cells.
These results suggest that although less V0a2-specific assemblymight occur, complete
V-ATPase assemblymight be somewhat increased.
Finally, as it is known that cytosolic CCDC115 can interact with the integral mem-
brane protein TMEM199125 , we investigated whether CCDC115 would be associated
with the membrane fractions. From yeast it is understood that cytosolic Vma22p can
associate withmembrane Vma12p122 and this interaction is required for V-ATPase as-
sembly inyeast. Thus,wehypothesized thata similar interaction is important inmam-
malian cells and that the loss of TMEM199 should cause lessmembrane association of
CCDC115. We interrogated the presence of CCDC115 in the earlier obtainedDSP-treated
membrane fractions andwe observed slightly less CCDC115 in themembrane fraction
of B1 cells, and almost no CCDC115 in the membrane fraction of B2 cells (Figure 4.5g).
We did not observe CCDC115 in the cytosolic fraction, which could be an indication of
cytosolic instability of CCDC115. Taken together, these results suggest that TMEM199
might be important for the specific assembly of a V0a2-containing V-ATPase, possibly
together with CCDC115.
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Figure 4.5: The role of TMEM199 inmammalian V-ATPase assembly. (a)Representative immunoblot of
cell lysates for the stability of V-ATPase subunits V0a1, V0a2, and V0a3, in parental HeLa cells (P, green) or
TMEM199KO cells (B1 and B2, orange) treated with cycloheximide (CHX) for the times indicated. GAPDH,
loading control. (b)Quantification of panel (a) for V0a1. Protein expression levels were normalized to GAPDH
signal. Data from 2 independent experiments. (c) Same as panel (b) but now for V0a2. (d) Same as panel (b)
but now for V0a3. (e)Representative immunoblot of V-ATPase subunit V1A inmembrane (M) and cytosolic
(C) fractions of cell lysates from parental HeLa cells (P, green) or TMEM199KO cells (B1 and B2, orange) after
crosslinking with DSP.Membrane and cytosolic fractions were obtained by ultracentrifugation. (f)Quantifi-
cation of panel (e). Each point represents the percentage of the V1Amembrane fraction, obtained by dividing
themembrane signal by the total V1A signal (membrane + cytosolic fraction) from one experiment. Data from
4 independent experiments. (g)Representative immunoblot of CCDC115 inmembrane (M) and cytosolic (C)
fractions of cell lysates from parental HeLa cells (P, green) or TMEM199KO cells (B1 and B2, orange) after
crosslinking with DSP.Membrane and cytosolic fractions were obtained by ultracentrifugation.
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4.4 Discussion
In this study, we investigated the function of TMEM199 in intraorganellar acidifica-
tion. The yeast homolog of TMEM199, Vma12p, is a known assembly factor of the V-
ATPase122,124 and is thereby involved in luminal pH maintenance. Our findings sug-
gest a specific role for TMEM199 in assembly of V0a2-containing V-ATPase, but not
or less V-ATPases with the other three V0a subunits in mammalian cells74–79. This
specific role seems to contrast yeast where Vma12p has a more general function in
V-ATPase assembly122,124.
In some of our experiments, we observed opposite phenotypes for the two
TMEM199KO strains: the subcellular localization of glycosyltransferases and the pH
measurements upon Bafilomycin A1 treatment were significantly altered in opposite
directions for the two strains. This might be a consequence of off-target effects of
the gRNA in one of these strains. Alternatively, the contrasting phenotypes could be
caused by the different residual expression of TMEM199, as strain B1 had somewhat
higher levels of TMEM199 than B2. This might result in differences of residual V-
ATPaseactivity andcause thedifferent luminalpHvalues and subcellular localization
of the glycosyltransferases. Moreover, Golgi pH is not only regulated by the V-ATPase,
but partly also by passive backflux of H+ ions and by ion channels such as GPHR291.
The activity and/or localization of these factorsmight also be sensitive to the levels of
V-ATPase activity, and thereby contribute to the different phenotypes observed in the
two TMEM199KO strains.
TMEM199 has been shown tomediate the V0 – V1 assembly in human lung adeno-
carcinoma A549 cells129. However, we were not able to observe this with our TMEM199
knockout HeLa models but instead mostly observed a lower intraorganellar pH, sug-
gesting elevated V-ATPase activity, at the ER and early Golgi compartments. The regu-
lation and function of the V-ATPase is altered in different kinds of tumor cells276 and
this might explain the differences observed between HeLa cells and A549 cells lack-
ing TMEM199. An important finding is the specific degradation of V0a2 in TMEM199-
lacking cells. Therefore, a possible explanation for the discrepancy between our study
and previous findings in A549 cells129 , could be that A549 cells are more dependent
on the V0a2-definedV-ATPase and are thereforemore sensitive to the loss of TMEM199.
HeLa cells might then bemore dependent on other V0a subunits, meaning the loss of
the V0a2-defined V-ATPase would not result in a loss of acidification.
However, we even observed an increased acidification in the ER and early Golgi
compartments inHeLa cells lacking TMEM199, suggesting that there ismore V-ATPase
present on these organellar membranes upon loss of TMEM199. This conclusion was
strengthened by the increased sensitivity of ER-localized V-ATPase to Bafilomycin A1
4
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in one of the TMEM199KO strains. One possibility for the increased luminal acidifica-
tion in TMEM199KO is that there might be increased assembly of V-ATPases, perhaps
as a compensatorymechanism for the reductionof theV0a2-containingV-ATPase. An-
other possibility is that TMEM199 is involved in the trafficking of the V-ATPase from
the ER to other organelles, and lack of TMEM199 results in elevated levels and activity
of the V-ATPase in the ER and early Golgi compartments.
The fractionationstudieswepresented in this study revealedapotentialmolecular
mechanismfor thephenotypesobserved inTMEM199-CDGpatients121. Our results sug-
gest that CCDC115 is recruited tomembranesby TMEM199. Mutations inbothCCDC115
and TMEM199 are a cause of glycosylation disorders, although the pathological condi-
tion inTMEM199-CDGseemmore limited (mostlyhepatological involvement)121 , while
CCDC115-CDG is characterized by more severe symptoms including neurological in-
volvement120. An explanation for this difference could be that there is anothermech-
anism for CCDC115 to exert its function in absence of TMEM199. Another, more likely,
explanation is that the genetic variants found in TMEM199-CDG patients still produce
TMEM199 protein, but that the binding affinity with for instance CCDC115 is reduced.
This might result in amilder phenotype for TMEM199-CDG than for CCDC115-CDG.
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4.5 Methods
4.5.1 Cell culture and transfection
HeLa cells (authenticated by ATCC through their human STR profiling cell authen-
tication service) and derived TMEM199KO cells were maintained in high glucose
DMEM with Glutamax (Gibco 31966021), supplemented with 10% fetal calf serum
(FCS, Greiner Bio-one, Kremsmünster, Austria) and antibiotic-antimycotic solution
(Gibco 15240-062). Cells were regularly tested for mycoplasma contamination. Cells
were transfected with plasmid vectors using Fugene HD (Promega E2311), using the
recommended protocol of the manufacturer. Cells were processed 48 hours post-
transfection. Only cells expressing low tomoderate levels of the transfected plasmids,
basedonfluorescence intensity andmanual localization scoring, were chosen for sub-
sequentmicroscopic analyses.
4.5.2 Antibodies
The following primary antibodies and dilutions were used in this study: rabbit
polyclonal anti-TMEM199 (Novus Biological, NBP1-88467, 1:250), rat monoclonal anti-
α-Tubulin (YOL1/34, Novus Biologicals NB100-1639, 1:2000) rabbit monoclonal anti-
MGAT1 (Abcam, ab180578, 1:100), mouse monoclonal anti-GALNT2 (1501421, Biole-
gend 682302, 1:100), mouse monoclonal anti-B4GALT1 (GT2/36/118, Enzo ALX-803-339-
c050, 1:100), mousemonoclonal anti-GM130 (35/GM130, BD Transduction Laboratories
610822, 1:100), rabbit polyclonal anti-ZFPL1 (SigmaHPA014909, 1:100), sheeppolyclonal
anti-TGN46 (BioRad AHP500GP, 1:1000), rabbitmonoclonal anti-GAPDH (14C10, Cell Sig-
naling Technology 2118, 1:2000), rabbit polyclonal anti-V0a1 (Novus Biological NBP1-
89342, 1:500), rabbit polyclonal anti-V0a2 (Novus Biological NBP1-59069, 1:500), mouse
monoclonal anti-V0a3 (Novus Biological H00010312-M01, 1:500), mouse monoclonal
anti-V1A (4F5, Santa Cruz Biotechnology sc-293336, 1:500), and rabbit polyclonal anti-
CCDC115 (Proteintech, 20636-1-AP, 1:250).
4.5.3 CRISPR/Cas9
Knockout of TMEM199 inHeLa cellswas achievedusingCRISPR/Cas9. Weused theprior
described gRNA sequence: 5’ – TATGG CGTCC TCTTT GCTTG CGG125. The gRNA sequence
was cloned in eSpCas9(1.1) (Gift from Feng Zhang, Addgene no. 71814)292 and trans-
fected into HeLa cells by Fugene HD (Promega). 72 hrs after transfection, the medium
of puromycin-resistant cells was changed for conditioned medium (collected from
parental HeLa cells at 70% confluency) supplemented 1:1 with fresh medium. Single
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clones were obtained and screened for knockout of TMEM199 by SDS-PAGE and West-
ern blotting and finally validated by Sanger sequencing. Residual TMEM199might be
a consequence of contamination by parental HeLa cells during cell culture.
4.5.4 Lectin stainings
Cells were plated in 6-well plates and incubated until confluent (≈72 h). Cells were
released from the culture substrate with 2 mM EDTA in PBS. Cells were then blocked
with Carbo-Free blocking solution (Vector Laboratories, SP-5040) and incubated with
and incubated with 4 µg/mL biotinylated SNA-I (Vector Laboratories, B-1305) diluted
in Carbo-Free Blocking solution. Cells were then incubated with Streptavidin-Alexa
Fluor 647 (ThermoScientific, S32357) and finally resuspended in FACS buffer (phos-
phate buffered saline + 0.5% FBS + 0.01% NaN3), supplemented with 300 ng/mL 4′,6-
diamidino-2-phenylindole (DAPI) for live/dead discrimination. Samples were run on
a FACSLyric flow cytometer (BD Biosciences) and analyzed with FlowJo X (FlowJo, LLC).
4.5.5 pHmeasurements
pH measurements were performed as described previously288. Briefly, RpHLuorin2-
tagged constructs were transiently overexpressed in cells followed by FLIM. The life-
time values were subsequently calculated to pH values using the prior generated cal-
ibration curve288. For the Bafilomycin A1 experiments, cells were pre-incubated with
200 nMBafilomycin A1 (CaymanChemical) or DMSO (ThermoFisher) for 1 hour at 37°C.
4.5.6 Confocal microscopy
Imaging of cells was performed in Leibovitz’s L-15 medium (Gibco). All confocal mi-
croscopy was performed a Leica SP8 SMD system at 37°C, equipped with an HC PL APO
CS2 63×/1.20 WATER objective. pHLuorin2 was excited at 488 nm with a pulsed white
light laser, operating at 80 MHz. Photons were collected for one minute or 30 seconds
for time-lapse experiments with a HyD detector set at 502 – 530 nm and lifetime his-
togramsof thedonorfluorophorewerefittedwith amonoexponential decay function
convoluted with the microscope instrument response function in Leica LAS X. For re-
constructing the images, tiff files with τ values were generated using FLIMFit284 and
2 × 2 spatial binning, and then convoluted with the fluorescent intensities using a
custom-written ImageJ macro.
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4.5.7 Immunofluorescence
Immunofluorescence experiments for glycosyltransferase localization were per-
formed as described previously207.
4.5.8 Crosslinking and cell fractionation
Cells were plated in 10 cm dishes and cultured until confluent. Once confluent,
cells were harvested by washing twice in ice-cold PBS followed by scraping into
homogenization buffer (250 mM sucrose, 10 mM N-[2-hydroxyethyl]-piperazine-N-[2-
ethanesulfonic acid] (HEPES), 1 mM Ethylenediaminetetraacetic acid (EDTA) and pro-
tease inhibitor cocktail (Roche)). Intracellular proteinswere subsequently crosslinked
with 500 µM dithiobis(succinimidyl propionate) in DMSO at RT for 30 mins with agi-
tation. The crosslinking reaction was then quenched by addition of Tris pH 7.6 to a
final concentration of 20mM and 15mins incubation at RT with agitation. Cells were
lysed by passing through a 25G needle sixteen times. Post-nuclear supernatants were
acquired by centrifuging at 500 × g for 10 mins. The supernatant was subsequently
ultracentrifuged at 100,000× g for 30mins to pellet themembrane fraction. Themem-
branepelletwas rinsed oncewithhomogenizationbuffer and resuspended inhomog-
enization bufferwith 1%SDS. Protein contentwas thendetermined and sampleswere
subsequently analyzed by SDS-PAGE and immunoblotting.
4.5.9 SDS-PAGE and immunoblotting
Whole cell lysates were prepared using SDS lysis buffer (1% SDS in 10 mM Tris-HCl pH
6.8). Prior to SDS-PAGE, protein concentrations were determined using the Micro BCA
assay (ThermoFisher).
4.5.10 Quantification and statistical analysis
Statistical analysis of three or more groups was performed using pair-wise t-tests, fol-
lowed by p-value adjustment using Bonferroni’s method. p < 0.05 was considered sig-
nificant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p ≤ 0.0001. All statistical analyses were
performed using R statistical software, using the ggpubr package. All numerical data
were visualized using R package ggplot2286 , with violins representing the overall dis-
tribution of the data andmeans ± 95% CI overlaid.
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4.6 Supplementary Information
Figure 4.6: FACS gating strategy for lectin stainings. The cell population shown is of the parental sample
shown in Figure 4.1b. FSC-A: forward scatter area, SSC-A: side scatter area, FSC-H: forward scatter height.
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Figure 4.7: Relocation of glycosyltransferase B4GALT1 in TMEM199KOHeLa cells. (a) Immunofluores-
cencemicroscopy of B4GALT1 (green inmerge) and ZFPL1 (magenta) in parental HeLa cells (green, P) or
TMEM199KO cells (B1 and B2, orange). Representative confocal micrographs. Scalebars, 10µm. DAPI in blue.
(b) Pearson’s correlation coefficients between B4GALT1 and ZFPL1 of panel(a). N = 194 (P), 138 (B1), and 147
(B2) from two independent experiments. (c) Same as panel (a) but now for B4GALT1 (green) and TGN46 (ma-
genta). (d) Pearson’s correlation coefficients between B4GALT1 and TGN46 of panel (c). N = 139 (P), 154 (B1),
and 161 (B2) from two independent experiments.
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Figure 4.8: Relocation of glycosyltransferase GALNT2 in TMEM199KOHeLa cells. (a) Immunofluores-
cencemicroscopy of GALNT2 (green inmerge) and ZFPL1 (magenta) in parental HeLa cells (green, P) or
TMEM199KO cells (B1 and B2, orange). Representative confocal micrographs. Scalebars, 10µm. DAPI in
blue. (b) Pearson’s correlation coefficients between GALNT2 and ZFPL1 of panel (a). N = 142 (P), 65 (B1), and
117 (B2) from two independent experiments. (c) Same as panel (a) but now for GALNT2 (green) and TGN46
(magenta). (d) Pearson’s correlation coefficients between GALNT2 and TGN46 of panel (c). N = 170 (P), 101
(B1), and 154 (B2) from two independent experiments.
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Figure 4.9: Altered glycosyltransferase expression and Golgi morphology in TMEM199KOHeLa cells. (Con-
tinued on the following page.)
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Figure 4.9: (a) Fluorescence intensities ofMGAT1 from Figure 4.2 relative to parental HeLa cells. N = 193 (P),
146 (B1), 198 (B2). (b) Same as panel (a) but now for B4GALT1 from Supplementary Figure 4.7. N = 333 (P),
226 (B1), 308 (B2). (c) Same as panel (a) but now for GALNT2 from Supplementary Figure 4.7. N = 312 (P), 166
(B1), 271 (B2). (d) Same as panel (a) but now for GM130 from Figure 4.2. N = 118 (P), 78 (B1), 99 (B2). (e) Same
as panel (a) but now for ZFPL1 from Supplementary Figures 4.7 and 4.8. N = 336 (P), 203 (B1), 264 (B2). (f)
Same as panel (a) but now for TGN46 from Figure 4.2 and Supplementary Figures 4.7 and 4.8. N = 384 (P), 257
(B1), 414 (B2). (g)Quantification of GM130 fluorescence labeling area from Figure 4.2. N = 118 (P), 78 (B1), 99
(B2). (h) Same as panel (g) but now for ZFPL1 from Supplementary Figures 4.7 and 4.8. N = 336 (P), 203 (B1),
264 (B2). (i) Same as panel (g) but now for TGN46 from Figure 4.2 and Supplementary Figures 4.7 and 4.8. N =
384 (P), 257 (B1), 414 (B2).
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Figure 4.10: FLIM-based pHmeasurements in TMEM199KOHeLa cells challengedwith V-ATPase inhibitor
Bafilomycin A1. (Continued on the following page.)
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Figure 4.10: (a) Full quantification of pH from Figure 4.4a. The values presented here were used to gener-
ate the∆pH plot. (b) Same as panel (a) but now for Figure 4.4c. (c)Representative confocal micrographs of
parental HeLa cells (P, green) or TMEM199KO cells (B1 and B2, orange) expressing GalT-RpHLuorin2, in the
absence (DMSO) or presence of Bafilomycin A1 (200 nMBafA1). The intensity image (left column) was con-
volutedwith the fluorescence lifetime value (middle column) and the calculated pH (right column) per pixel.
FLIM, fluorescence lifetime imagingmicroscopy. Scalebars, 10µm. (d) Same as panel (a) but now for panel
(c). (e)Quantification of the difference in pH (∆pH) between vehicle control (DMSO) and cells challenged
with Bafilomycin A1 from panel (c). N = 68 (P, DMSO), 50 (P, 200 nMBafA1), 48 (B1, DMSO), 49 (B1, 200 nM
BafA1), 46 (B2, DMSO), and 44 (B2, 200 nMBafA1) from 2 independent experiments.
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5.1 Abstract
The soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE)
syntaxin 5 (Stx5) in mammals and its ortholog Sed5p in Saccharomyces cerevisiae me-
diate anterograde and retrograde endoplasmic reticulum (ER)-Golgi trafficking. Stx5
and Sed5p are structurally highly conserved and are both regulated by interactions
with other ER-Golgi SNARE proteins, the Sec1/Munc18-like protein Scfd1/Sly1p and the
membrane tethering complexes COG, p115, and GM130. Despite these similarities,
yeast Sed5p and mammalian Stx5 are differently recruited to COPII-coated vesicles,
and Stx5 interacts with the microtubular cytoskeleton, whereas Sed5p does not. In
this review, we argue that these different Stx5 interactions contribute to structural
differences in ER-Golgi transport between mammalian and yeast cells. Insight into
the function of Stx5 is important given its essential role in the secretory pathway of
eukaryotic cells and its involvement in infections and neburodegenerative diseases.
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5.2 Introduction
The secretory pathway is essential for secretion of cytokines, hormones, growth fac-
tors, and extracellular matrix proteins, as well as for the delivery of receptors and
transporters to the cell membrane and lytic proteins to endo-lysosomal compart-
ments. Proteins destined for the secretory pathway are synthesized at the endoplas-
mic reticulum (ER) and subsequently transported to their destinationbyvesicular traf-
ficking via the cis- to medial- to trans-Golgi cisternae and finally to the trans-Golgi
network14,202,293. ER-Golgi transport has beenmostly studied inmammalian cells and
the yeast Saccharomyces cerevisiae, andalthough thebasicmechanismsof this ER-Golgi
trafficking are well conserved among eukaryotic cells, there are three pronounced dif-
ferences between the yeast S. cerevisiae andmammalian cells (Figure 5.1).
The first difference concerns the spatial organization of the Golgi apparatus. In
most mammalian cell types, a single large Golgi apparatus is juxtaposed with the nu-
cleus and surrounds themicrotubule organizing center (MTOC)14–16. In contrast, in S.
cerevisiae, the Golgi is organized into discrete cisternae, consisting of individual cister-
nae that are scattered throughout the cytoplasm,while inother yeast, suchasbudding
Pichia pastoris and Schizosaccharomyces pombe, the Golgi is present asmini-stacks that
are dispersed in the cytoplasm15,16.
The second difference is the presence of an intermediate compartment between
the ER and cis-Golgi in mammals called the ER-Golgi intermediate compartment (ER-
GIC) or vesicular-tubular cluster (VTC)63. Yeast does not have an ERGIC, and antero-
grade trafficking from the ER occurs directly to the cis-Golgi294 via vesicles coatedwith
the cage protein complex COPII, while retrograde trafficking in the reverse direction
occurs via vesicles coated with COPI14,15. Inmammalian cells, anterograde trafficking
from the ER also occurs via COPII-coated vesicles, but in this case, proceeds to the ER-
GIC14–16 In mammalian cells, not only retrograde trafficking from the ERGIC back to
the ER but also further anterograde trafficking to the cis-Golgi might occur via COPI-
coated vesicles64.
A final difference in ER-Golgi trafficking is the involvement of microtubules in
mammalian cells, but not in yeast14–16.
In this review, we argue that thesemechanistic differences betweenmammals and
yeast are partly attributable to one of the central players in ER-Golgi trafficking: the
SNARE protein syntaxin 5 (Stx5) inmammals and its yeast ortholog Sed5p.
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Figure 5.1: Schematic overview of the early secretory pathway in Saccharomyces cerevisiae (A) andmam-
malian cells (B).Abbreviations: ER, endoplasmic reticulum; ERES, endoplasmic reticulum exit sites; ERGIC,
endoplasmic reticulum-Golgi intermediate compartment; MT, microtubule; MTOC, microtubule organizing
center; TGN, trans-Golgi network.
5.3 SNARE Proteins in ER-Golgi and Intra-Golgi Transport
The SNARE protein family consists of about 38 members in humans and about 24 in
yeast and is responsible for most intracellular fusion events of organellar traffick-
ing57,58,118. The central hallmark of SNAREproteins is the presence of one or two SNARE
motifs of 50–70 residues in size. Based on the structures of these motifs, SNAREs can
be grouped into R-SNAREs, with an arginine residue located at the center of the SNARE-
motif, and Qa-, Qb- and Qc-SNAREs, with a central glutamine residue57,58. Membrane
fusion requires three or four cognate SNARE proteins that together contribute four
SNARE motifs, one of each group (R, Qa, Qb, Qc). For membrane fusion, these cog-
nate SNARE proteins need to be anchored to both the donor membrane (e.g., COPII
vesicle) and acceptor membrane (e.g., cis-Golgi) via a C-terminal transmembrane he-
lix or by lipidmodifications57,58. SNAREs in the donormembrane are called v-SNAREs
(vesicular-SNAREs) and SNAREs in the acceptor membrane t-SNAREs (target-SNAREs).
Cognate SNAREproteins can forma tightα-helical coiled-coil bundle, called the SNARE
complex, whichovercomes the energy barrier ofmembrane fusion. In addition to this,
the fusogenic activity of ER-Golgi SNAREs is tightly regulated by numerous interacting
proteins and by N-terminal-regulatingmotifs, which are present onmost SNAREs57,58.
After membrane fusion, the SNARE complex is disassembled by the AAA ATPase N-
ethylmaleimide-sensitive factor (NSF) in mammals and Sec18p in yeast, which are re-
cruited by the adaptor protein-soluble NSF-attachment protein α (α-SNAP) in mam-
mals and Sec17p in yeast57,58.
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In mammalian cells, the Qa-SNARE Stx5 is an integral component of ER-derived
COPII transport vesicles and is required for the docking and fusion of these vesicles to
assemble the ERGIC64,295 by forming a SNARE complexwith GosR2 (GS27, membrin; Qb-
SNARE) or GosR1 (GS28; Qb), Bet1 (Qc), and Ykt6 (R) or Sec22b (Ers24; R) (Figure 5.2)194–200.
This process is well conserved in yeast, where the fusion of COPII vesicles is believed
to occur directly at the Golgi294 by interactions of the orthologs of the mammalian
SNAREs Sed5p (Qa), Bos1p (Qb), Bet1p (Qc), and Sec22p (R)201,296,297. Stx5/Sed5p is not
involved in COPI-mediated retrograde transport from the Golgi to the ER, but this is
mediated by Stx18 (Qa), Sec20 (Qb), Use1 (Qc), and Sec22b (R) in mammals and Ufe1p
(Qa), Sec20p (Qb), Use1p (Qc), and Sec22p (R) in yeast202,203,298. However, Stx5 is involved
in COPI-dependent intra-Golgi retrograde trafficking between cisternae and/or retro-
grade trafficking fromendosomes to the trans-Golgi networkby forminga SNARE com-
plex with GosR1 (Qb), Bet1L (GS15; Qc), and Ykt6 (R)195,198,202,204–206. In yeast, intra-Golgi
retrograde trafficking is mediated by Sed5p forming a SNARE complex with Gos1p
(Qb), Sft1p (Qc), and Ykt6p (R)202,208,210. Anterograde vesicular trafficking is in principle
not required for intra-Golgi transport, as in the widely-accepted cisternalmaturation
model, the cisternaeareverydynamicentities, constantly formingat the cis-sidebyho-
motypic or/andheterotypic vesicular fusion, anddisassembling into anterograde and
retrogrademembrane carriers at the trans-side14. In thismodel, all intra-Golgi vesicu-
lar traffic is going in a retrograde direction to recycle Golgi enzymes, cargo receptors
and SNAREs14. In contrast, according to the vesicular transport model, the cisternae
are relatively static with a constant enzyme composition. In this case, the cisternae
accept anterograde vesicleswith cargomolecules and shed retrograde vesicleswith re-
cycling SNAREs and cargo receptors14. In favor of the vesicular transport model, Stx5
was found to mediate anterograde trafficking within the Golgi, at least in Drosophila
melanogaster 299.
Both knockdown and overexpression of Stx5 induce Golgi fragmentation inmam-
malian cells196,300,301 and D. melanogaster 302. Because ER-Golgi transport is at the base
of most exocytic trafficking, knockdown of Stx5 also causes downstream defects in
lysosomal trafficking and autophagy303. In yeast, Sed5p is rate-limiting for ER-Golgi
transport, because overexpression of Sed5p and to a lesser extent other SNAREs in-
volved in ER-Golgi trafficking (Bos1p, Bet1p, Sec22p) resulted in higher secretion of
overexpressed cellulase304. Most importantly, Stx5/Sed5p is an essential protein, and
Stx5/Sed5p knockout is lethal for mammalian cells305 and yeast306 , while the STX5
gene knockout is not viable for mice307 and D. melanogaster 308.
Thereare twonotabledifferencesbetween the functionof SNAREs inER-Golgi trans-
port and exocytic and endocytic trafficking. First, inmammals, Bet1 is proposed to be
the v-SNARE for anterograde trafficking200,202,204–206 , although another study reported
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Figure 5.2: Schematic overview of SNARE complexes of the early secretory pathway in Saccharomyces cere-
visiae (A) andmammalian cells (B). The grey boxes indicate the known SNARE complexes and their location
along the secretory pathway. Colors of the SNAREs: red, Qa-SNAREs; dark green, Qb-SNAREs; light green,
Qc-SNAREs; blue, R-SNAREs. Abbreviations: ER, endoplasmic reticulum; ERGIC, endoplasmic reticulum-Golgi
intermediate compartment; TGN, trans-Golgi network.
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that this is Sec22b194 , and Bet1L is the v-SNARE for retrograde trafficking in intra-Golgi
transport200,202,204–206. Similarly, in yeast, the v-SNAREs for antero- and retrograde
traffic are the yeast orthologs Bet1p and Sft1p, respectively208–210. This differs from
other described SNARE-mediated trafficking routes, where R-SNAREs generally act as
v-SNAREs, e.g., synaptobrevin in exocytosis, and the Qa-, Qb-, and Qc-SNAREs form an
acceptor t-SNARE complex in the target membrane57,58,118. The second difference is in
thepromiscuityof SNAREs. Most SNAREs involved inexocytic andendocytic trafficking
areverypromiscuous, andnearly every combinationofaQa-, Qb-, Qc-, andR-SNAREcan
form a SNARE complex in vitro118. Because of this promiscuity, exocytic and endocytic
SNAREs are often functionally redundant, and knockout or knockdown mostly has
no or a very minor phenotype118. This is different for Stx5/Sed5p and other ER-Golgi
SNAREs, which have been shown in in vitro studies to be highly stringentwith purified
Sed5ponlybeingable to formaSNAREcomplexwithother SNAREs involved inGolgi-ER
trafficking Gos1p (Qb), Bos1p (Qb), Sft1p (Qc), Bet1p (Qc), Ykt6p (R), and Sec22p (R)309,310.
In line with this, Sed5p forms two distinct non-overlapping Golgi SNARE complexes in
vivo (Sed5p-Bos1p-Bet1p-Sec22p and Sed5p-Gos1p-Ykt6p-Sft1p)210.
In contrast to Stx5, which distributes evenly throughout the Golgi stack, electron
microscopy revealed that Bet1L and Bet1 have opposite distributions within the Golgi
stack with Bet1L more present at the trans-Golgi and Bet1 more present at the cis-
Golgi205. This finding is the base of the SNARE gradient model, where retrograde
trafficking is mediated by SNARE complex formation of Bet1L with Stx5, GosR1, and
Ykt6 and anterograde trafficking by complex formation of Bet1 with Stx5, GosR2, and
Sec22b202,205,293. Electron microscopy also revealed that within each Golgi layer, the
SNAREsare alsoheterologouslydistributedwithBet1L, Stx5, andGosR1more located to
the center of each stack, whereas Bet1, Sec22b, andGosR2 locatemore to the rimswhere
they can bemore efficiently incorporated into transport vesicles311. As Bet1 and Bet1L
mediate anterograde and retrograde intra-Golgi trafficking, respectively200,202,204–206 ,
this finding suggests that SNAREs involved in retrograde trafficking might be Golgi
resident, whereas the SNAREs involved in anterograde trafficking might dynamically
cycle through the Golgi layers. However, it is unclear how this relates to the cisternal
maturationmodel that mainly relies on retrograde vesicular transport and in princi-
ple does not require any anterograde intra-Golgi vesicular transport14.
Stx5 is also involved in ER-Golgi trafficking of specialized cargo molecules. First,
Stx5 is required for ER exit of pro-collagens, which are too large to fit in COPII trans-
port vesicles, because its knockdown results in a reduction of pro-collagen I and VII
secretion and accumulation of these pro-collagens in the ER312. Second, Stx5 medi-
ates the specific export of very low-density lipoproteins (VLDLs) from the ER. VLDLs are
synthesized in the ER of liver cells and then transported to the Golgi prior to secretion
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at the plasmamembrane. This transport occurs via unique ER-derived vesicles called
VTVs (VLDL-transport vesicles)313. These vesicles differ from the other protein export-
ing vesicles as they are larger, have a lower buoyant density, and have different cargo
and protein compositions313. It was found that VTVs contain Sec22b, which is able
to make a SNARE complex at the cis-Golgi together with Stx5, GosR1, and Bet1314. Stx5
is able to bind to the cytoplasmic C-terminal domain of the VLDL receptor (VLDL-R),
thereby influencing the receptor’s glycosylation and trafficking315. Overexpression of
Stx5 was found to prevent Golgi-maturation of VLDL-R and resulted in the decreased
presence of VLDL-R at the trans-Golgi315. However, VLDL-R did not accumulate at the
ER nor Golgi and was still translocated from the ER to the cell surface, indicating that
overexpressionof Stx5 resulted in circumventionof the regular secretorypathwayand
immature VLDL-R reached the cell surface via an alternative pathway315. In addition
to VLDL, Stx5 mediates trafficking of another lipoprotein in intestinal cells. Dietary
long-chain fatty acids are esterified to triacylglycerol and packaged in the chylomi-
cron, which is the unique lipoprotein of the intestine. Rate-limiting for the transit of
chylomicrons through the enterocyte is the exit of chylomicrons from the ER to the cis-
Golgi in specialized 250 nm-sized transport vesicles. This process involves a t-SNARE
complex of Stx5, Vti1a, and Bet1 and the v-SNARE VAMP7, which, based on inhibition
of these SNAREswith antibodies, is believed tomediate the fusionof the chylomicrons
with the cis-Golgi316. Note that in contrast to canonical ER-Golgi transport, where Bet1
acts as the v-SNARE200,202,204–206 , in these lipoprotein trafficking routes, Bet1 is believed
to act as a t-SNARE together with Stx5. However, this has never been studied side-by-
side with the same assays, and whether the dual function as Bet1 as both a t- and v-
SNARE is true remains to be established.
5.4 Subcellular Localization of Stx5 Isoforms
In mammalian cells, translation of Stx5 can occur at two different starting methion-
ines resulting in two distinct isoforms: a 34.1-kDa short isoform of 301 residues and
a 39.6-kDa long isoform that is extended by 54 N-terminal residues (Figure 5.3)215. In
yeast, only a single 38.8-kDa and 340 residue-long isoformof Sed5p is expressed, which
corresponds to the short isoformof Stx5 inmammalian cells. Both the short and long
Stx5 isoforms in mammalian cells and yeast Sed5p are so-called tail-anchored pro-
teins that contain a C-terminal transmembrane helix, which after translation is in-
serted into the ERmembrane by Asna1 inmammals317 and its yeast ortholog Get3p318
of the tail recognition complex (TRC) pathway. The subcellular localizationof Stx5 and
Sed5p at the ER-Golgi interface is largely determined by its transmembranehelix. Stx5
and Sed5p have a short transmembrane helix of only 20 residues in length, which is
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Hs Stx5   MIPRK RYGSK NTDQG VYLGL SKTQV LSPAT AGSSS SDIAP LPPPV TLVPP PPDTM SCRDR 60
Sc Sed5p  ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----M NIKDR 6
                                                                          * . :**
Hs Stx5   TQEFL SACKS LQTRQ NGIQT NK--- ----- ----- -PALR AVRQR SEFTL MAKRI GKDLS 106
Sc Sed5p  TSEFQ QSVLS YKKRN KNFRE QQRER LQEKE SENFA NNTTG NGKSV SEFQK KASGI AHEIS 66
          *.**  .:  *  :.*: :.::  ::                  :     :.  ***    *. * .:::*
Hs Stx5   NTFAK LEKLT ILAKR KSLFD DKAVE IEELT YIIKQ DINSL NKQIA QLQDF VRAKG S--QS 164
Sc Sed5p  STAQL LSKLA VLAKR KPMFN DNPVE IAELS FLIKR KIYAI EQSLV QLSQL KKTDV NGNTS 126
          .*    *.**: :**** * :*: *: ** * **: ::**: .* :: ::.:. **.::  ::.  .   *
Hs Stx5   ----- GRHLQ THSNT IVVSL QSKLA SMSND FKSVL EVRTE NLKQQ RSRRE QFSR- ---AP 215
Sc Sed5p  NQSSK QPSAV QHSKN VVNLL NTQMK NISGS FKDVL EERQR LEMAN KDRWQ KLTTD TGHAP 186
                       **:. :*  * ::::  .:*.. **.** * * .     : :.* : :::      **
Hs Stx5   VSALP LAPNH LGG-- ----G A---- VVLGA ESHAS K--DV AIDMM DSRTS QQLQL IDE-- 261
Sc Sed5p  ADDQT -QSNH AADLT TYNNS NPFMT SLLDE SSEKN NNSSN QGELS FPQND SQLML MEEGQ 245
          ..       **  ..       .        :*.  .*. . :  .    ::    :.. .** * ::*   
Hs Stx5   --QDS YIQSR ADTMQ NIEST IVELG SIFQQ LAHMV KEQEE TIQRI DENVL GAQLD VEAAH 319
Sc Sed5p  LSNNV YLQER NRAVE TIEST IQEVG NLFQQ LASMV QEQGE VIQRI DANVD DIDLN ISGAQ 305
           .::  *:*.*   ::: .**** * *:* .:*** ** ** :** * .**** * **  . :*: :..*:
Hs Stx5   SEILK YFQSV TSNRW LMVKI FLILI VFFII FVVFL A 355
Sc Sed5p  RELLK YFDRI KSNRW LAAKV FFIIF VFFVI WVLVN - 340
           *:** **: : .**** * .*: *:*:: ***:* :*:.  
Figure 5.3: Conserved and distinct interactions of mammalian Stx5 and yeast Sed5p. Alignment of human
(Hs) Stx5 and S. cerevisiae (Sc) Sed5p. Indicated are: the double arginine ER retrieval motif of the long isoform
of Stx5215,324; the alternative startingmethionine of the short isoform of Stx5215; the binding site to Scfd1
(mammals) and Sly1p (yeast)211,212; Sec24C/D binding site to the IxMmotif of Stx5201,325; Sec24p binding
sites to the YNNSNPFmotif (A-site) and LxxMEmotif (B-site) of Sed5p326; Caspase-3 cleavage site of Stx5327;
monoubiquitination site of Stx5328; phosphorylation site of Sed5p329 .
much shorter thanmost other SNAREs (≈24 residues), and this supports their recycling
to the cis-Golgi and ER319,320. The membranes of the ER and Golgi have thinner mem-
branes than other organelles, because they contain less cholesterol, and thereby pro-
vide a better matching with the short lengths of the short transmembrane helices of
Stx5 and Sed5p320. In fact, overexpression of truncation constructs revealed that the
transmembrane domains of Stx5 and Sed5p are sufficient for proper localization to
the cis-Golgi321–323. Both isoforms of mammalian Stx5 and yeast Sed5p contain an N-
terminal Habc domain, which, at least for Stx5, can interact with its SNAREmotif and
thereby inhibit SNARE complex formation194 , similar tomany other syntaxins118.
Although both the short and the long isoforms of mammalian Stx5 can be found
at ER-derived COPII vesicles63 , the long isoform caries a double-arginine ER retrieval
motif, which makes it localize more at the ER (Figure 5.3)215,324,330. The short iso-
form of mammalian Stx5 lacks this ER retrieval motif and can be found more at the
Golgi215,324,330. Yeast Sed5p does not contain an ER retrieval motif, and when it is
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heterologously expressed in mammalian cells Sed5p, locates to the cis-Golgi and ER-
GIC, similar to the short isoform of Stx5322. In yeast, Sed5p localizes to COPII vesicles,
and Sed5p immune-isolated vesicles carry early Golgi mannosyltransferases (Mnt1p,
Van1p, and Mnn9p), whereas late Golgi and ER proteins are almost completely ab-
sent331.
The presence of an ER retrievalmotif argues that the long isoformof Stx5might be
more involved in retrograde transport, while the short isoformmediates anterograde
transport. However, this might be too simplistic, as immunoprecipitation revealed
that Bet1L, the v-SNARE of retrograde intra-Golgi trafficking, forms a SNARE complex
mainlywith the short and lesswith the long isoformof Stx5, whereasGosR1, whichhas
both retro- andanterograde trafficking roles, exclusively interactedwith the short Stx5
isoform161,197 , indicating that retrograde Golgi transport is mainly mediated by the
short isoform of Stx5. Instead, the long form of Stx5 is involved in the regulation of
the ER structure by linking the ER membrane to microtubules (Figure 5.3)332 possibly
via the adapter protein CLIMP-63332,333. In addition to regulation of ER structure, Stx5
has been implicated in calcium storage at the ER. Both the long and short isoform
of Stx5 directly interact with the calcium channel polycystin-2 (PC2) via their SNARE
motifs, and this blocks channel activity and prevents calcium leakage from the ER326.
The localization of both the long and short isoform ofmammalian Stx5 and yeast
Sed5p is regulated not only by the presence or absence of an ER retrieval motif and
their transmembrane helices but also by a number of protein-protein interactions.
First, Stx5 is regulated by other SNAREs, because in mammalian cells, overexpression
of mutant forms of Bet1L, the v-SNARE of retrograde trafficking, results in altered dis-
tribution of Stx5, its SNARE partner GosR1, and the medial-Golgi protein Golgi man-
nosidase II to cis-Golgi and ER204 , possibly because of increased retrograde transport
of Stx5. Second, the subcellular localization of Stx5 ismediated by the COG (conserved
oligomericGolgi) tethering complexas experiments targeting theCog4 subunit of COG
tomitochondria showed that this interaction resulted in delocalization of Stx5 tomi-
tochondria162. Third, in both mammals and yeast, the sorting of Stx5 and Sed5p to
COPII vesicles ismediated by the COPII subunit Sec24. Inmammals, Sec24 is present in
four different isoforms from gene duplication, called Sec24A–D. Sec24A and B recruit
Sec22b, whereas Sec24C and D recruit a Q-SNARE complex of Stx5, GosR2, and Bet1 to
COPII-coated vesicles201,325 , but the functional role of this differential binding is still
unclear. In yeast, only a single form of Sec24p is present that interacts with Sed5p via
two distinct sites (Figure 5.3 and Figure 5.4A)334,335. The first site of Sec24p, called the
A-site, binds to a YNNSNPF motif of Sed5p (residues 203–209)334 and is not conserved
inmammalian Sec24 isoforms (Figure 5.3 and Figure 5.4A). Binding of Sec24p to a pre-
assembled t-SNARE complex of Sed5p, Bos1p, and Sec22p is favored compared to single
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Sed5p, as this assembly results in a conformation change that exposes the YNNSNPF
motif334. The second site of Sec24p, called the B-site, binds to a LxxME motif present
in both Bet1p and Sed5p (residues 238–242)334. The LxxME motif seems conserved in
Stx5 (Figure 5.3), and the B-site seems conserved in Sec24A and B (not in C and D) (Fig-
ure 5.4A), suggesting thatmammalian Sec24A and B can also bind to Stx5, but this has
notbeenproven. The recruitmentofmammalian Stx5 to Sec24CandDoccurs bydirect
interactions of the open formof Stx5 (thus theN-terminalHabc-domainnot bound to
its SNARE motif) to the IxM cargo-binding site of Sec24C or D via a conserved region
on Stx5 (residues 242–249; Figure 5.3 and Figure 5.4B)201,325. This recruitment of Stx5
to COPII-coated vesicles, therefore, differs markedly from the recruitment of Sed5p in
yeast.
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Hs Sec24A   691 LLSGQYSD 698
Hs Sec24B   866 LLSSQYSD 873
Hs Sec24C   698 LFPNQYVD 705
Hs Sec24D   636 LFPSQYVD 643
Sc Sec24p   501 LASEDYMD 508
                *   :* *    
Hs Sec24A   910  KSFQTGTNARLDER
Hs Sec24B   1085 KAFRTGTSTRLDDR
Hs Sec24C   915  DVLQPGAEVTTDDR
Hs Sec24D   853  CVLLSRPEISTDER
Sc Sec24p   721  MAFRSGIVP-SDHR
                   :        *.*
Hs Sec24A   1062 ----KANF 1065
Hs Sec24B   1237 ----KAEF 1240
Hs Sec24C   1059 ----EMLF 1062
Hs Sec24D   997  ----EMVF 1000
Sc Sec24p   891  VATLRLWA 898 
                     .        
A-site
Hs Sec24A   428 IVRCRSCRTYIN 439
Hs Sec24B   602 IVRCRSCRTYIN 613
Hs Sec24C   422 PLRCNRCKAYMC 433
Hs Sec24D   360 PVRCNRCKAYMC 371
Sc Sec24p   228 IVRCRRCRSYMN 239
                 :**. *::*:     
Hs Sec24A   494 SEYML-- 498
Hs Sec24B   668 SDYML-- 672
Hs Sec24C   490 VDYCKNN 496
Hs Sec24D   428 LDYCRKS 434
Sc Sec24p   294 KEYTL-- 298
                 :*        
Hs Sec24A   746 EAVMRIRCT 754
Hs Sec24B   921 EAVMRIRCT 929
Hs Sec24C   750 DAVMRVRTS 758
Hs Sec24D   688 DAIMRVRTS 696
Sc Sec24p   555 ETVMRARGS 563
                :::** * :    
Hs Sec24A   771 TDLL 774
Hs Sec24B   946 TDLL 949
Hs Sec24C   775 TTDV 778
Hs Sec24D   713 TTDV 716
Sc Sec24p   580 SDLC 583




Hs Sec24A   889  GLMVPF 894 
Hs Sec24B   1064 ALMAPS 1069
Hs Sec24C   894  QLILPE 899 
Hs Sec24D   832  QLILPE 837 
Sc Sec24p   700  PLRLCA 705 
                  *         
IxM binding site
Figure 5.4: Interactions of Stx5/Sed5pwith Sec24 and Scfd1/Sly1p. (a)Crystal structure of yeast Sec24p
(green) bound to the YNNSNPFmotif of Sed5p (A-site) and the LxxMEmotif of Bet1p (B-site)326 . Alignments
of interacting regions of Sec24pwithmammalian Sec24A–D are shown. Substrate-interacting residues are in
bold and colored. Note that the A-site is not conserved, whereas the B-site seems conserved inmammalian
Sec24A and B (not C andD). (b)Crystal structure of mammalian Sec24D (green) with the IxMmotif of Stx5
(magenta; residues 241–248)325 . Note that the IxM binding site is not conserved inmammalian Sec24A–D. (c)
Conserved interactions between Stx5/Sed5p and Scfd1/Sly1p. Crystal structure of yeast Sly1p (orange) with
the N-terminal region of Sed5p (magenta; residues 1–21)212 alignedwith an NMR structure of mammalian
Scfd1 (yellow)211 . Interacting residue F10 of the short isoform of Stx5 and Sed5p is indicated211,212 .
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5.5 PosttranslationalModifications
Stx5 is dynamically regulated during the cell cycle by ubiquitination. During mi-
tosis, particularly the short isoform of Stx5 is monoubiquitinated at K270 (K324 in
the long isoform)328 by HACE1, and this prevents its complex formation with Bet1
and results in Golgi fragmentation328 [65]. After mitosis, Stx5 is deubiquitinated by
VCIP135, enabling SNARE complex formation with Bet1 and reassembly of the Golgi
fragments328,336. K324 is conserved in yeast Sed5p (K310) (Figure 5.3), but since the nu-
cleus remains intact during budding of yeast, it is a question if Sed5p is regulated in a
similar manner as Stx5 inmammals. Inmammalian cells, Golgi reassembly after cell
division is also regulated by interactions of Stx5 with the triple AAA ATPase p97/VCP
(valosin-containing protein) subunit p47336,337. The activity of Stx5 is not only blocked
during mitosis but also in cells undergoing apoptosis. In this case, Stx5 is cleaved by
caspase-3 at conserved D263 resulting in a 26-kDa product (Figure 5.3)327 , whichmight
well be the same as the prominent 31-kDa breakdown product originally reported197.
Finally, in yeast, Sed5p is regulated by phosphorylation at serine 317, presumably by
protein kinase A329 , which is conserved inmammalian cells (human: S331; Figure 5.3).
The phosphomimeticmutant (serine to aspartate) of Sed5p results in enlarged ER, dis-
ruption of Golgi trafficking, and impaired cell growth, whereas the phospho-deadmu-
tant (serine to alanine) does not affect ER-Golgi transport nor cell growth, but results
in enlargement of the Golgi329. The precise role of this phosphorylation of Sed5p is
not known, but it is speculated that it might play a role in Golgi inheritance during
mitosis, as it allows for the Golgi to cycle between ordered and dispersed states329.
5.6 Scfd1/Sly1p
ER-Golgi transport and trafficking within the Golgi stack are regulated by the
Sec1/Munc18-like protein Scfd1 in mammals and its ortholog Sly1p in yeast.
Sec1/Munc18-like proteins regulate the assembly and activity of SNARE complexes in
membrane fusion events338 , and in mammals, Scfd1 functions with Stx5 in ER-Golgi
trafficking and also functions in the assembly of pre-Golgi intermediates through
interactions with Stx17 and Stx1863,211,212,214,339,340. In yeast, Sly1p is implicated in
antero- and retrograde ER-Golgi trafficking339. Scfd1/Sly1p binds to Stx5/Sed5p in
the Golgi via a well-conserved N-terminal region upstream of the Habc-domain (Fig-
ure 5.3)211,212,214,339. This N-terminal region is also present in mammalian Stx17 and
Stx18 and in yeast Ufe1p (Stx18 ortholog), which also bind Scfd1/Sly1p. Inmammalian
cells, Scfd1 regulates ER-Golgi anterograde transport via the assembly of pre-Golgi Stx5
5
102 | Chapter 5. Stx5-Mediated ER-Golgi Transport in Mammals and Yeast
SNARE intermediates63,214,340 and retrograde trafficking via association with the Cog4
subunit of the COG tethering complex341. Scfd1 is also involved in a secretory pathway
that is independent of COPII, as in zebrafish chondroblasts, the loss of Scfd1blocks the
transport of type II collagen from the ER342. Scfd1 mediates pro-collagen export from
the ER inmammalian cells as well by binding to the protein TANGO1312.
The crystal structure of yeast Sly1p bound to theN-terminal fragment of Sed5phas
been resolved212 and an NMR structure for mammalian Scfd1 bound to the short iso-
form of Stx5211 , showing that the high-affinity binding of the N-terminal fragment
of Stx5/Sed5p to Scfd1/Sly1p is well conserved (Figure 5.3 and Figure 5.4C). Given the
conservation and location of this interaction site, Scfd1 is predicted to bind to both
the short and long isoforms of Stx5, and Scfd1/Sly1p is predicted to bind to both un-
bound Stx5/Sed5p and to Stx5/Sed5p in complex with other SNAREs14,213. However, at
least for yeast Sly1p, this high-affinity binding to Sed5p is not required for its regula-
tion of ER-Golgi transport, but this is mediated by a second lower affinity binding to
Sed5p and other SNAREs343. This second bindingmodemight accelerate the assembly
of the Sed5p-Bos1p-Bet1p-Sec22p SNARE complex by releasing the Habc-domain from
the SNAREmotif of Sed5p344,345 , although in another study, they found no significant
difference in the kinetics of SNARE complex formation213. In mammalian cells, Scfd1
might have no effect on SNARE complex formation as well, because although it is re-
quired for ER-Golgi transport, Scfd1 does not promote accessibility of the Stx5 SNARE
motif for an antibody that only binds Stx5 in its open conformation346. An alterna-
tive, or complementary, explanation for how Sly1p regulates ER-Golgi transport is by
preventing the interactions of Sed5pwithnon-cognate SNAREs, whichwould avert the
formation of non-productive SNARE complexes213. In linewith this, overexpression of
Scfd1 inmammaliancellswas found toneutralize thedominant-negative effects of ex-
cess Stx5onER-Golgi trafficking340. Finally, Sly1p/Scfd1mightprevent thedissociation
of partly-formed SNARE complexes prior to fusion, as in yeast, Sly1p co-assembleswith
the α-SNAP ortholog Sec17p to prevent disassembly of the Sed5p-Bet1p-Bos1p-Sec22p
SNARE complex by the NSF ortholog Sec18p347. In contrast to Ufe1p, another interact-
ing SNARE of Sly1p, Sly1p binding does not affect the stability of Sed5p348. Both the
short and long isoform of Stx5 also interact with the chaperone hsc70, and at least in
vitro, this promotes SNARE complex formation of Stx5, GosR2, Bet1, and Sec22b349.
5.7 Tethering Complexes
Prior to SNARE complex formation, Golgi transport vesicles are captured to the target
organelle by two types of membrane tethering complexes154,350. The first family con-
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sists of long coiled-coil proteins and includes the Golgins p115 and GM130, whichme-
diate ER-Golgi transport, intra-Golgi transport, and Golgi biogenesis14,350. The second
family consists of multi-subunit tethering complexes of a heterogeneous structure
and composition and includes the COG complex, which organizes vesicle tethering in
intra-Golgi retrograde trafficking14,154. These tethering complexes regulate the speci-
ficity of Golgi trafficking by interacting with SNARE proteins, Rab-GTPases, and COPI
and COPII vesicle coats, and this, in turn, facilitates the complex formation of cognate
SNARE proteins14,154,202,350.
In mammalian cells, the COG complex has been shown to interact with Stx5 and
other Golgi SNAREs, and this interaction enhances the fusogenic assembly of SNARE
complexes161,351–353. The COG complex is composed of eight different subunits called
Cog1–Cog8. Cog1–Cog4 are organized in lobe A, which is mainly located at the Golgi
stacks, whereas Cog5–Cog8 form lobe B, which locates predominantly at vesicle-like
structures164. The COG complex is well conserved in yeast14 , and yeast COG interacts
with Sed5p161,354. In mammalian cells, Stx5 interacts with Cog6161,162,353 and Cog8162 ,
and these interactions are required for the assembly of the Stx5-GosR1-Bet1L-Ykt6
SNARE complex352. However, the best-characterized COG interactions of Stx5 are with
subunit Cog4161,162,341,353. Cog4 interacts with the SNARE domain of the short isoform
of Stx5161 , and as this domain is present in both Stx5 isoforms, it seems likely that
Cog4 interacts with the long isoform of Stx5 as well. Adjacent to the Stx5 binding site
of Cog4 is a site that interacts with Scfd1, and this promotes SNARE complex forma-
tion161. Knockdown of COG subunits or overexpression of a dominant-negative Cog4
fragment containing the Stx5 and Scfd1 binding sites results in blockage of Golgi-ER
retrograde trafficking, mislocalization of Stx5, GosR1, and Bet1L away from the Golgi,
and impaired SNARE complex formation of the short Stx5 isoform with GosR1, Bet1L,
and Ykt6, whereas SNARE complex formation of the short and long isoforms of Stx5
with Bet1 is not affected161,341,353.
The Golgins p115 and GM130 also interact with Stx5. The C-terminal region of
p115 contains four coiled-coil domains (CC1–CC4), and the first coiled-coil domain
CC1 bears weak sequence homology to a SNARE motif and can bind to Stx5355. In ad-
dition to Stx5, CC1 can bind to other SNAREs involved in both antero- and retrograde
Golgi trafficking (GosR1, GosR2, Ykt6, Sec22, Bet1, Bet1L) and to Scfd1350. These inter-
actions of p115 with Stx5 and other ER-Golgi SNAREs enhance in vitro SNARE complex
assembly355. p115 is conserved in yeast, and its ortholog Uso1p binds to Sed5p by a
region containing CC1 and CC2356. Not only CC1, but also CC4 are required for Golgi
trafficking by interacting with multiple Golgi SNAREs (GosR1, GosR2, Ykt6, Bet1, and
Bet1L)350. Thereby, p115 might connect t- and v-SNAREs in opposing membranes350
and facilitate SNARE complex formation precedingmembrane fusion293. Knockdown
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of p115 results in Golgi fragmentation and blocks ER-Golgi trafficking293. p115 also
interacts with the Golgin GM130, which in turn also binds to Stx5357 via a membrane-
proximal region of GM130358. However, in this case, GM130 binding to Stx5 is proposed
to prevent its interaction with other SNAREs358. Binding of p115 to GM130 releases
Stx5 from GM130 and allows SNARE complex formation andmembrane fusion down-
stream of tethering358. Duringmitosis, the interactions of GM130 with p115 are inhib-
ited, whereas binding of GM130 to Stx5 is increased, likely due to phosphorylation of
GM130, which would reduce membrane fusion, and hence suggests a role for GM130–
Stx5 interactions in the disassembly of the Golgi during cell division358.
5.8 Infections andNeurodegenerative Disease
Stx5 is involved in neurodegenerative diseases and infections of intracellular para-
sites andviruses. Thismakes it a therapeutic target, and ina screen for smallmolecule
inhibitors of retrograde Golgi-ER transport of Shiga toxin, the compounds Retro-1 and
Retro-2were identified, which result inmislocalization of Stx5 away from theGolgi ap-
paratus359,360. Stx5 localizes to vacuoles containing the intracellular pathogen Leish-
mania amazonensis, where it mediates the communication with early secretory vesi-
cles, and knockdown or blockage of Stx5 using the small molecule inhibitor Retro-2
was found to reduce the size of these parasitophorous vacuoles and impair Leishma-
nia replication and infection359,361. Stx5 has also been described to play a role in viral
infections. First, infection with human cytomegalovirus (HCMV) results in increased
cellular levels of Stx5, which is recruited to the viral assembly site and is required for
theefficientproductionofviralparticles362. Second, Stx5 is required for infectionwith
adeno-associated virus (AAV), although here, it is likely responsible for viral transport
from endosomes to the trans-Golgi network363.
Both in Alzheimer’s and Parkinson’s disease, Stx5 has been implicated. The short
and the long isoforms of Stx5mediate ER-Golgi transport of presenilin 1 and 2, which
are subunits of the γ-secretase that cleaves β-amyloid pre-protein (APP) and is respon-
sible forβ-amyloid peptide production324,364,365. Stx5 interacts directlywithpresenilin
1 and 2 via both its Habc regulatory domain and transmembrane helix, and these in-
teractions are reduced in amutant of presenilin 1 that is associated with Alzheimer’s
disease324,364,365. Moreover, Stx5 expression is upregulated in neurons under ER and
Golgi stress366 , and overexpressionof the short, but not long, isoformof Stx5 causes ac-
cumulationofAPP in theERand inhibits the formationofβ-amyloidpeptides324,365,366.
Stx5 may also play a role in Parkinson’s disease, as a disease-related mutant of α-
synuclein (A53T) binds to Stx5 and GosR2, and this reduces the formation of the Stx5-
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GosR2-Bet1-Sec22b SNARE complex, thereby possibly impairing ER-Golgi transport367.
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5.9 Discussion
Despite the high conservation inmammals and S. cerevisiae of Stx5/Sed5p and its well-
conserved interactions with cognate ER-Golgi SNAREs, the Sec1/Munc18-like protein
Scfd1/Sly1p, and the tethering complexes COG, p115, and GM130, there are several im-
portant differences in the function and regulation of Stx5/Sed5p. First, Stx5/Sed5p in-
teracts differently with the COPII coat protein Sec24p in yeast and Sec24C/D in mam-
malian cells201,213,325,335 , indicating a different mechanism of recruitment to COPII-
coated vesicles. Based on sequence alignments (Figure 5.3 and Figure 5.4A), one of
the two sites of Sed5p binding to Sec24p in yeast seems to be conserved for Stx5 bind-
ing to Sec24A/B in mammals, but this remains to be proven. The different binding
of Sed5p/Stx5 to Sec24 might relate to differences in COPII function among yeast and
mammals. In yeast, COPIImediates anterograde trafficking from the ER directly to the
cis-Golgi294 , whereas in mammals, COPII vesicles fuse together to form the ERGIC14,15.
Second, Stx5 is present as two isoforms inmammalian cells, but there is only one short
isoform of Sed5p in yeast. The long isoform of Stx5 interacts with microtubules332 ,
which correlates with the finding that the microtubular cytoskeleton is involved in
ER-Golgi trafficking in mammalian cells, but not in yeast14–16. Moreover, the long
isoform of Stx5 is retrieved to the ER, while the short isoform of Stx5 locates more to
the Golgi215,324,330. These findings suggest that in mammalian cells, the long isoform
of Stx5 has a role in early ER and cis-Golgi trafficking, whereas the short isoform of
Stx5 is involved in later trafficking at the medial- and trans-Golgi. These potentially
distinct trafficking roles of Stx5 isoforms might contribute to how mammalian cells
maintain a complex Golgi structure of intercalated tubular networks of cis-, medial,
and trans-Golgi intercalating into a large network, whereas in yeast, with only a sin-
gle Sed5p isoform, the Golgi is organized into discrete cisternae that are scattered
throughout the cell14–16. An intriguing possibility that thus emerges from this re-
view is that the different organization of ER-Golgi trafficking between yeast andmam-
malian cellsmight be partly attributable to the interactions of a single SNAREprotein:
Stx5/Sed5p, although there are presumably other reasons for this such as the differen-
tial role of microtubules and the larger number of proteins involved in ER-Golgi traf-
ficking inmammals versus yeast. Thismightnot be surprising, given the rate-limiting
function of Stx5/Sed5p in ER-Golgi transport304 and its central role in the organiza-
tion of the Golgi structure196,300,301. Moreover, Stx5 is tightly regulated during cell di-
vision328,336,337,358 and is hijacked by several pathogens to promote their replication
within infected cells361–363,368 , and dysregulation of Stx5-mediated trafficking is im-
plicated in neurodegenerative diseases324,364,365. Thus, Stx5/Sed5p plays a pivotal role
in the early secretory pathway, and understanding its function is important for un-
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derstanding the organization of eukaryotic cells and diseasemechanisms.
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6.1 Abstract
The SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor)
protein syntaxin-5 (Stx5) is essential for Golgi transport. In humans, the STX5mRNA
encodes twoprotein isoforms, Stx5 Long (Stx5L) fromthefirst startingmethionineand
Stx5 Short (Stx5S) fromanalternative startingmethionine at position 55. In this study,
we identified a novel human disorder caused by a singlemissense substitution in the
second starting methionine (p.M55V), resulting in complete loss of the short isoform.
Patients suffer from an early fatal multisystem disease, including severe liver disease,
skeletal abnormalities and abnormal glycosylation. Primary human dermal fibrob-
lasts isolated from these patients showed defective glycosylation, altered Golgi mor-
phology as measured by electron microscopy and mislocalization of glycosyltrans-
ferases. Measurements of anterograde trafficking, based on biotin-synchronizable
forms of Stx5 (the RUSH system), and of cognate binding SNAREs, based on Förster res-
onance energy transfer (FRET), revealed that the short isoform of Stx5 is essential for
intra-Golgi transport. This is thefirst timeamutation inanalternative starting codon
is linked to human disease, demonstrating that the site of translation initiation is an
important new layer of regulating protein trafficking.
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6.2 Introduction
In eukaryotes, proteins destined for the secretory pathway are synthesized at the en-
doplasmic reticulum (ER) and then transported to the Golgi apparatus, where they are
sorted for their ultimate destinations at the trans-Golgi network. Central to this pro-
cess is intracellular membrane fusion, which is mediated by members of the SNARE
(solubleN-ethylmaleimide-sensitive factor attachment protein receptor) protein fam-
ily. Cognate SNARE proteins that are present in both the carrier vesicle and target
membranes, called v- and t-SNAREs respectively, engage and forma tight alpha-helical
coiled-coil bundle that overcomes the energy barrier ofmembrane fusion. Membrane
fusion requires a single R-SNARE, characterized by an arginine residue located central
in the SNARE bundle, and three Q-SNAREs, with glutamine residues instead. Generally
inmammalian cells, the R-SNAREs act as vesicle (v-) SNAREs and theQ-SNAREs together
form the t-SNARE complex on the targetmembrane57. In contrast, the Qc-SNAREs Bet1
and Bet1L (GS15) function as the v-SNAREs at the ER/Golgi interface204,208–210 , while, for
anterograde ER to Golgi trafficking, the recipient t-SNARE complex is formed by the
Qa-SNARE syntaxin-5 (Stx5)63,194,196,295 , together with the Qb-SNAREs GosR1 (GS28) (also
known as GS27 or membrin), and R-SNAREs Ykt6 or Sec22b (Ers24)195,198,199. This dif-
ferent allocation of the Qc-SNAREs Bet1 and Bet1L as v-SNARE instead of t-SNARE pos-
sibly prevents the formation of non-functional SNARE complexes during ER to Golgi
transit. In addition, Stx5 functions in retrograde intra-Golgi transport by forming a re-
cipient t-SNARE complexwith GosR1, and Ykt621,204 and in retrograde trafficking from
endosomes to the trans-Golgi network (TGN)202,206 , making it a unique SNARE protein
involved in both anterograde and retrograde Golgi transport.
STX5 is highly conserved and is an essential gene in animals and fungi307,369. In an-
imals, Stx5 exists as a long and a short isoform translated from the same mRNA: 39.6
kDa sized Stx5 Long (Stx5L) and34.1 kDa sized Stx5 Short (Stx5S)21,215. This is in contrast
to lower organisms such as Saccharomyces cerevisiae, which only express a single iso-
formof Stx5 (Sed5p). Although Sed5pwas originally believed to resemblemammalian
Stx5S21 , it is now clear that it likely more resembles Stx5L, since an N-terminal COPI-
binding tribasic motif has been identified in Sed5p370. The emergence of a second
Stx5 isoformcanbe tracedback to thepacificpurple seaurchin, Strongylocentrotuspur-
puratus, and is also present in the model organism Danio rerio, but not in Drosophila
melanogaster nor Caenorhabditis elegans. Compared to Stx5S, Stx5L contains 54 extra
N-terminal residues bearing an Arginine – Lysine – Arginine (RKR) ER retrieval motif,
and as a result, Stx5L locates more to the ER whereas Stx5S locates more to the Golgi
network21,215,324,330,332. The evolutionary necessity of the two Stx5 isoforms remains
unclear but it has been suggested that Stx5L is important to maintain ER structure
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by binding microtubules, possibly via CLIMP-63332,333. In addition, immunoprecipita-
tions showed that GosR1 and Bet1L preferentially interact with Stx5S over Stx5L161,197 ,
suggesting that Stx5S might act in more fusogenic complexes later at the ER-Golgi in-
terface whereas Stx5Lmight bemore involved in earlier fusion steps.
In the present study, we identified a genetic variant in the second translation
codon methionine-55, fully abrogating the production of Stx5S and providing a
unique opportunity to study the physiological relevance of the existence of two iso-
forms in humans. Patients homozygous for this mutation have a very severe clini-
cal phenotype associatedwith infantilemortality and defective protein glycosylation.
We demonstrate that although Stx5L can largely compensate for the lack of Stx5S, the
loss of Stx5S leads to defects in intra-Golgi traffickingwithmislocalization of glycosyl-
transferases, which results in pronounced defects in glycosylation. Moreover, by syn-
chronizing the intracellular traffickingof Stx5 isoforms,we reveal differential traffick-
ing routes for either isoform and identify Stx5S as the dominant Qa-SNARE for intra-
Golgi transport. This is the first time that a mutation in an alternate starting site of
ribosomal translation is related to human disease. This finding reveals that protein
function can be regulated at the level of translation initiation and has profound ef-
fects on intracellular membrane trafficking and Golgi function.
6.3 Results
6.3.1 Clinical data
The family history (Supplementary Figure 6.8) revealedmultiple deceased individuals
(IV:3, IV:9, IV:10) shortly after birth, spontaneous abortions (IV:5, IV:6, IV:7), and elective
abortions in the 20th-21st week of pregnancy due to abnormal fetal ultrasound (US)
(IV:4, IV:8). Fetal US of individuals IV:8, IV:9, and IV:10 showed shortening of the long
bones with suspicion of chondrodysplasia. Patients IV:9 and IV:10 showed highly dys-
morphic facial features (high forehead, frontal bossing, prominentglabella, short and
upturned nose, long philtrum, micrognathia and dysplastic ears), skeletal dysplasia
(short extremities andnarrow thorax), profoundhypotonia, hepatomegaly, andmany
abnormal laboratory parameters including elevated cholesterol (Supplementary Ta-
ble 6.1). After birth, themain clinical problem for both patients IV:9 and IV:10 was pro-
gressive liver failure with cholestasis and hyperinsulinemic hypoglycemia ( Supple-
mentary Table 6.1). Liver failurewas themain causeofdeathat theageof 28days and8
months, in patients IV:9 and IV:10, respectively. Autopsy of fetus IV:8 revealed bilateral
hydronephrosis and sacral lordosis. Autopsy of patient IV:9 showed hepatomegaly
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with stage 3 to 4 liver fibrosis, agenesis of left kidney, hyperemia of internal organs,
ventricular septal defect and suggestive pathohistological features of chondrodyspla-
sia. Autopsy of patient IV:10 showed biliary cirrhosis and nodular regenerative hyper-
plasia, pancreatic hypertrophia/hyperplasia, andnarrow thoraxwithnormal lungde-
velopment.
6.3.2 Abnormal protein glycosylation suggests a defect in Golgi trafficking
Known genetic causes for skeletal dysplasias were excluded (IV:8), no submicroscopic
chromosomal abnormalities were found, while most metabolic investigations were
normal except for the Congenital Disorders of Glycosylation (CDG) (IV:9 and IV:10). CDG
screening revealed a strong hyposialylation of protein N-glycosylation and mucin-
type O-glycosylation, as analyzed by isofocusing of respectively plasma transferrin
(Figure 6.1a, Supplementary Table 6.2) and apolipoprotein CIII (ApoCIII-IEF, Figure 6.1b,
Supplementary Table 6.2). ApoCIII-IEF showed a strong increase of non-sialylated
apoCIII (ApoCIII-0) band intensitysities compared to the intensities of the fully gly-
cosylated form, even stronger than observed for genetic defects in the Conserved
Oligomeric Golgi (COG) complex, a known group of disorders with disturbed Golgi
homeostasis and abnormal glycosylation13.
To gain more insight into the abnormal N-glycan structures, mass spectrometry
was performedof intact transferrin (Figure 6.1c-e, Supplementary Figure 6.9) and of to-
tal plasma protein derived N-glycans (Figure 6.1c-e, Supplementary Figure 6.10). Anal-
ysis of intact transferrin of individuals IV:9 and IV:10 revealedmultiple abnormal gly-
can structures, divided into two categories: high mannose structures and truncated
glycans. Compared to the peak height of completely glycosylated transferrin, a dom-
inant accumulation was found of high-mannose glycans suggesting a problem with
MGAT1, the enzyme that adds the next N-acetylglucosamine during N-glycosylation.
Furthermore, a series of transferrin isoforms was observed with reduced incorpora-
tionof galactoseandsialic acid residues. Similar glycosylationpatternswereobserved
in COG5-CDG173,185–187. Analysis of N-glycans released from total plasma proteins reca-
pitulated the two categories of abnormal glycanswith the accumulation of highman-
nose glycans, as well as reduced incorporation of galactose and sialic acid residues.
Together, these data indicate that the activities ofmultiple glycosyltransferases in the
Golgi apparatus are affected, coveringbothN- andO-glycosylation, thereby suggesting
a general disturbance in Golgi trafficking.
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Figure 6.1: A novel, lethal, genetic variant suggests a defect in protein glycosylation related to Golgi traffick-
ing. (a)Glycosylation screening by isoelectric focusing (IEF) of serum transferrin. The accompanying numbers
represent the total number of sialic acids in the different proteoforms. Both patients show a reduction in the
number of sialic acids. Quantification of bands is shown in Supplementary Table 6.2. (b)Glycosylation screen-
ing by IEF of serumApolipoprotein C3 (ApoCIII). ApoCIII has onemucin-typeO-linked glycanwith one or two
sialic acids in controls. Both patients show a reduction in the number of sialic acids. Quantification of bands is
shown in Supplementary Table 6.2. (c Schematic overview of N-glycosylation intermediates in the Golgi. For
mass spectrometry analysis of glycan structures, glycosylated transferrin was enriched from all secreted gly-
coproteins in human serum and subjected to intact protein mass spectrometry. In parallel, a different serum
sample was treated with PNGase F to cleave and analyze N-glycans from all plasma proteins. (d)Nanochip-C8
QTOFmass spectra of enriched intact serum Transferrin of Stx5M55V patient IV:9 (top spectrum) and healthy
control (lower spectrum). Key transferrin glycoforms are shown, indicating a strong increase of high-mannose
glycans and glycans lacking sialic acid and galactose. (e)MALDI-TOFmass spectra of total plasmaN-glycans
of Stx5M55V patient IV:9 (top spectrum) and healthy control (lower spectrum). Structural analysis shows a
strong increase of high-mannose glycans and glycans lacking sialic acid and galactose.
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6.3.3 Molecular investigations result in the identification of variants in STX5
Chromosomal microarray analysis (CMA) using HumanCytoSNP-12 microarrays re-
vealed multiple long contiguous stretches of homozygosity (LCSH, >5 Mb) distributed
across the entire genome, with several regions of homozygosity on chromosome 11 in
all three affected sibs (IV:8, IV:9 and IV:10, Supplementary Table 6.3). Exome sequenc-
ing was performed in proband IV:9 to find the genetic variant that could be associ-
atedwith thedisease. Only twohomozygous rareprotein-altering variantswithoutho-
mozygous individuals in the gnomAD v3 database were identified in shared homozy-
gous stretches on chromosome 11. First, a missense variant in the VPS37C gene was
discovered (NM_017966.4:c.760G>T p.(Gly254Cys) rs201088253). However, as this variant
reaches an allele frequency of 0.9% in Estonia, it is unlikely to cause a rare genetic
disorder. The second variant was identified in the STX5 gene (NM_003164.4:c.163A>G
p.(Met55Val), Figure 6.2a). This is a missense mutation affecting the alternative start-
ing codon for the production of the short Stx5 isoform. The variant is absent from the
gnomAD v3 database and was thus classified as a potentially disease-causing variant.
The variant was confirmed by Sanger sequencing as homozygous in all affected indi-
viduals (IV:8, IV:9, and IV:10) and as heterozygous in the mother (III:2). Paternal DNA
was not available for testing.
To confirmtheeffect of thegenetic variantonbothStx5proteoforms, immunoblot-
ting was performed in primary dermal fibroblasts of patients IV:9 and IV:10. While
Stx5L was present, a total absence of Stx5S was found in both patient fibroblasts (Fig-
ure 6.2b, c). We next tested the expression of known interaction partners of Stx5. The
levels ofQc-SNAREBet1L,which formsa complexwith Stx5upon retrograde intra-Golgi
trafficking21,202,204,206 , were also reduced. In contrast (Figure 6.2b, c), the expression of
Qc-SNARE Bet1, which forms a complex with Stx5 upon anterograde ER-Golgi traffick-
ing21,195,198,200 was not reduced (Figure 6.2b, c). Likewise, the expression of Qb-SNAREs
GosR1 and GosR2, which can complex with Stx5 for anterograde ER-Golgi trafficking
and retrograde intra-Golgi trafficking21,194,195,197,198,204 were unaltered in patient der-
mal fibroblast lysates. We hypothesized that a compensatorymechanismmight exist
by upregulating the expression of the trans-Golgi Qa-SNARE Stx16371 , usually involved
in endosome-to-TGN trafficking118 , but we did not detect a change of Stx16 expression
in patient fibroblast lysates (Figure 6.2b, c). As a first step to confirm that fibroblasts
offer a usefulmodel to recapitulate the cell biological abnormalities due to loss of the
Stx5S isoform, we studied glycosylation by fluorescently-labeled lectins.
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Figure 6.2: Primary dermal fibroblasts are an accuratemodel of the glycosylation defect observed in
Stx5M55V patients. (Continued on the following page.)
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Figure 6.2: (a) Schematic representation of the intron-exon structure of STX5 and the encoded proteoforms
resulting from the two starting codons in exon 2. The Stx5M55V genetic variant is indicated by a dashed red
line. Orange regions have a secondary helical structure. TMD, transmembrane domain. Ha, Hb, Hc: regulatory
Habc-domain. (b)Representative immunoblot for SNARE proteins of cell lysates of primary human dermal
fibroblasts from two unique individual healthy donors (green, Ctrl) or Stx5M55V patients (orange, Stx5M55V).
α-Tubulin, loading control. (c)Quantification of (b). Protein levels were first normalized to the loading control,
then to the average expression of both control lines. Each point represents one cell line from 2 independent
experiments. (d) Fibroblasts of healthy donors (green, Ctrl) or Stx5M55V patients (orange, Stx5M55V) were
probedwith SNA-I lectin (green inmerge). Representative confocal micrographs. Scalebars, 25µm. DAPI in
blue. (e)Quantification of (d). All data were log10-transformed and then normalized to the healthy donor. N =
124 (Ctrl) and 111 (Stx5M55V) cells from 2 unique individuals tested twice. (f-g) Same as panels (d-e), but now
for PNA lectin. N = 117 (Ctrl) and 122 (Stx5M55V) cells from 2 unique individuals tested twice.
6.3.4 Glycosylation defects in Stx5M55V patient fibroblasts
Patient fibroblasts could be cultured normally and we did not observe apparent dif-
ferences in growth rate or viability between healthy control and patient-derived cell
lines. Cell surface staining with the lectin SNA-I from Sambucus nigra, which binds ter-
minal sialic acid in an α-2,6 linkage of fully-formed N-glycanmoieties and, to a lesser
extent, sialic acid in an α-2,3 linkage, showed that glycosylation was also impaired at
the cellular level in patient fibroblasts. Compared to fibroblasts of healthy donors,
we observed a more than two-fold reduced SNA-I labeling intensity in Stx5M55V pa-
tient fibroblasts (Figure 6.2d,e). Moreover, most signal came from punctuated struc-
tures in the Stx5M55Vpatient fibroblasts, instead of themore uniformcellmembrane
labeling observed in the healthy donor fibroblasts. To confirm this glycosylation de-
fect, we performed cell surface staining with the lectin PNA (Peanut agglutinin) from
Arachis hypogaea, which binds terminal galactose residues present onmucin O-glycan
moieties of incompletely glycosylated proteins. Opposite to our findings with SNA-I,
we observed an increased labeling intensity in Stx5M55V patient fibroblasts relative
to healthy control by about six-fold (Figure 6.2f,g). These findings show that patient-
derived fibroblasts, which express Stx5L but lack Stx5S, have a glycosylation defect.
Next, we evaluated the expression levels of Stx5S and Stx5L in lysates of peripheral
blood mononuclear cells (PBMCs) obtained from four different healthy donors (Sup-
plementary Figure 6.11). While total Stx5 expression levels varied strongly (more than
two-fold), the ratio of Stx5S and Stx5L was approximately equimolar for all individu-
als, demonstrating that the expression ratio is similar in PBMCs of different healthy
subjects.
To determine the role of Stx5S in Golgi transport, we generated a Stx5L-lacking
fibroblast cell line from one of the prior used control lines, using CRISPR/Cas9 (Fib
Stx5∆L, Supplementary Figure 6.12a). We then performed the same cell surface stain-
ing as described above. While we observed a similar decrease in SNA-I labeling inten-
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sity in Stx5∆L fibroblasts as in Stx5M55V patient fibroblasts, the staining pattern was
more similar to healthy control and showed a uniform plasma membrane-localized
SNA-I labeling (Supplementary Figure 6.12b-c). In addition, opposite to Stx5M55V fi-
broblasts, the low PNA labeling intensity was reduced further in Fib Stx5∆L (Supple-
mentary Figure 6.12d-e). To investigate this difference further, we generated two clonal
HeLa cell lines lacking Stx5L using the same method (Stx5∆L: B1A7 and C1F4, Supple-
mentary Figure 6.12f), andwe observed a decrease in the already low SNA-I labeling in-
tensityasmeasuredbyFACScompared to theparentalHeLacells, whilePNA labeling re-
sulted in opposite changes between the two Stx5∆L lines (Supplementary Figure 6.12g-
k). The difference in PNA labeling between theHeLa Stx5∆L cell lines therefore likely is
attributable by clonal variation and/or off-target effects of CRISPR/Cas9. These results
demonstrate thatwhile the loss of Stx5S or Stx5L both result inN-glycosylationdefects,
the defect is strongerupon the loss of Stx5S, as this results in lower levels andapunctu-
ated distribution of sialic acidmoieties. Moreover, themucin-type O-glycosylation de-
fect seems specific to the loss of Stx5S. As these results reiterate the glycosylationdefect
observed on serum transferrin, total plasma N-glycans and apoCIII mucin O-glycans,
patientfibroblasts are a suitablemodel to investigate the cell biological consequences
of the complete disruption of the Stx5S isoform.
6.3.5 Stx5M55Vmutation results in mislocalization of glycosyltransferases
Given that Stx5 mediates ER-Golgi trafficking21,194–200,204,206 , we next investigated
whether the glycosylation defect in Stx5M55V patient fibroblasts was caused by the
mislocalization of glycosyltransferases. We performed immunofluorescence labeling
of mannosyl (α-1,3)-glycoprotein β-1,2-N-acetylglucosaminyltransferase (MGAT1, also
known as GnTI), which catalyzes the addition of GlcNAc to the immature man-5 N-
glycan. Compared to healthy donor fibroblasts, MGAT1 colocalizes only slightly less
with the cis-Golgi marker GM130 in patient fibroblasts (Figure 6.3a, b), but colocalized
substantially less with the trans-Golgi network marker TGN46 (Figure 6.3c, d). In ad-
dition, alpha-mannosidase 2 (MAN2A1), which catalyzes the final hydrolytic step in
the N-glycan maturation pathway after MGAT1 conversion, colocalized substantially
less with both GM130 (Supplementary Figure 6.13a, b) and TGN46 in patient fibrob-
lasts (Supplementary Figure 6.13c, d). Similarly to MGAT1, beta-galactoside alpha-2,6-
sialyltransferase 1 (ST6GAL1), which catalyzes the transfer of sialic acid to galactose
residues of N-glycans in an α-2,6 linkage, colocalized less with both GM130 (Supple-
mentary Figure 6.13e, f) and TGN46 in patient fibroblasts (Supplementary Figure 6.13g,
h). Finally, N-acetylgalactosaminyltransferase 2 (GALNT2), which catalyzes the initial
reaction in mucin O-linked glycan synthesis, localized more to the cis-Golgi (marker
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Zincfingerprotein-like1 (ZFPL1)287) (Figure6.3e, f) and less to the trans-Golgi inpatient
fibroblasts (Figure 6.3g, h).
To exclude the possibility that our conclusions were affected by potential mislo-
calization of TGN46 in the patient cells, we repeated these experiments but now co-
stained for another trans-Golgi marker, the trans-Golgi coiled-coil protein p230372
(Supplementary Figure 6.14). Indeed, we observed similar Pearson correlation coeffi-
cients for p230 as for TGN46 with MGAT1, GALNT2, MAN2A1, and ST6GAL1 (Supplemen-
tary Figure 6.14). Moreover, to confirm that the observed changes in colocalization
were not due to lower expression of glycosyltransferases, we performed immunoblot-
ting for several glycosyltransferases and could not detect consistent differences be-
tween control and Stx5M55V fibroblasts, although we noticed substantial variation
in protein expression levels of some of the glycosyltransferases between the sam-
ples (Supplementary Figure 6.15), reflecting expressiondifferences among individuals
and/or fibroblast lines.
Taken together, the loss of Stx5S results in irregular localization of glycosyltrans-
ferases to the Golgi apparatus. An altered Golgi organization and mislocalization of
glycosyltransferases can have a profound impact on glycosylation as shown by com-
putational simulations54. We investigated the organization of the Golgi complex in
Stx5M55V fibroblasts inmore detail.
6.3.6 Stx5Smediates retrograde Golgi-ER and intra-Golgi trafficking
Transmission electron microscopy showed dilation of rough ER and Golgi cisternae
in the Stx5M55V patient fibroblasts (Figure 4.4a-c, gallery Supplementary Figure 6.16),
similar to previously observed alteration in the ultrastructure of the Golgi in several
COG defects156,170,183. Notwithstanding these large alterations in Golgi morphology,
the polarized arrangement of Golgi apparatus cisternae was still present in Stx5M55V,
as observed by immunofluorescence labeling of cis- and trans-Golgi markers (Supple-
mentary Figure 6.17). These results indicate that although Stx5L is sufficient to main-
tain normal Golgi apparatus cisterna polarization, Stx5S is required for physiological
ER and Golgi ultrastructure and proper trafficking of glycosylation enzymes.
To address the role of the Stx5 isoforms inmore detail, we studied the distribution
of Stx5 isoforms in the Golgi network. Because Stx5L contains an RKR ER-retrieval mo-
tif in its N-terminal extension, it locates more at the ER compared to Stx5S21,215,330,332.
In linewith this, we observed amore dominant localization of Stx5L at the ER and less
at various Golgi compartments in Stx5M55V fibroblasts compared to total Stx5 local-
ization in healthy control fibroblasts (Supplementary Figure 6.18a, b, d, e, Supplemen-
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Figure 6.3: Glycosylation enzymesmislocalize in Stx5M55V patient fibroblasts. (a) Immunofluorescencemi-
croscopy ofMGAT1 (green inmerge) and GM130 (magenta) in primary dermal fibroblasts of healthy donors
(green, Ctrl) or Stx5M55V patients (orange, Stx5M55V). Representative confocal micrographs. Scalebars, 10
µm. DAPI in blue. N = 157 (Ctrl) and 126 (Stx5M55V) cells from 2 unique individuals tested twice. (b) Pear-
son’s correlations coefficients betweenMGAT1 andGM130 of panel (a). N = 157 (Ctrl) and 126 (Stx5M55V)
from 2 unique individuals tested twice. (c-d) Same as panels (a-b), but now forMGAT1 (green) and TGN46
(magenta). N = 157 (Ctrl) and 162 (Stx5M55V) cells from 2 unique individuals tested twice. (e-f) Same as pan-
els (a-b), but now for GALNT2 (green) and ZFPL1 (magenta). N = 240 (Ctrl) and 146 (Stx5M55V) cells from 2
unique individuals tested twice. (g-h) Same as panels (a-b), but now for GALNT2 (green) and TGN46 (magenta).
N = 172 (Ctrl) and 152 (Stx5M55V) cells from 2 unique individuals tested twice.
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Figure 6.4: Loss of Stx5S alters ER andGolgi morphology. (a)Representative transmission electronmicro-
graphs from healthy donor fibroblasts (left) or Stx5M55V patient fibroblasts (right). Scalebars, 1µm. N, nu-
cleus; G, Golgi apparatus; ER, endoplasmic reticulum;M, mitochondrion. More electronmicrographs in Sup-
plementary Figure 6.16. (b) ER perimeter and area quantification of panel (a), the ratios of the perimeters
over the areas are plotted. N = 144 (both Ctrl and Stx5M55V) ER sections. (c) Same as panel (b), but now for
Golgi. N = 400 (both Ctrl and Stx5M55V) Golgi sections. (d) Immunofluorescencemicroscopy of Stx5L (green
inmerge) and GM130 (magenta) in primary dermal fibroblasts of healthy donors (green, Ctrl) or Stx5M55V
patients (orange, Stx5M55V). Representative confocal micrographs. Scalebars, 10µm. DAPI in blue. (e) Pear-
son’s correlations coefficients between Stx5L and GM130 of panel (d). N = 102 (Ctrl) and 135 (Stx5M55V)
cells from 2 unique individuals tested twice. (f-g) Same as panels (d-e), but now for Stx5L (green) and TGN46
(magenta). N = 147 (Ctrl) and 156 (Stx5M55V) from 2 unique individuals tested twice.
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tary Figure 6.19a, b, d, e).
A notable difference was the farmore diffuse staining in Stx5M55V patients of the
COPI coat protein βCOP (Supplementary Figure 6.18a, c) and of TGN46 (Supplementary
Figure 6.18d, f). In contrast, we observed a small increase in GM130 fluorescence in
Stx5M55V patients (Supplementary Figure 6.19f). Since Western blot showed that to-
tal cellular levels of βCOP and GM130 were not consistently altered in Stx5M55V pa-
tients (Supplementary Figure 6.18g), the more diffuse staining of βCOP is suggestive
of reduced association with COPI-coated vesicles, while the higher staining intensity
ofGM130 suggestsmoreassociationwith the cis-Golgi. In contrast, total TGN46protein
levels were somewhat reduced in patient fibroblasts (Supplementary Figure 6.18h).
These findings suggest that loss of Stx5S results in reduced COPI trafficking between
GM130-marked cis- and TGN46-marked trans-Golgi compartments.
Using an antibody specific to Stx5L (antibody specificity validated in Supplemen-
tary Figure 6.20), wenext investigatedwhether the loss of Stx5S affects the intracellular
distribution of Stx5L. An altered cellular localization of Stx5L might imply a compen-
satory mechanism. Indeed, in Stx5M55V, Stx5L localizes more to the cis-Golgi as mea-
sured by increased colocalization with GM130 (Figure 6.4d, e). A slight increase in ER
localizationasmeasuredbyPDI colocalizationwasalsoobserved (Figure 6.4f, g). Taken
together, the loss of Stx5S causes Stx5L to relocalize more towards the cis-Golgi.
As COPI is involved in retrogradeGolgi-ER transport80 , we investigatedwhether traf-
ficking at this interface is compromised in Stx5M55V fibroblasts by using the fungal
metabolite Brefeldin A (BFA), which inhibits COPI vesicle formation96. If loss of Stx5S
results in reduced retrograde Golgi-ER transport, we expect reduced relocalization of
Golgi-resident proteins to ER upon BFA treatment. Indeed, redistribution of GALNT2
from the Golgi to the ER was incomplete in patient fibroblasts (Figure 6.5a-c), support-
ing a role for Stx5S in retrograde COPI trafficking. In addition, washout of BFA caused
a more rapid localization of GALNT2 to the Golgi apparatus in Stx5M55V, likely due to
its incomplete redistribution to the ER (Figure 6.5a, b, d, Supplementary Figure 6.21a-
c). We investigated the role of Stx5L in Golgi trafficking further using temperature-
synchronizable vesicular stomatitis virus G protein (VSVG) fused to GFP373 in patient
fibroblasts. At 40°C, VSVG does not fold correctly and the VSVG-GFP protein remains
trapped in the ER. A temperature shift to 32oC enables the correct refolding of VSVG re-
sulting in the synchronized release of VSVG-GFP from the ER, transit through the Golgi
network, and finally delivery at the plasma membrane where it becomes accessible
to antibody labeling. VSVG-EGFP appears at a Golgi-like compartment in both control
and Stx5M55V fibroblasts at 30 mins after temperature shift from 40°C to 32°C (Sup-
plementary Figure 6.21d), but after 60 mins plasma membrane localization of VSVG
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is strongly reduced in Stx5M55V fibroblasts (Figure 6.5e-g). Taken together, these find-
ings show that Stx5L is sufficient for anterograde trafficking until the Golgi, but the
loss of Stx5S significantly impairs intra- and/or post-Golgi trafficking, likely by the de-
crease of Stx5S-mediated intra-Golgi trafficking.
To further delineate the role of Stx5L in retrograde Golgi-ER trafficking, we per-
formed a BFA experiment in the Stx5L-lacking HeLa cells. In these cells, BFA resulted
in faster relocalization of GALNT2 to the ER compared to parental HeLa (Supplemen-
tary Figure 6.22a, b), indicating that Stx5S suffices for retrograde COPI trafficking and
the expression of Stx5L counteracts this process. Further investigation of anterograde
ER-Golgi trafficking in Stx5ΔL cells with H-89 washout (Supplementary Fig. 15c, d), the
retention using selective hooks (RUSH) system for synchronized ER-Golgi transport266
(Supplementary Figure 6.22e, f) and temperature-synchronizableVSVG373 (Supplemen-
taryFigure6.22g, h) revealednophenotype relating to the lossof Stx5L. Thus, thesedata
suggest Stx5L has no necessary function in ER-Golgi trafficking as Stx5S can compen-
sate, while Stx5L canonlypartly compensate for the loss of Stx5S in retrogradeGolgi-ER
and intra-Golgi transport.
6.3.7 Faster Golgi exit of Stx5L due to ER-retrieval motif
Our results in patient fibroblasts indicate differential trafficking roles of the two Stx5
isoforms in ER-Golgi trafficking. To gain more insight in this process, we fused each
Stx5 isoform to streptavidin-binding protein (SBP) and mCitrine (Stx5L-SBP-mCitrine
and Stx5S-SBP-mCitrine; Stx5L-SBP-mCitrine carries theM55Vmutation to suppress ex-
pression of Stx5S). Moreover, we generated a mutant form of Stx5L where the RKR ER-
retrievalmotifwas converted to3×alanine (AAA) (Stx5L∆ER-SBP-mCitrine)215 , todelin-
eate the role of thismotif in ER-Golgi transport. The co-expression of these constructs
withER-localized streptavidinenabled the synchronized releaseof the Stx5 fusionpro-
teins from the ER using biotin, which is the so-called RUSH system266 (Figure 6.6a). Co-
expressing each Stx5 isoform with the Golgi marker Giantin fused to mScarlet374 in
HeLa cells, allowed to visualize the trafficking of Stx5-SBP-mCitrine to the Golgi follow-
ing the addition of biotin (Figure 6.6a, b). All three constructs were expressed at sim-
ilar levels, as judged from the fluorescent intensities, and all Stx5 forms reached the
Golgi with the same rate and achievedmaximal Golgi localization after about 20min-
utes (Figure 6.6c). However, the subsequent decrease in Golgi localization, attributed
to recycling to the ER or degradation of the fusion proteins, was faster for Stx5L-SBP-
mCitrine than for Stx5S or Stx5L∆ER (Figure 6.6c, d). Thus, the RKR ER retrieval motif
of Stx5L is necessary and sufficient for the attenuated presence of Stx5L at the Golgi,
supporting that themain role of Stx5S is COPI trafficking specifically at the Golgi.
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Figure 6.5: Loss of Stx5S compromises ER-Golgi trafficking. (Continued on the following page.)
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Figure 6.5: (a) Immunofluorescencemicroscopy of GALNT2 (green inmerge) in primary human dermal fibrob-
lasts of healthy donors (green, Ctrl) or Stx5M55V patients (orange, Stx5M55V) in the absence or presence
of Brefeldin A (BFA) for 6min andwashout for the indicated times. Representative confocal micrographs
are shown. Scalebars, 10µm. DAPI in blue. (b) Timecourse of relativemaximumfluorescence intensities of
GALNT2 from panel (a). All data were normalized to the DMSO condition (vehicle). (c)Quantification of the 0
min washout timepoint from panels (a) and (b). N = 76 (Ctrl) and 85 (Stx5M55V) cells from 2 unique individu-
als tested twice. (d) Same as (c), but now for the 90min timepoint. N = 97 (Ctrl) and 152 (Stx5M55V) cells from
2 unique individuals tested twice. (e) Immunofluorescencemicroscopy of VSVG-EGFP in primary human der-
mal fibroblasts of healthy donors (green, Ctrl) or Stx5M55V patients (orange, Stx5M55V) cultured overnight
at 40°C. Representative confocal micrographs are shown. Scalebars, 10µm. DAPI in blue. (f) Same as (e), but
now after 60mins at 32°C. (g)Quantification of the ratio of surface to intracellular of VSVG after 60mins at
32°C. N = 45 (Ctrl) and 39 (Stx5M55V) cells from 2 unique individuals tested twice.
6.3.8 The two isoforms of Stx5 differently engage in SNARE complexes
Since interactions of Stx5with Bet1 andBet1Lmediate anterograde ER-Golgi transport
andretrograde intra-Golgi transport, respectively204,208–210 , wehypothesized that Stx5S
would interact more strongly with Bet1L, whereas Stx5L would interact more strongly
with Bet1. We set out to test this hypothesis by performing co-immunoprecipitation
with our RUSH Stx5 constructs. However, we were unable to consistently resolve differ-
ences in binding to endogenous cognate Qc-SNAREs between the two Stx5 isoforms, ei-
ther with or without 30mins biotin (Supplementary Figure 6.23). A likely explanation
is that interactions might occur in vitro during the immunoprecipitation. Therefore,
we developed an approach to visualize SNARE complexes based on a combination of
theRUSHsystem26644andourpreviouslydevelopedFörster resonanceenergy transfer-
fluorescence lifetime imaging microscopy (FRET-FLIM) approach for visualization of
SNARE complexes268 (Figure 6.7a). This FRET-FLIM approach employed Stx5 isoforms
C-terminally fused with a donor fluorophore (mCitrine) and Bet1L C-terminally fused
with an acceptor fluorophore (mCherry). The formation of a post-fusion SNARE com-
plex results in the close proximity of the donor and an acceptor fluorophore result-
ing in FRET which can be measured from a decreased donor fluorescence lifetime (τ ).
Contrary to ratiometric FRET, FRET-FLIM is not dependent on local concentration dif-
ferences or excitation intensities of the donor and acceptor fluorophores, as τ is an in-
trinsic property of the fluorophore itself. By combining the FRET-FLIM approach with
the RUSH system, we were able to control the spatial localization of Stx5 isoforms and
measure interactions specifically at the ER (no biotin) or the Golgi apparatus (20 min
afterbiotinaddition). 30minutesprior to imaging, cellswere incubatedwith cyclohex-
imide in culturemedium tomake sure background interaction fromany ER-localized
newly-synthesized acceptor construct wasmitigated.
For the mCitrine donor-only Stx5 constructs, we measured similar lifetimes for
both isoforms (Figure 6.7c, Supplementary Figure 6.24a, Stx5L: 3.02 ns ± 0.004, Stx5S:
6















































































































































Figure 6.6: Faster Golgi exit of Stx5L than Stx5S. (Continued on the following page.)
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Figure 6.6: (a) Schematic overview of the design of Stx5 trafficking experiment, based on the RUSH system. In
absence of biotin (left panel), the reporter cargo (Stx5-SBP-mCitrine) is trapped at the ER by the lumenal Str-
KDEL hook. When biotin is added (right panel), biotin outcompetes the interaction with streptavidin, allowing
Stx5-SBP-mCitrine to traffic freely to its destination compartment. SBP, streptavidin binding protein; Str,
streptavidin. (b) Snapshots of live-cell imaging of Stx5-SBP-mCitrine (green inmerge). Magenta: Golgi marker
Giantin-mScarlet. Scale bars, 10µm. (c)Quantification of mCitrine fluorescence at the Golgi of Stx5S-SBP-
mCitrine (green), Stx5L-SBP-mCitrine (orange) and Stx5L∆ER-SBP-mCitrine (blue) over time from panel (b).
N = 44 (Stx5S), 47 (Stx5L) and 19 (Stx5L∆ER) cells from 4 independent experiments. (d)Quantification of the
slopes from panel (c) of the post-Golgi section (≈20mins onwards).
2.99 ns ± 0.007) prior to biotin addition, while these lifetimes slightly decreased fol-
lowing biotin addition (Figure 6.7d, Supplementary Figure 6.24a, Stx5L: 2.90 ns ± 0.006,
Stx5S: 2.86 ns ±0.011). We attribute this reduced lifetime to the fact that mCitrine is
somewhat pH-sensitive375 and the pH of the Golgi apparatus is lower than in the ER
lumen22. We then co-expressed the Stx5 isoforms with mCherry-tagged Bet1L (Bet1L-
mCherry) (Figure 6.7a,b). At the ER, thus before the release of Stx5 with biotin, we ob-
served reduced lifetimes for both Stx5S and Stx5L with Bet1L-mCherry, compared to
the donor-only controls (Figure 6.7b, c, Stx5L: 2.82 ns ± 0.01, Stx5S: 2.79 ± 0.01), whereas
the lifetimes of Stx5S and Stx5L did not significantly differ from each other. After the
release in the presence of biotin, this difference between Stx5L and Stx5S became sig-
nificant and lifetimes were 2.63 ns (± 0.01) for Stx5L while Stx5S dropped to 2.52 ns
(± 0.03) (Figure 6.7b, d). To validate that the observed effect is indeed caused by func-
tional SNARE complex formation, we repeated this experiment with VAMP8 instead of
Bet1L as the acceptor R-SNARE. VAMP8 has no role in ER-Golgi membrane fusion but
rather associates with the late endosomal/lysosomal compartment58,118,268,376–379. We
only observedminor decreases influorescence lifetimes for both Stx5L and Stx5S (Sup-
plementary Figure 6.24b, c, prior to biotin Stx5L: 2.92 ns ± 0.01, Stx5S: 2.86 ± 0.02, upon
biotin addition Supplementary Figure 6.24b, d, Stx5L: 2.82 ns ± 0.01, Stx5S: 2.76 ± 0.02).
These FLIM results demonstrate that Stx5S interacts more strongly with Bet1L at the
Golgi than Stx5L. Thus, Stx5S is the dominant Qa-SNARE for intra-Golgi trafficking.
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Figure 6.7: Stx5S is the dominant Qa-SNARE for intra-Golgi trafficking. (a) Schematic overview of experi-
mental design for complex formation of Stx5 isoformswith Bet1L, based on the RUSH system and SNARE
complexmeasurement by FRET-FLIM. In absence of biotin (left panel), the reporter cargo (Stx5-SBP-mCitrine)
is trapped at the ER by the lumenal Str-KDEL hook, and no FRETwith Golgi-localized Bet1L-mCherry occurs.
When biotin is added (right panel), biotin outcompetes the interaction with streptavidin, allowing Stx5-SBP-
mCitrine to traffic freely to its destination compartment, and SNARE complex formation with Golgi-localized
Bet1L-mCherry results in FRET. SBP, streptavidin binding protein; Str, streptavidin; FRET, Förster resonant
energy transfer. FLIM, fluorescence lifetime imagingmicroscopy. (b)Representative confocal micrographs of
HeLa cells co-expressing Stx5-mCitrine (green inmerge) and Bet1L-mCherry (magenta) without (ER) or with
(Golgi) biotin. Scalebars, 10µm. (c-d) Stx5-mCitrine lifetimes at the ER (c) and Golgi (d) from panel (b). N = 52
(Stx5S Donor ER), 74 (Stx5L Donor ER), 47 (Stx5S Bet1L ER), 51 (Stx5L Bet1L ER), 50 (Stx5S Donor Golgi), 71
(Stx5L Donor Golgi), 58 (Stx5S Bet1L Golgi) and 58 (Stx5L Bet1L Golgi) cells from 3 independent experiments.
6
6.4. Discussion | 129
6.4 Discussion
Since the advent of the genomic age, close to 6,000monogenic disorders have been dis-
covered380. While nearly all of these disorders result in a truncated, unstable and/or
nonfunctional protein, e.g., due to a genetic variant in the catalytic site or proteinmis-
folding, isoform-specific mutations are rare. Here we present the first known muta-
tion in an alternate site of ribosomal translation leading to human disease, namely
the mutation of the second starting methionine of Stx5. This mutation leads to the
complete and specific loss of Stx5S. Although STX5 is an essential gene for embryonic
development inmice307,369 , herewe show that inhumans the loss of Stx5S still allowed
a completed pregnancy. Nevertheless, patients have a very severe clinical pathology
characterized by infantile mortality due to liver disease, skeletal abnormalities and
protein glycosylation defects. While the exact mechanism for alternative translation
is unclear, this might be an actively regulated process. It could also be simply reg-
ulated by the affinity of the ribosome for the nucleotide sequence upstream of the
starting codon. Supporting the latter option, analysis of translation initiation sites
with NetStart381 revealed that the starting codon of Stx5S is located in a more opti-
mal nucleotide context than the starting codon for Stx5L (Supplementary Figure 6.25).
This could lead to more leaky ribosomal scanning382,383 , resulting in the more or less
equimolar ratio of expression of Stx5L and Stx5S that we observed in fibroblasts and
PBMCs of healthy individuals. On the other hand, Western blot revealed different ra-
tios of the two Stx5 isoforms in different organs in rats215 , suggesting (i) that differ-
ent cell types express different levels of Stx5S and Stx5L and this is probably related
to their exocytic function, and (ii) that the initiation of starting translationmight be
regulated and notmerely dependent on the binding affinities of the ribosome.
Cofractionation and microscopy studies have revealed that the localization of
Stx5L and Stx5S overlap to a large extent, but that they are generally distributed as
a gradient between ER, ERGIC, andGolgi apparatus330. This observationhas previously
led to the suggestion that Stx5Lmight play a role in early Golgi trafficking, while Stx5S
functions in late Golgi trafficking21,194–200,204,206. Our data now shows that this is not
the case and that both Stx5 isoforms canmediate both early and late anterograde and
retrograde Golgi trafficking with sufficient fidelity to keep the layered Golgi morphol-
ogy intact. However, the role of Stx5S is more important for retrograde Golgi-ER and
intra-Golgi trafficking, and its absence leads to an altered ER and Golgi morphology,
distribution of glycosylation enzymes and trafficking proteins. The cumulative effect
of slight mislocalization of all glycosyltransferases might well explain the observed
hypoglycosylation in the Stx5M55Vpatients. Indeed, recentmodeling showed that the
slight mislocalization of glycosyltransferases can result in large differences in glyco-
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sylation patterns, because glycosylation is the result of the sequential addition and
removal of different sugarmoieties at the various Golgi compartments384.
The dominant role of Stx5S in retrogradeGolgi-ER and intra-Golgi trafficking is cor-
roborated by the observation that cellular levels of Bet1L, with known roles in intra-
Golgi trafficking, are lower in Stx5M55V patient cells. Interestingly, genetic variants in
conserved oligomeric Golgi (COG) tethering complex components, which are also im-
plicated inCDGs, also resulted in lower levels of Bet1L aswell and thiswas attributed to
amislocalization of Bet1L to the ERwhere it was degraded157. Possibly, a similarmech-
anismmight explain the reduction in Bet1L levels in Stx5M55V patients. Although the
Stx5-Bet1L interaction has been reported in several studies80,202 , our study now shows
this interaction in situ using FLIM. This interaction is localization dependent and oc-
curs mostly when Stx5 is localized at the Golgi. Moreover, we observed stronger inter-
action of Bet1L with Stx5S compared to Stx5L at the Golgi, which is likely the result of
the differential localization of both isoforms.
An important function of the Golgi apparatus is protein glycosylation385. Collec-
tively, somatic mutations affecting glycosylation are classified as CDGs and currently
over 100 monogenic diseases affecting glycosylation have been identified31,56. A sig-
nificant number of these include defects in Golgi trafficking, such as the components
of the conserved oligomeric Golgi tethering complex (COG)165,172,176–179,183,193,386 , muta-
tions in genes coding for the vacuolar H+-ATPase and its assembly factors112,120,121,387 ,
and novel genes involved in Golgi ion homeostasis130,131,388. Furthermore, defects are
known in components associatedwith COPI-coated vesicles144 that result in deficient
protein glycosylation in patient cells, but are not linked to abnormal glycosylation of
proteins in plasma and thus escape routine CDG screening. Our study is the first ex-
ample of an ER-Golgi SNARE being implicated in CDG, thus highlighting the potential
of glycosylation screening in patients to uncover novel cell biological mechanisms.
While the cellular effects of the loss of Stx5S in Stx5M55V mutant fibroblasts are
subtle, there can be pronounced consequences in secretory cells, such as exocrine
and endocrine cells, which are sensitive to minor disruptions of the secretory path-
way144,385,389,390. Not only can the defects in intra-Golgi trafficking explain the hypogly-
cosylation in Stx5M55V patients, but also of other pathologies. For instance, Stx5 can
participate in the trafficking andprocessing of the very low-density lipoprotein recep-
tor (VLDL-R) and this role is heavily dependent on the expression of Stx5315 , thus pro-
viding an explanation for the observed cholesterol homeostasis defect with elevated
cholesterol in all Stx5M55V patients.
In summary, we have demonstrated that amutation in an alternative translation
start site in Stx5 has a severe impact on intracellular membrane trafficking, leading
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to the discovery of a novel CDG.While there aremany previous descriptions of alterna-
tive start site variations leading to disease391 , this is the first known mutation in an
alternative starting codon leading to human disease by the loss of an isoform.
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6.5 Methods
6.5.1 Ethics
The study was approved by Research Ethics Committee of the University of Tartu (ap-
proval dates 19.12.2011, 20.02.2012 and 17.03.2014, and approval numbers 210/M-17,
212/M-31 and 235/M-13, 17.03.2014, respectively) and were strictly in accordance with
the Declaration of Helsinki. Informed consent for carrying out researchwas obtained
from the family of investigated individuals. Buffy coats and whole blood were ob-
tained as anonymous coded specimens from the Dutch blood bank (Sanquin) and
were handled according to known practice and legal guidelines. The research with
human blood samples at the Department of Tumor Immunology complies with all in-
stitutional and national ethics regulations and has been approved by the ethics com-
mittee of Sanquin.
6.5.2 Glycosylation studies
Screening for CDG was carried out as described before120. Plasma N-glycan profiling
wasperformedbyMALDI-TOFmass spectrometry of permethylated glycans93 , using 10
µL of plasma. High resolutionmass spectrometry of intact transferrinwas performed
on a 6540 nanochip QTOF (Agilent), according to published protocols392.
6.5.3 Microarray analysis
DNA was extracted either from peripheral blood according to the standard salting
out protocol (IV:9 and IV-:10) or from amnionic fluid cell culture (IV:8). Screening for
chromosomalabnormalitieswasperformedusingHumanCytoSNP-12BeadChips (Illu-
mina Inc., SanDiego, CA, USA). 200 ng of total DNAper samplewas processed according
to the protocol supplied by the manufacturer. Genotypes were called by GenomeStu-
dio v2011.1 software and the datawere analyzed using GenomeStudio Genome Viewer
tool (Illumina Inc.). The minimum threshold for LCSH (long contiguous stretches of
homozygosity) regions was set at 5 Mb.
6.5.4 Exome sequencing
GenomicDNAwas extracted fromfibroblasts frompatient IV:9 according to themanu-
facturer’s protocol using aQiagenMini Kit (Qiagen) andwas checked for DNAdegrada-
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tion on agarose gels. Next generation sequencing (NGS) and analysis were performed
as described121. In brief, exome enrichment was performed using the SureSelect Hu-
man All Exon 50 Mb Kit (Agilent), covering ≈21,000 genes. The exome library was se-
quenced on a SOLiD 5500xl sequencer (Life Technologies). Color space readswere itera-
tively mapped to the hg19 reference genome with the SOLiD LifeScope software ver-
sion 2.1. Called variants and indels were annotated using an in-house annotation
pipeline393,394 and common variants were filtered out based on a frequency of >0.5%
in dbSNP and a frequency of >0.3% in our in-house database of >5,000 exomes. Quality
criteria were applied to filter out variants with less than 5 variant reads and less than
20% variation. Furthermore, synonymous variants, deep intronic, intergenic and UTR
variants were excluded. The identified variant was confirmed by Sanger sequencing
in all affected individuals (IV:8, IV:9, and IV:10) and their mother (III:2). Paternal DNA
(III:1) was not available.
6.5.5 Cell culture
HeLa cells (authenticated by ATCC through their human STR profiling cell authenti-
cation service), including Stx5∆L cell lines, were maintained in high glucose DMEM
with Glutamax (Gibco 31966021). Human primary dermal fibroblasts were obtained
from patients or healthy donors and maintained in Medium 199 with EBSS and L-
glutamine (Lonza BE12-119F). Allmedia were supplementedwith 10% fetal calf serum
(FCS, Greiner Bio-one, Kremsmünster, Austria) and antibiotic-antimycotic solution
(Gibco 15240-062). All cells were regularly tested for mycoplasma contamination. Hu-
man peripheral blood mononuclear cells (PBMCs) were obtained from buffy coats as
previously described395.
6.5.6 Plasmids and transfection
Str-KDEL_ManII-SBP-EGFP was a gift from Franck Perez (Addgene plasmid #65252).
VAMP8-mCherry was constructed earlier268 and previously deposited to Addgene
(Addgene plasmid #92424). Str-KDEL_Stx5L-SBP-mCitrine and Str-KDEL_Stx5S-
SBP-mCitrine were constructed by replacing the ManII-SBP-EGFP cassette in Str-
KDEL_ManII-SBP-EGFP using the AscI and XbaI restriction sites. Stx5 coding sequences
were codon-optimized for Homo sapiens using JCat and ordered from Genscript,
the Stx5L coding sequence carries the M55V mutation to suppress production of
Stx5S. Stx5L∆ER coding sequence was generated with Q5-polymerase site-directed
mutagenesis, using the Stx5L cDNA as a template with the following primer: 5’- CTTCG
AATTC AATGA TTCCG GCCGC CGCCT ACGGC AGCAA GAACA CC. Sequences were verified
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with Sanger sequencing. HeLa cells were transfected with plasmid vectors using
Fugene HD (Promega E2311), using the recommended protocol of the manufacturer.
Only cells expressing low to moderate levels of the transfected plasmids, based on
fluorescence intensity and manual localization scoring, were chosen for subsequent
microscopic analyses.
6.5.7 CRISPR/Cas9
Stable knock out of Stx5L in fibroblasts andHeLa cells was obtained using the CRISPR-
CAS9method. For this, pairsofgRNAsequencesweredesignedupstreamof theSTX5 ini-
tiationcodon (crispr.mit.edu, pair 1: ATAACCTCGGACTGTTGTGGAGGandATGATCCCGC
GGAAACGCTACGG; pair 2: TAACCTCGGACTGTTGTGGAGGGandTGATCCCGCGGAAACGC-
TAC GGG). The gRNA sequences were cloned in pSpCas9n(BB)-2A-Puro (PX462) V2.0 (gift
from Feng Zhang, Addgene no. 62987)396 and transfected into fibroblasts or HeLa cells
by electroporation (Neon Transfection System, Thermofisher, MA). After initial selec-
tion with puromycin, the medium was changed for conditioned medium (collected
fromparental fibroblasts or wildtype HeLa cells at 70% confluency) supplemented 1:1
with fresh medium. Single clones were obtained and screened for knockout of Stx5L
by SDS-PAGE andWestern blotting.
6.5.8 Immunofluorescence
Cells were plated on cleaned 12 mm glass coverslips (Electron Microscopy Services,
72230-01) and the following day fixed with 4% paraformaldehyde for 15 minutes at
room temperature. Following quenching with 50 mM NH4Cl in PBS, cells were perme-
abilized and blocked in 2% normal donkey serum (Rockland, 017-000-121) and 0.1%
saponin (permeabilization buffer) for 30mins at RT. Primary and secondary antibod-
ies (list of antibodies and dilutions in Table 6.4) were diluted in permeabilization
buffer and incubated for 1 hour at room temperature. Finally, cells were washed with
0.1%Triton X-100 in PBS to remove background staining andmountedwithmounting
mediumcontaining 0.01%Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic
acid) and 68% glycerol in 200 mM sodium phosphate buffer at pH 7.5 with 0.1 µg/ml
DAPI. Coverslips were sealed with nail polish. Cells were imaged on a Leica SP8 SMD
confocal laser scanningmicroscope, equippedwith anHC PL APOCS2 63×/1.20WATER
objective. Colocalization analysis was performed using the pearsonr function from
the Python package SciPy397. Briefly, individual cells were saved to separate .tiff files
with ImageJ without anymodifications, and then processed in a fully automated and
unbiased fashion using the pearsonr function.
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6.5.9 Lectin stainings
Cells were plated on cleaned 12 mm glass coverslips for microscopy or 6-wells plates
forflowcytometryandafter 72hours culturingfixedwith4%paraformaldehyde. Cells
were blocked with Carbo-Free Blocking solution (Vector Laboratories, SP-5040) and in-
cubated with 4 µg/mL biotinylated SNA-I (Vector Laboratories, B-1305) or PNA (Vector
Laboratories, B-1075) diluted in Carbo-Free Blocking solution. Cells were then incu-
bated with Streptavidin-Alexa Fluor 647 (ThermoScientific, S32357) before coverslips
were mounted as described above. Cells were imaged on a Leica SP8 SMD confocal
laser scanning microscope, equipped with an HC PL APO CS2 63×/1.20 WATER objec-
tive. For flow cytometry, cells were resuspended in FACS buffer (phosphate buffered
saline + 0.5% FBS + 0.01%NaN3). Flow cytometry samples were run on a FACSLyric flow
cytometer (BD Biosciences) and analyzed with FlowJo X (FlowJo, LLC).
6.5.10 Brefeldin A assay
Fibroblasts were plated on 12 mm coverslips and cultured until 80% confluent. Cells
were either treated with 10 µg/mL Brefeldin A in DMSO (Cayman Chemicals, 11861) or
DMSO alone for 6minutes in a humified incubator. Washout was performed by wash-
ing five times with Leibovitz’s L-15 (Gibco 21083027) with 10% FBS, then incubating in
Leibovitz’s L-15 with 10% FBS at 37°C for the indicated times. After incubation, plates
were transferred immediately to ice and cells were fixed with 4% paraformaldehyde,
after which the above immunofluorescence protocol was performed. Microscopy
images were acquired using a a Leica SP8 SMD confocal laser scanning microscope,
equipped with an HC PL APO CS2 63×/1.20 WATER objective. HeLa cells were plated
on 12 mm coverslips and incubated in the same way with Brefeldin A, but fixed with
100%methanol at -20°C for 15mins. Imaging of these sampleswas performedusing a
Leica DMI6000B epifluorescence microscope equipped with an HC PL APO 63x1.40 OIL
objective. Cells were analyzed using Fiji (http://fiji.sc/) by first removing noise outliers
(bright outliers, radius 2.0 pixels, threshold 50), thenmanually selecting cells andmea-
suring the maximum fluorescence intensity in these ROIs. Data were normalized to
themean of the DMSO control of each group.
6.5.11 H-89 assay
HeLa cells were plated on 12 mm coverslips and incubated the following day for 30
mins with 100 µM H-89 (Cayman Chemicals, 10010556) in DMSO or DMSO alone (vehi-
cle) and H-89 was washed out with fresh medium for 5 mins. Cells were fixed with
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4% paraformaldehyde for 15 mins at RT and permeabilized with 100% methanol at
-20°C for 15 mins prior to immunostaining with ERGIC53 mouse monoclonal anti-
body (G1/93 or OTI1A8) before epifluorescence imaging as described for the BFA assay.
Cells were analyzed using Fiji and the number of ERGIC53-positive spots was quanti-
fied with the Spot Counter plugin. Data were normalized to the mean fluorescence
of the DMSO control of each group. Data was analyzed with a Mann-Whitney U non-
parametric test.
6.5.12 Transmission electronmicroscopy
Fibroblasts were grown in 12-wells plates and fixed with 2% glutaraldehyde (Sigma-
Aldrich, G5882) in PB (0.1 M phosphate buffer, pH 7.4) for 60 mins at room tempera-
ture. Subsequently, cells were washed four times with PB and post-fixed with 1% os-
mium tetroxide and 1% potassium ferrocyanide in PB for 60 mins at room tempera-
ture. Then, cellswere againwashed four timeswith PB and four timeswithwater. Cells
were incubated overnight in 0.5% uranyl acetate and dehydrated with graded steps of
ethanol (30%, 50%, 70%, 96%, 100%) andembedded inEpon resin. 70nmsectionswere
stained with 2% uranyl acetate solution and lead citrate solution. Stained sections
were then examined using a CM12 transmission electronmicroscope (Phillips).
6.5.13 Live-cell epifluorescencemicroscopy
Cells were seeded in four-compartment dishes (Greiner 627870) and transfected as de-
scribed above (3:1 weight ratio reporter construct:Golgi label). Before imaging, the cul-
ture medium was exchanged for Leibovitz’s L-15 (Gibco 21083027). Samples were im-
aged using a DMI6000B (Leica Microsystems) with a heated stage (Pecon) and objec-
tive heater. All samples were imaged using an HC PL APO 63×/1.40–0.60 OIL objective.
VSVG-ts045-EGFP experiments were performed at 32°C after overnight incubation at
40°C,while all other epifluorescence experimentswereperformedat 37°C. For RUSHex-
periments, an equal amount of Leibovitz’s L-15 supplemented with biotin was added
to thewell immediately before imaging, to reach afinal concentration of 40µMbiotin.
Live cell imaging was started immediately with 15 sec or 30 sec frame rates. Analysis
was performed with Fiji, after registration of the image stacks, the increase in fluo-
rescence was measured in the Golgi area by using the thresholded mScarlet-Giantin
signal as an imagemask.
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6.5.14 FRET-FLIM
All imaging took place in Leibovitz’s L-15 supplementedwith 10 µg/mL cycloheximide
(Sigma-Aldrich, C4859) and cells were pulsed with biotin as described above. Imaging
was performed on a Leica SP8 SMD system at 37°C, equipped with an HC PL APO CS2
63×/1.20 WATER objective. Fluorophores were excited with a pulsed white light laser,
operating at 80MHz. mCitrine was excited at 514 nm, two separate HyD detectors were
used to collect photons, set at 521-565 nm and 613-668 nm respectively. Photons were
collected for oneminute and lifetimehistogramsof thedonorfluorophorewerefitted
with monoexponential decay functions convoluted with the microscope instrument
response function in Leica LAS X.
6.5.15 Immunoprecipitation
HeLa cells were lysed 48 hours post-transfection with IP lysis buffer (20 mM Tris-
HCl pH 7.6, 137 mM NaCl, 1% IGEPAL, 2 mM EDTA and complete protease inhibitors
(Roche 5892791001)). Protein levels were equilibrated and lysates were immunoprecip-
itated with 1 µg anti-GFP-antibody (Rockland 600-401-215) and protein A beads (Ther-
moFisher, 20333) for 1 hour at 4°C with constant agitation. After three washes with IP
lysis buffer, sampleswere boiled in 5x SDS sample bufferwith β-mercaptoethanol and
resolved with SDS-PAGE and subsequent immunoblotting.
6.5.16 SDS-PAGE and immunoblotting
Cells were plated in 12-wells plates in culture medium and lysed the following day
with SDS lysis buffer (1% SDS, 10 mM Tris-HCl pH 6.8). Lysates were diluted to equal
protein content (30 µg per lane) with SDS lysis buffer, separated with SDS-PAGE on 4–
20%Mini-PROTEAN TGX Precast Protein Gels (Biorad, 4561094) and subsequently trans-
ferred onto 0.45 µm PVDF membranes. Small molecular weight proteins (Bet1 and
Bet1L) were separated on 16% Schaegger gels398.
6.5.17 Quantification and statistical analysis
All mean values represent the average of all cells analyzed. All comparisons between
two groups were first checked for similar mean andmedian values and acceptable (<
3x) difference in variance, before statistical analysis with an unpaired two-sided Stu-
dent’s t-test. Relative intensity data was first transformed using the binary logarithm
before analysis with an unpaired two-sided Student’s t-test. H-89 data was analyzed
6
138 | Chapter 6. Congenital Disorder of Glycosylation Caused by Starting Site-Specific Variant in Syntaxin-5
with a Mann-Whitney U non-parametric test. Stx5 kinetics data were analyzed with
a one-way ANOVA, followed by a post-hoc Tukey’s honestly significant difference test.
Stx5 FLIM data were analyzed with a two-way ANOVA, with the isoform and timepoint
as independent variables, followed by a post-hoc Tukey’s honestly significant differ-
ence test. p < 0.05 was considered significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p
≤ 0.0001. All statistical analyses were performed using R statistical software. All nu-
merical datawere visualized using R package ggplot2286 , with violins representing the
overall distribution of the data andmeans ± 95% CI overlaid.
6.5.18 Data and code availability
Microarray data, exome sequencing data and ImageJ macros for quantification of
the RUSH experiments are available upon request. Primary microscopy data was de-
posited to Zenodo.
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6.6 Supplementary Information
I:1
II:1 II:2 II:3 II:4 II:5 II:6
III:1 III:2
IV:2 IV:3 IV:4 IV:5 IV:6 IV:7 IV:8 IV:9 IV:10IV:1
I:2
Affected
Abortion, unknown carrier status
Clinically normal
Deceased
Figure 6.8: Family pedigree of Stx5M55V patients. Black filled squares and circles indicate affected patients.
Empty squares and circles indicate clinically normal individuals. Triangles with diagonal stripes indicate
aborted individuals or individuals with unknown carrier status. The diagonal line indicates deceased individu-
als.
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Figure 6.9: Glycan structural changes in STX5M55V patients by intact transferrinmass spectrometry. The
nanochip-C8QTOFmass spectra of enriched intact serum transferrin of Stx5M55V patient IV:10 (a), patient
IV:9 (b) and healthy control (c) are shown.
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Figure 6.10: Glycan structural changes in STX5M55V patients byMALDI-TOFmass spectrometry of total
plasma protein derivedN-glycans. TheMALDI-TOFmass spectra of all plasmaN-glycans of Stx5M55V pa-
tient IV:10 (a), patient IV:9 (b) and healthy control (c) are shown.
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Figure 6.11: Interindividual Stx5 expression variation. (a)Representative immunoblot for Stx5 on lysates of
peripheral bloodmononuclear cells (PBMCs) isolated from four healthy donors. GAPDH, loading control. (b)
Quantification of (a).
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Figure 6.12: Stx5L-lacking cell line generation and lectin stainings. (Continued on the following page.)
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Figure 6.12: (a)Representative immunoblot for Stx5 of cell lysates of primary human dermal fibroblasts of
a healthy donor (green, Ctrl), Stx5L-lacking (blue, Fib Stx5∆L) or Stx5M55V patients (orange, Stx5M55V).
GAPDH, loading control. The band corresponding to Stx5L in Fib Stx5∆L shows residual Stx5∆L expression
due to incomplete CRISPR/Cas9 knockout. (b) Fibroblasts of healthy donors (green, Ctrl) or Stx5∆L (blue, Fib
Stx5∆L) were probedwith SNA-I lectin (green inmerge). Representative confocal micrographs. Scalebars,
25µm. DAPI in blue. (c)Quantification of (b). All data were log10-transformed and then normalized to the
healthy donor. N = 134 (Ctrl) and 107 (Stx5∆L) from 2 independent cell lines repeated twice. (d-e) Same as
panels (b-c), but now for PNA lectin. N = 113 (Ctrl) and 111 (Stx5∆L) from 2 independent cell lines repeated
twice. (f)Representative immunoblot for Stx5 of cell lysates of HeLa cells of parental (green, P) or two clonal
Stx5L-lacking lines (blue, Stx5∆L B1A7 and C1F4). GAPDH, loading control. (g) FACS gating strategy for lectin
stainings, cell population shown is the unstained control. FSC-A: forward scatter area, SSC-A: side scatter
area, FSC-H: forward scatter height. (h)Quantification of parental HeLa (green, P) or Stx5∆L (blue, Stx5∆L),
probedwith SNA-I lectin followed by FACS. Geometric means were taken and log10-transformed, then nor-
malized to wildtype. 10.000 events analyzed per condition per experiment from 4 independent experiments.
(i) Same as panel (h), but now for PNA lectin. 10.000 events analyzed per condition per experiment from 4
independent experiments.
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Figure 6.13: Glycosylation enzymesmislocalize in Stx5M55V patient fibroblasts. (a) Immunofluorescencemi-
croscopy ofMAN2A1 (green inmerge) and GM130 (magenta) in primary dermal fibroblasts of healthy donors
(green, Ctrl) or Stx5M55V patients (orange, Stx5M55V). Representative confocal micrographs. Scalebars, 10
µm. DAPI in blue. N = 127 (Ctrl) and 143 (Stx5M55V) cells from 2 independent cell lines repeated twice. (b)
Pearson’s correlations coefficients betweenMAN2A1 andGM130 of panel (a). (c-d) Same as panels (a-b), but
now forMAN2A1 (green) and TGN46 (magenta). N = 155 (Ctrl) and 171 (Stx5M55V) cells from 2 independent
cell lines repeated twice. (e-f) Same as panels (a-b), but now for ST6GAL1 (green) and GM130 (magenta). N =
56 (Ctrl) and 78 (Stx5M55V) cells from 2 independent cell lines repeated twice. (g-h) Same as panels (a-b) but
now for ST6GAL1 (green) and TGN46 (magenta). N = 57 (Ctrl) and 86 (Stx5M55V) cells from 2 independent
cell lines repeated twice.
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Figure 6.14: Glycosylation enzymesmislocalize in Stx5M55V patient fibroblasts. (a) Immunofluorescence
microscopy ofMGAT1 (green inmerge) and p230 (magenta) in primary dermal fibroblasts of healthy donors
(green, Ctrl) or Stx5M55V patients (orange, Stx5M55V). Representative confocal micrographs. Scalebars, 10
µm. DAPI in blue. N = 153 (Ctrl) and 147 (Stx5M55V) cells from 2 independent cell lines repeated twice. (b)
Pearson’s correlations coefficients betweenMGAT1 and p230 of panel (a). (c-d) Same as panels (a-b), but now
for GALNT2 (green) and p230 (magenta). N = 166 (Ctrl) and 160 (Stx5M55V) cells from 2 independent cell
lines repeated twice. (e-f) Same as panels (a-b), but now forMAN2A1 (green) and p230 (magenta). N = 184
(Ctrl) and 75 (Stx5M55V) cells from 2 independent cell lines repeated twice. (g-h) Same as panels (a-b) but
now for ST6GAL1 (green) and p230 (magenta). N = 128 (Ctrl) and 149 (Stx5M55V) cells from 2 independent
cell lines repeated twice.
6





































Figure 6.15: No consistent changes in expression of glycosyltransferases in healthy and patient fibroblasts.
Representative immunoblot for glycosyltransferases of cell lysates of primary human dermal fibroblasts of
healthy donors (green, Ctrl) or Stx5M55V patients (orange, Stx5M55V).α-Tubulin, loading control.
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Figure 6.16: Gallery of transmission electronmicrographs of healthy donor and Stx5M55V fibroblasts. Scale-
bars, 1µm. N, nucleus; G, Golgi apparatus; ER, endoplasmic reticulum;M, mitochondrion.
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Figure 6.17: Golgi cisterna polarization is maintained in Stx5M55V patient fibroblasts. (a) Immunofluores-
cencemicroscopy of GM130 (green inmerge) and TGN46 (magenta) in primary dermal fibroblasts of healthy
donors (green, Ctrl) or Stx5M55V patients (orange, Stx5M55V). Representative confocal micrographs. Scale-
bars, 10µm. DAPI in blue. The yellow arrows indicate the cross-sections used for the line plots in panel (b). (b)
Fluorescence intensity line plots from panel (a). Data for eachmarker was normalized to themaximumfluores-
cent intensity per cross-section.
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Figure 6.18: Reduced localization of Stx5 to trans-Golgi network in Stx5M55V patients. (Continued on the
following page.)
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Figure 6.18: (a) Immunofluorescencemicroscopy of Stx5 (green inmerge) and βCOP (magenta) in primary
dermal fibroblasts of healthy donors (green, Ctrl) or Stx5M55V patients (orange, Stx5M55V). Representa-
tive confocal micrographs. Scalebars, 10µm. DAPI in blue. (b) Pearson’s correlations coefficients between
Stx5 and βCOP of panel (a). N = 109 (Ctrl) and 87 (Stx5M55V) cells from 2 independent cell lines repeated
twice. (c) Fluorescence intensities of βCOP from panel (a) relative to the healthy control. N = 109 (Ctrl) and
87 (Stx5M55V) cells from 2 independent cell lines repeated twice. (d-f) Same as panels (a-c), but now for Stx5
(green) and TGN46 (magenta). N = 128 (Ctrl) and 114 (Stx5M55V) cells from 2 independent cell lines repeated
twice for colocalization, N = 822 (Ctrl) and 783 (Stx5M55V) cells from 2 independent cell lines repeated six
times for intensity measurements. (g)Representative immunoblot for GM130 and βCOP of the cells from
panel A. GAPDH, loading control. (h) Same as panel (g), but now for TGN46.
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Figure 6.19: Stronger localization of Stx5 to ER in Stx5M55V patient fibroblasts. (Continued on the following
page.)
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Figure 6.19: (a) Immunofluorescencemicroscopy of Stx5 (green inmerge) and PDI (magenta) in primary der-
mal fibroblasts of healthy donors (green, Ctrl) or Stx5M55V patients (orange, Stx5M55V). Scalebars, 10µm.
DAPI in blue. (b) Pearson’s correlations coefficients between Stx5 and PDI of panel (a). N = 101 (Ctrl) and 76
(Stx5M55V) cells from 2 independent cell lines repeated twice. (c) Fluorescence intensity of PDI from panel (a)
relative to healthy donor. N = 93 (Ctrl) and 84 (Stx5M55V) cells from 2 independent cell lines repeated twice.
(d-f) Same as panels (a-c), but now for Stx5 (green) and GM130 (magenta). N = 105 (Ctrl) and 80 (Stx5M55V)
cells from 2 independent experiments for colocalization, N = 415 (Ctrl) and 436 (Stx5M55V) cells from 2 inde-
pendent cell lines repeated four times for intensity.
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Figure 6.20: Stx5L-specific antibody validation. Immunofluorescencemicroscopy of Stx5L (green inmerge)
in parental HeLa (HeLa, green) or HeLa Stx5∆L (Stx5∆L, blue). Representative epifluorescencemicrographs.
Scalebars, 10µm. DAPI in blue.
6





























































































































































Figure 6.21: BFA and VSVG experiments in Stx5M55V fibroblasts. (Continued on the following page.)
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Figure 6.21: (a) Immunofluorescencemicroscopy of GALNT2 (green inmerge) in primary human dermal fi-
broblasts of healthy donors (green, Ctrl) or Stx5M55V patients (orange, Stx5M55V) in the absence or pres-
ence of Brefeldin A (BFA) for 6min andwashout for the indicated times. Representative confocal micrographs.
Scalebars, 10µm. DAPI in blue. (b)Quantification of the 30min timepoint from panel (a). N = 64 (Ctrl) and
119 (Stx5M55V) cells from 2 independent cell lines repeated twice. (c) Same as (b), but now for the 60min
timepoint. N = 68 (Ctrl) and 83 (Stx5M55V) cells from 2 independent cell lines repeated twice. (d) Immunoflu-
orescencemicroscopy of VSVG-EGFP in primary human dermal fibroblasts of healthy donors (green, Ctrl) or
Stx5M55V patients (orange, Stx5M55V) cultured overnight at 40°C and then 32°C for 30mins. Representa-
tive confocal micrographs are shown. Scalebars, 10µm. DAPI in blue.
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Figure 6.22: Loss of Stx5L does not affect anterograde ER-Golgi trafficking. (Continued on the following
page.)
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Figure 6.22: (a) Immunofluorescencemicroscopy of GALNT2 (green inmerge) in parental HeLa (WT, green)
or HeLa Stx5∆L (Stx5∆L, blue) in the absence or presence of Brefeldin A (BFA) for 6min. Representative
epifluorescencemicrographs. Scalebars, 10µm. DAPI in blue. (b)Relativemaximumfluorescence intensities
of GALNT2 from panel (a). All data were normalized to the DMSO condition (vehicle). N = 103 (WT) and 212
(Stx5∆L) cells from 2 independent experiments. (c) Immunofluorescencemicroscopy of ERGIC53 (green in
merge) in the absence or presence of H-89 and after washout of H-89 in parental HeLa (WT, green) or HeLa
Stx5∆L (Stx5∆L, blue). H-89 inhibits export of cargo from ER exit sites via inhibition of protein kinase A, and
causes redistribution of ERGIC53 to the ER, both of which are restored uponwashout399,400 . Representative
epifluorescencemicrographs. Scalebars, 10µm. DAPI in blue. (d) The relative number of ERGIC53 punctae
of panel (a). All data were normalized to the average of the DMSO condition of each of the lines. N = 140 (WT
DMSO), 90 (WTH-89), 92 (WTWashout), 169 (Stx5∆L), 188 (Stx5∆L H-89) and 167 (Stx5∆LWashout) cells
from 2 independent experiments. (e) Trafficking ofManII-SBP-EGFP in parental HeLa (WT, green) or HeLa
Stx5∆L (Stx5∆L, blue) over time (n≈40 cells/condition). As part of the RUSH system266 , ManII-SBP-EGFP
is held at the ER in absence of biotin by interaction with a streptavidin-KDEL hook protein. After addition
of biotin at t = 0,ManII-SBP-EGFP can exit the ER normally and traffic to the Golgi. ManII-SBP-EGFP inten-
sity at the Golgi wasmeasured, corrected to the total cellular intensity ofManII-SBP-EGFP per frame, and
normalized to t = 0. SBP, streptavidin binding protein. (f)Quantification of slope coefficients from panel (c)
of the linear section (3-6min). No differences betweenWT and Stx5∆Lwere observed. N = 38 (WT) and
79 (Stx5∆L) cells from 2 independent experiments. (g) Trafficking of VSVG-ts045-EGFP in parental HeLa
(WT, green) or HeLa Stx5∆L (Stx5∆L, blue) over time after shift to 32°C (n≈40 cells/condition). When cells
expressing VSVG-ts045-EGFP are cultured at 40°C, the tagged protein misfolds and is retained at the ER.
Shifting the cells to 32°C at t = 0 refolds the protein and enables it to exit the ER normally and traffic to the
Golgi373 . VSVG-ts045-EGFP intensity at the Golgi wasmeasured, corrected to the total cellular intensity of
VSVG-ts045-EGFP per frame, and normalized to t = 0. (h)Quantification of slope coefficients from panel (e) of
the linear section (3-15min). No differences betweenWT and Stx5∆Lwere observed. N = 51 (WT) and 103
(Stx5∆L) cells from 2 independent experiments.
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Figure 6.23: Co-immunoprecipitation of RUSH Stx5-mCitrinewith cognateQc-SNAREs. (a)HeLa cells were
transfectedwith Stx5L-SBP-mCitrine (L), Stx5S-SBP-mCitrine (S), or left untransfected (-), lysates were im-
munoprecipitated by anti-GFP, then blotted for Bet1 and Bet1L. Biotin was added 30minutes prior to lysis.
Shown is a representative immunoblot from 3 independent experiments. Arrowhead, heavy IgG chain; aster-
isk, molecular weight marker; GAPDH, loading control; SBP, streptavidin binding protein. (b)Quantification of
band intensities from panel (a). Each band intensity was first normalized to the loading control, and then to the
condition without biotin. Each point represents one independent experiment.
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Figure 6.24: Fluorescence lifetime imagingmicroscopy (FLIM) of Stx5-mCitrine or with co-expression of
VAMP8-mCherry. (a)Representative confocal micrographs of HeLa cells expressing Stx5S-mCitrine or Stx5L-
mCitrine (green inmerge) without (ER) or with (Golgi) biotin. Scale bars, 10µm. (b) Same as panel (a), but
now for HeLa cells co-expressing Stx5-mCitrine (green inmerge) and VAMP8-mCherry (magenta). (c-d) Stx5-
mCitrine lifetimes at the ER (c) and Golgi (d) from panel (b). N = 52 (Stx5S Donor ER), 74 (Stx5L Donor ER), 51
(Stx5S VAMP8 ER), 61 (Stx5L VAMP8 ER), 50 (Stx5S Donor Golgi), 71 (Stx5L Donor Golgi), 39 (Stx5S VAMP8
Golgi) and 53 (Stx5L VAMP8Golgi) cells from 3 independent experiments.
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Figure 6.25: Translation initiation predictions of STX5. NetStart 1.0381 (https://services.
healthtech.dtu.dk/service.php?NetStart-1.0) was used to predict translation start of the
STX5mRNA transcript (accession code: NM_003164.5). The starting codons of Stx5L and Stx5S respectively
are shown in bold red. In gray is the 5’ UTR of STX5. AA, amino acid.
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Table 6.1: Phenotypes of patients affected by Stx5M55V genetic variant
Patient IV:9 Patient IV:10












Renal involvement Agenesis of left kidney Unilateral
hydronephrosis
Liver involvement Liver failure,
hepatomegaly, stage 3 to















Nervous system Hypotonia Severe hypotonia,
delayedmotor
development, brain MRI
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Table 6.2: Quantification of Transferrin-IEF and ApoCIII-IEF bands
IV:9 IV:10
Transferrin isofocusing (Figure 6.1d)
TF-6 2.1 (3.2-7.8) n.d. (3.2-7.8)
TF-5 9 (18.7-31.5) 2.66 (18.7-31.5)
TF-4 31.1 (47.3-62.7) 9.09 (47.3-62.7)
TF-3 12.9 (4.9-10.6) 22.03 (4.9-10.6)
TF-2 14.6 (3.3-7.6) 32.73 (3.3-7.6)
TF-1 13.2 (0-5.0) 22.35 (0-5.0)
TF-0 17.2 (0-3.2) 11.14 (0-3.2)
Apolipoprotein CIII isofocusing (Figure 6.1e)
ApoCIII-2 15.1 (26.2-56.7) 9.3 (40.4-60.9)
ApoCIII-1 29.1 (42.7-69.8) 49.6 (37.1-54.5)
ApoCIII-0 55.8 (0.2-4.5) 41.1 (1.3-11.7)
The numbers behind TF and ApoCIII refer to the number of sialic acids. The numbers indicate the relative
distribution of the individual protein isoforms (in %). The range between brackets indicates the reference
range (age-related for ApoCIII).
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Table 6.3: Chromosomal microarray analysis
Chromosome Starting position (bp) hg19 Ending position (bp) hg19
Common LCSH areas in two patients (IV:8 and IV:9)
2 41 051 123 47 273 511
5 113 980 360 123 909 500
11 23 410 903 32 583 695
11 33 423 590 48 994 066
11* 55 091 268 76 733 313
Common LCSH areas in three patients (IV:8, IV:9, and IV:10)
11 23 410 903 32 583 695
11 33 423 590 48 994 066
11* 55 091 268 70 906 073
*STX5 gene is located on the chromosome 11 (62 806 897 - 62 832 088). The variant was confirmed by Sanger
sequencing as homozygous in all affected individuals, and heterozygous in themother.
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Table 6.4: Antibodies used in this study
Target Catalog number Application
Stx5 (polyclonal) Synaptic Systems, 110 053 IF (5 µg/mL)
Stx5 (B-8) Santa Cruz Biotechnology, sc-365124 WB (0.4 µg/mL), IF (4 µg/mL)
Stx5L Abcam, ab217130 WB
GAPDH (14C10) Cell Signaling Technology, 2118 WBWB (0.5 µg/mL)
MGAT1 Abcam, ab180578 IF (10 µg/mL), WB (2 µg/mL)
MAN2A1 Abcam, ab12277 IF (5 µg/mL)
ST6GAL1 Abcam, ab225793 IF (20 µg/mL)
GALNT2 (1501421) Biolegend, 682302 IF (5 µg/mL)
B4GALT1 (GT2/36/118) Enzo, ALX-803-339-c050 WB (2 µg/mL)
GALNT3 R&D Systems AF7174 WB (2.9 µg/mL)
ST6GalNacI Abcam ab69066 WB (4 µg/mL)
GM130 (35/GM130) BD Biosciences, 610822 WB (0.5 µg/mL), IF (2.5 µg/mL)
TGN46 BioRad, AHP500GT WB (0.25 µg/mL), IF (0.25 µg/mL)
βCOP Abcam, ab2899 WB (4.4 µg/mL), IF (2.2 µg/mL)
Alpha-Tubulin (YOL1/34) Novus Biologicals, NB100-1639 WB (0.2 µg/mL)
GosR1 (1/GS28) BD Biosciences, 611185 WB (0.25 µg/mL)
GosR2 (25/GS27) BD Biosciences, 611034 WB (0.25 µg/mL)
Stx16 Synaptic Systems, 110 162 WB (1 µg/mL)
Bet1 (17) Santa Cruz Biotechnology, sc-136390 WB (0.2 µg/mL)
Bet1L (19/GS15) BD Biosciences, 610960 WB (1 µg/mL)
ERGIC53 (G1/93) Alexis Biochemicals, 802-602-C100 IF (10 µg/mL)
PDI (RL90) Novus Biologicals, NB300-517 IF (10 µg/mL)
ERGIC53 (OTI1A8) Enzo, enz-ABS300-0100 IF (10 µg/mL)
VSV-G (8G5F11) Kerafast EB0010 IF (20 µg/mL)
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7.1 The Clinical Foundation of this Thesis
The field of membrane trafficking in glycobiology is rapidly advancing. The work pre-
sented in this thesis representsonlya fractionof thenewdevelopmentsof thepastfive
years. While much is still unknown, many advancements have contributed to the for-
mationof this thesis. The startingpoint formuchof the experimentalworkpresented
in this thesis was found in the clinic: chapters 4 and 6 originate from novel genetic
variants in the genes coding for themembrane trafficking-related proteins TMEM199
and syntaxin-5 observed in patients with congenital disorders of glycosylation (CDG).
Recent advances in thediagnostics of CDGhavenotonly improved the sensitivity ofde-
tectionof various glycosylationdefects but also provide insights as towhere exactly in
the glycosylation process the defects occur. Where classic diagnostic approaches only
interrogate the sialic acid content of glycans using isoelectric focusing (IEF)238 , mod-
ern approaches use mass spectrometry to investigate full glycan structure profiles in
anunbiased fashion174,392,401. For Stx5-CDG, discussed in chapter 6, the combinationof
IEF andmass spectrometry-based diagnostics allowedme to identify a glycan profile
unique to Stx5-CDG patients (strong decrease of sialic acid and galactose incorpora-
tion, but strong increase inMan-5 glycan abundance). Moreover, this observation can
already be linked to a step in the glycosylation pathway: as the Man-5 glycan is a very
earlyN-glycan, thedefectmust relate toa component early in theGolgi apparatus. This
informationwould have been overlooked if only the IEF datawould have been consid-
ered. Together with advances in next-generation sequencing94,95 , the genomic loca-
tion of the variant could quickly be identified in STX5. This offered a stepping stone
to understanding the cell biologicalmechanismbehind the clinical presentation. Hu-
man disease therefore can bring an understanding of the function of proteins in the
cell, and chapters 4 and 6 are good examples of howadvancements in CDGdiagnostics
pave the way to elucidate the role of membrane trafficking components.
Inversely, understanding the cell biological mechanisms in disease is paramount
for the development of treatment options. As CDGs are rare diseases that do not affect
many individuals13 , treatment options are scarce but desirable. A better understand-
ing of the underlying cell biological and biochemical processes affected in the cells
of CDG patients opens up new therapeutic opportunities, which can be as straightfor-
ward asmonosaccharide supplementation402–404. In some cases, such as the Stx5-CDG
patients presented in chapter 6, treatment options are currently not feasible. Consid-
ering the breadth of the disorder, and that it likely affects embryonic development,
straightforward supplementation strategieswouldnot be sufficient to ameliorate the
patient phenotypes. Possible therapeutic opportunities include the use of gene re-
placement therapy, similar to the treatment of spinal muscular atrophy (SMA)405. For
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Stx5-CDG patients, this would need to be performed early in development and is there-
fore technologically and ethically complicated.
These rare diseases also offer the opportunity for new initiatives both for patients
and researchers. One such opportunity is the Noordzeeziekte foundation406 , which is
a patient organization for individuals suffering from the homozygous G144W muta-
tion in the Golgi trafficking protein GOSR2224–226 , partner SNARE for syntaxin-5. No-
ordzeeziekte has been identified in 25 patients so far worldwide, with most of them
living in the north of the Netherlands, and is characterized by muscle spasms and
epilepsy. The Noordzeeziekte foundation offers a platform for (family of) patients to
understand the disease and the therapeutic options, as well as to share the research
progress of scientists affiliated with the foundation. Similarly, the foundation en-
ables the continuation of basic research through donations, advancing the under-
standing and treatment options of the disease. Analogous patient organizations also
exist for CDG inmany different countries407.
7.2 On Tissue-Specific Glycosylation
Many CDGs are characterized by tissue-specific defects, even though the affected
machinery is present in most cells of the human body. In this thesis, I discuss
Stx5M55V-CDG (chapter 6) which primarily has skeletal and hepatological involve-
ment, TMEM199-CDG (chapter 4)whichmainlyaffects the liver121 , andCCDC115-CDG120
which affects the liver, spleen and, brain. Especially TMEM199 and CCDC115 are of in-
terest as it is hypothesized that they act in concert to facilitate V-ATPase assembly125 ,
and my data in chapter 4 suggests that TMEM199 recruits CCDC115 to membranes,
raising the question why the patient phenotype is different. Another clear example
of tissue-specific glycosylation is found in GNE-CDG, caused by genetic variants in
GNE (Glucosamine (UDP-N-Acetyl)-2-Epimerase/N-AcetylmannosamineKinase), the en-
zyme responsible for the two first steps in sialic acid biosynthesis408–412. In GNE-CDG,
all skeletalmuscle tissue is affected except for the quadriceps. A likely explanation for
this phenomenon is that the expression levels of glycosyltransferases vary between
tissues and cell types13,15,41,65–68. Several distinct isoforms exist of most glycosyltrans-
ferases10 , which is likely important for the tissue distribution of glycans. Moreover,
differences in expression levels of glycosyltransferases can shift the balance towards
distinct glycosylation steps, similarly how the ratio of syntaxin-5 isoform expression
can dictate intracellular trafficking as seen in chapter 6. The ratio of glycosylation en-
zymesmighthence alter both the substrate andproduct levels of certain intermediate
glycans, producing different glycans on the same protein in different cell types.
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The studies I performed in chapters 3, 4, and 6 in this thesis made use of one or
two different cell types, but it would be much more valuable to interrogate glycosyla-
tion disorders caused by mutant trafficking proteins in various types of tissues. in-
duced pluripotent stem cells (iPSCs) are ideal with their capacity to differentiate in
multiple tissues. Coupled with the retention using selective hooks (RUSH) system266
and glycoproteomics, glycoproteins can be followed almost in real-time during their
transit through the secretory pathway inmultiple cell types, with concurrent analysis
of the attached glycan structures. Proteins of interest fused to fluorescent proteins
can be imaged by live-cell microscopy, while the same tag can be used to purify the
glycoprotein via immunoprecipitation for downstream mass spectrometry analysis
of not only glycans but also interacting proteins at each step in the trafficking path-
way. In theory, this systemcould also bemultiplexed byusingmultiple different cargo
molecules (e.g., cytokines, ECM proteins, or immunoglobulins) with different (fluores-
cent) tags. Using such high spatial and temporal resolution where glycosylation and
traffickingmeet is highly interesting to elucidate how and where differential glycosy-
lation occurs. Moreover, the same processes can be studied in iPSCs derived from CDG
patients to observe howmutations affect the transit of glycoproteins.
7.3 The Use of Primary HumanMaterial in Cell Biological Studies
One important limitation from chapter 6 concerns the use of primary human der-
mal fibroblasts. While primary patient material is the most accurate model to study
disease effects on a cellular level, there are three important aspects to using patient-
derived cells: (1) high interindividual variation, (2) primary patientmaterial ismostly
difficult tomanipulate by i.e., fluorescent protein expression, and (3) primary human
dermal fibroblasts are often not themost relevant cell type with regards to the patho-
physiology.
First, as all individuals are unique, so are the cells derived from both healthy
donorsandpatients. Asopposed tostudiesperformed ingeneticallyuniformcell lines
or animals, many considerations need to be taken when working with material from
humans. Many different aspects including age, treatment, diet, environment, and ge-
netic makeup influence the biology of cells in the human body and therefore influ-
ence the results of cell-based assays. We observed this by different protein expression
levels between donors as measured by Western blot, as well as by the different glyco-
sylation results dependent on the availability of N-glycans in blood serum. While this
affects the interpretation of these experiments, an important improvement would be
to include more different patients to account for the variation. Ultimately, the obser-
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vations in chapter 6 are a testament to how humans are all unique.
Second, cell biological techniques often use the exogenous expression of fluores-
cent proteins in live cells to interrogate many different processes. For short-term ex-
periments, a suitable technique involves transient delivery, or transfection, of plas-
mid DNA for temporary expression of the desired protein. Many different methods
for transient transfection exist, such as complexing plasmid DNAwith cationic lipids
for endosomal uptake413,414 or high voltage electroporation415 , but these are oftennot
ideal for the transfection of primary material compared to transformed and immor-
talized cell lines416,417. This severely limits the options for studying cell biological pro-
cesses in live primary cells. Viral delivery of plasmid DNA is generally a more suitable
option for stable transduction of primary human cells and offers high levels of trans-
duction efficiency. Unfortunately, viral transductionmethods comewith severe draw-
backs regarding the production of viral particles, toxicity, and immunogenicity which
are undesirable in certain experimental contexts413,418–420.
Themost idealmethodwould be to generate cell lines that express fluorescent (fu-
sion) proteins in a mostly endogenous context. CRISPR/Cas9 technology has enabled
robust genomic engineering with a relatively small investment necessary, enabling
wide-spread applications421–424. Recently, improvements to the CRISPR/Cas9 system
facilitate thedevelopmentof genome-edited cells even furtherby increased specificity
and less off-target effects292 and by inferring resistance to a potent cytotoxic drug
concurrently with the desired edit to improve the selection of positive cells425. Most
importantly, well-designed CRISPR/Cas9 constructs do not affect the nucleotide con-
text of the edited gene, therefore maintaining physiological promoter function and
expression regulation. This eliminates artifacts commonly associated with overex-
pression426,427. Experiments of use would be to perform the same FLIM-FRET-based
approach as outlined in chapter 6 but with endogenous SNAREs, to truly measure
SNARE fusion in situ in an endogenous system. The same is true for other trafficking
assays; when the RUSH system is introduced endogenously rather than with overex-
pression, all copies of the protein of interest can be captured, thereby removing the ef-
fect of the unedited protein from the experiment. Another noteworthy avenue would
be to perform CRISPR/Cas9 genome editing in iPSCs428,429. The pluripotent property
of these cells would allow the investigation of protein function in many different tis-
sue types, all arising from a single progenitor. Moreover, robust iPSC generation can
be performed using frompatient-derived fibroblasts frompatients with uncharacter-
izedmutations resulting in, for example, CDGs.
Another interesting addition to the genome editing arsenal is the development of
base editing and prime editing430–432. Base and prime editing use a similar genomic
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targeting strategy to CRISPR/Cas9 and allow for precise single nucleotide changes.
New generation prime editing tools use a catalytically impaired Cas9 fused to re-
verse transcriptase432. A prime editing guide RNA (pegRNA) specifies both the tar-
get site for the fusion complex and the desired genomic edit, which is then inserted
using a single strand DNA break. Contrary to CRISPR/Cas9, base and prime editing
do not induce double-strand breaks in DNA which are the source of random inser-
tions and deletions at the target locus433,434. Moreover, double-strand breaks can in-
duce a p53-mediated DNA damage response which strongly inhibits the application
of CRISPR/Cas9 in pluripotent stem cells435,436.
While prime and base editing can only edit a single nucleotide, the technology is
ofmajor interest to deploy in patient cells. In our case, we could have repaired the sin-
gle nucleotide mutation in Stx5M55V patient cells (chapter 6) to investigate whether
restoring Stx5S protein expression would rescue the patient phenotype. These tech-
nologies are currently only feasible in laboratory settings, however, in the future, these
strategies could also be applied to efficiently and safely restore congenital mutations
in humans.
7.4 How Advancements in Microscopy Advance Golgi and Glycosyla-
tion Research
Other advancements that are of interest regarding this thesis are advances in optical
microscopy. Most optical microscopy presented in this thesis was performed using
confocal microscopy systems, which have a maximum resolution of 200 nm in the x
and y dimensions and about 1 µm in the z dimension (depending on the wavelength
of the emitted light)437. Amajor drawback is that the space between cisterna, approxi-
mately 20 nm, is indiscernible using confocalmicroscopy, and the highly compact na-
ture of the Golgi makes it very difficult to resolve fluorescent signals belonging to dif-
ferent Golgi cisternae438. This is of particular importance for chapters 4 and 6, where
I used confocal microscopy to investigate the localization of glycosyltransferases in
Golgi cisternae. As confocalmicroscopy lacks the resolution to accurately separate the
different cisternae, I could only make general conclusions about the localization of
the glycosyltransferases instead of accurately naming the cisternaewhere the protein
of interest resides in. The latter would be of much interest for understanding glyco-
sylation in the context of different disorders. Using computational approaches, it is
currently possible to resolve cargo in transit between different cisternae439 but this is
still relatively complicated and does not offer a high temporal resolution.
Recently, super-resolution microscopy techniques such as STED (stimulated emis-
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sion depletion), SIM (structured illumination microscopy), PALM (photo-activated lo-
calization microscopy), and STORM (stochastic optical reconstruction microscopy)
have becomemuchmore accessible and could therefore be of interest to image Golgi
trafficking and related processes. Traditionally, electronmicroscopy has been applied
to visualizing Golgi membranes, but more recent approaches combine both electron
microscopy and optical fluorescence microscopy as correlated light and electron mi-
croscopy (CLEM)440. CLEM allowsmaintaining the flexibility of fluorescence-based op-
tical microscopy experiments, potentially with super-resolution modalities441 , with
the robust lateral resolution of electronmicroscopy. Improving the resolution axially
and laterally is possible through focused ion beammilling combined with scanning
electron microscopy (FIB-SEM) and cryogenic super-resolution to obtain images at 4
nm isotropic resolution with 40 nm accuracy in fluorescence imaging442. While the
lateral and axial resolution is unparalleled with FIB-SEM with cryo-SIM, it is highly re-
stricted in temporal resolution as live samples cannot be imaged and full image ac-
quisition per sample can be very long. Moreover, depending on the complexity and
dimensions of the sample, datasets can be restrictively large and typically range from
100 GB to about 19.5 TB442,443 , making FIB-SEMwith cryo-SIM difficult to scale.
As in many optical microscopy techniques, any increases in spatial resolution de-
crease the temporal resolution. This raises thequestion: what is thehighest spatial res-
olution achievable with high temporal resolution? A perfect technique for the time-
lapse experiments I performed in this thesis would be lattice light sheet microscopy
(LLSM)444. LLSM can currently achieve the highest spatiotemporal resolution in bio-
logical samples with SIM-levels of spatial resolution and temporal resolution of only
a few milliseconds444. The underlying principle is the creation of a structured light
sheet that only illuminates a very small volume in the cell (approx. 1 µmdeep) which
is then captured by a camera. This enables confocal-like imaging (i.e., imaging a small
focal plane rather than the whole sample as with epifluorescence microscopy) with
thecapture speedofepifluorescencemicroscopyas imagesarenot reconstructed from
single-pixel scans. Furthermore, phototoxicity is significantly reducedby thedecrease
of sample illumination, thus making LLSM particularly suitable for imaging cells in
all dimensions of spacetime. Current LLSM setups are also suitable for fluorescence
lifetime imagingmicroscopy (FLIM)445 , a technique I applied to several research ques-
tions throughout this thesis (chapters 3, 4, and 6).
LLSM could greatly improve the time-lapse studies I performed in this thesis. For
instance, following the transit of tumor necrosis factor (TNF)-α in chapter 3 was cur-
rently performed at a temporal resolution of 1 minute per frame. LLSM could speed
this imaging up by orders of magnitude, thereby enabling highly accurate pH mea-
surements in time. The sameholds for the syntaxin-5 trafficking experiments of chap-
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ter 6. With LLSM, the localization of the syntaxin-5 isoforms could much more ac-
curately be determined, both spatially and temporally. LLSM hence allows for much
more precise analyses of intracellular trafficking dynamics. As the exactmechanisms
ofGolgi transport are still unclear, LLSMcouldofferadditional insights intohowGolgi-
related trafficking processes occur.
7.5 IntersectingMembrane Trafficking and Glycosylation
The work I performed in this thesis contributes to the understanding of intracellular
membrane trafficking in the context of glycosylation. Understanding the fundamen-
tal transport processes of the Golgi improves our understanding of glycosylation, and
vice versa, understanding the exact mechanism of glycosylation improves our under-
standing of Golgi membrane trafficking.
Even though the complexity of Golgi transport transcends current advances in bi-
ology, a variation of the cisternal maturation model seems the most likely transport
theory80,446,447. Cisternalmaturationpostulates that anew cis-Golgi cisterna is formed
from vesicles containing newly synthesized (glyco)proteins emanating from the ER.
This new cisterna is thenmatured by renewing its biochemical contents, through do-
nating some of its Golgi-resident proteins to younger cisternae and receiving other
Golgi-resident proteins from older cisternae. This is a continuous process until the
cisterna becomes part of the trans-Golgi network and subsequently fragments into se-
cretory vesicles and other carriers80,446,447. The cisternal maturation theory improves
upon the thought that Golgi cisternae are stable entities with specific compositions,
as this compartmentalized idea is not compatible with observations of the distribu-
tion of glycosyltransferases and other Golgi-associated proteins19,68,230,447–449. The con-
trol of trafficking pathways to, from, and within the Golgi are also needed to dictate
Golgi transport dynamics447 and important components include adapter proteins447 ,
GTPases450 , tethering proteins133,134 and SNARE proteins202.
Not only the basal dynamics of the Golgi apparatus itself but also the kinetics of
proteins that pass through the Golgi are of importance for the entire Golgi traffick-
ing model. Considering two different types of secretory cargo, one transmembrane
and the other soluble, large differences appear between their trafficking routes451. In
this case, albumin, a soluble, non-glycosylated, protein that is secreted can traverse
the Golgi within 5 minutes while a model transmembrane glycoprotein VSVG (vesic-
ular stomatitis virus G protein) moves much slower through the Golgi451. Similarly,
the transport of procollagen is also distinct as its large size (> 250 nm) is incompatible
with the sizeof transport vesicles451,452. Theseobservations suggest that (glyco)protein
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topology and potential post-translational modifications influence the transport of
proteins through the Golgi apparatus, meaning that separate transport routes for
each proteinmust exist.
Further insights into the role of glycosylation in the transit of proteins through
the Golgi can be gathered by engineering a model protein with one or more glyco-
sylation sites, potentially with different locations in the amino acid sequence, and
observing how the trafficking of the protein is altered. Moreover, Golgi transport in
different cell types can be fundamentally different, depending on the expression lev-
els of trafficking machinery and Golgi-resident proteins. This is an important point
as the glycosylation requirement of certain cell types (i.e., cell types highly dependent
on secretion) can reshape intracellularmembrane trafficking pathways. The opposite
is also true: differences in intracellular membrane trafficking pathways can reshape
glycosylation mechanisms in different cell types. Evidence for this also arises from
this thesis, as I demonstrated in chapters 4 and 6 that modulating Golgi trafficking
components (a putative factor in Golgi acidification in chapter 4, and SNARE protein
syntaxin-5 in chapter 6) strongly affects the structure of the Golgi and the localization
of glycosyltransferases with striking downstream effects on glycosylation.
7.6 Concluding Remarks
Ultimately, the various insights gathered from advances in microscopy, Golgi trans-
port, glycobiology and diagnostic strategies for CDGs together strengthen our knowl-
edge andwill benefit patients down the line. The results presented in this thesis iden-
tify the mechanism behind two distinct glycosylation disorders and thus offer the
basis for novel therapeutic opportunities. Fundamentally understanding how both
Golgi transport and glycosylation are linked to each other is therefore of utmost im-
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8.1 English Summary
8.1.1 Glycosylation
Each cell in our body is a specialized factory with defined functions: brain cells se-
crete substances which are important for brain function, immune cells secrete com-
pounds important for cellular communicationandantibodies toprotect us fromdan-
gers fromoutside the body, and pancreatic cells secrete, among others, insulin to help
regulate blood sugar levels.
Within each cell exists a network of interconnected machines, also known as or-
ganelles. The organelle central to secretion is the Golgi apparatus, or the Golgi. The
Golgi is an important distribution center that receives newly synthesized proteins
from the endoplasmic reticulum, performs quality control and final modifications
to assert their function and stability, and finally sends them to the proper location in-
side or outside the cell. In humans, the Golgi consists of a stack of distinct Golgi layers,
each with their own roles in these modifications. Similar to man-made distribution
centers, having the right materials and products at the right time and right location
is of critical importance for optimal Golgi function.
An important modification performed by the Golgi is the attachment of distinct
sugars to proteins; this process is called glycosylation10. These attached sugars, also
knownas glycans (Figure 8.1)when the structure is complete,make sure that thesepro-
teins have the correct structure, function, stability and mode of transport. The Golgi
environment, including theacidity inside theGolgi and the localizationofall proteins
involved in Golgi processes, is precisely regulated to make sure all processes run well.
Impairments in the cells that may affect the Golgi or glycosylation result in various
diseases that can influence one ormore organs.
8.1.2 Golgi transport
Of utmost importance for all transport steps in human cells is the delivery of proteins
from organelle to organelle. At the Golgi, these transport steps are mainly executed
bymeans of vesicles. These are small membrane-enclosed sacs in which proteins can
be carried. Depending on their content, these vesicles are also assigned their destina-
tions. If these vesicles are not delivered in the right place or at the right time how-
ever, the consequences can be severe. In chapter 2 I have reviewed the literature of
all known genetic variants in genes involved in Golgi transport which also lead to a
class of diseases called glycosylation disorders. I have learned from this that many
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Figure 8.1: Some examples of glycans. Glycans are attached to proteins on the amino acid residue asparagine
(N) and can form distinct branched structures. Each separate sugar molecule is incorporated in the glycan
structure in a step-by-step fashion.
of these genetic variants result in diseases with impaired secretion; communication
in the brain is often affected or there are developmental problems of the skin or the
function of the liver. Developments improving diagnostics of these type of disorders
have strongly improved in recent years, offering us better understanding of howGolgi
transport works and how this relates to disease.
An important factor for precise Golgi transport is the aciditywithin the Golgi itself.
Golgi acidity is tightly regulatedandensures thatGolgi-localizedenzymes functionop-
timally and are at the right location. In chapter 2 I identified several genetic variants
in proteins involved in Golgi acidity regulation, which lead to glycosylation disorders.
To study the effects of these genetic variants on Golgi acidity in detail, I developed a
novel method to measure the acidity within organelles by microscopy in chapter 3.
By labeling organelle-specific proteins with a special acidity-sensitive fluorescent tag,
we can use a specialized microscope to accurately determine the acidity within the
cell. Moreover, by synchronizing the transport of the cellular communication protein
TNFα, I demonstrate that we can accurately monitor the acidity of all organelles this
protein passes through when it is secreted.
I then applied this novel method in chapter 4 to study the function of possible
Golgi acidity regulator TMEM199. I found genetic variants in TMEM199 in chapter 2
that lead toglycosylationdisorders anddecreased liver function, but theprecisemech-
anism for these symptoms was not determined. I developed TMEM199-deficient cells
using CRISPR/Cas9 and next measured acidity within these cells using the method
from chapter 3 as well as performed analyses of glycosylation. From these experi-
ments I could conclude that TMEM199 is at least partly responsible for the regula-
tion of Golgi acidity and it does so in concert with the other acidity-regulating protein
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CCDC115.
8.1.3 Syntaxin-5, themost important SNARE protein for Golgi transport
For each cellular transportation step the fusion of a vesicle with another vesicle or
the destination organelle is of absolute importance. In the case of Golgi transport,
this implies that the lipid membranes of the vesicle and the Golgi fuse. This process
requires the action ofmembers of the SNAREprotein family, ofwhichhumanshave 36
different species. For successful membrane fusion, a complex of four SNARE proteins
is necessary; these ensure that the vesiclemembrane and organellemembranemerge
properly. Specific combinations of SNARE proteins result in unique SNARE complexes
for each transport step. This is especially the case for Golgi transport. Transport to,
fromandwithin the Golgi ismediated by unique SNARE complexeswith one constant
member: the SNARE protein syntaxin-5.
Syntaxin-5 exists as a short form and a long form in humans; however, it is still
unclear why these two forms exist. In chapter 5 I reviewed the literature to find differ-
ences and similarities in syntaxin-5 between both humans and yeast, to understand
how the function of the protein has changed during evolution. Yeast only expresses
one form of syntaxin-5, which we now understand compares best to the long form in
humans, but yeast does not have the same layered Golgi structure humans do have.
Subsequently in chapter 6, I discovered in collaboration with colleagues a new ge-
netic variant in syntaxin-5 leading to severe disease with infant mortality. This ge-
netic variant is very rare (three patients were identified in total) and results in ex-
pression of only the long form of syntaxin-5. Using patient skin cells with this ge-
netic variant I determined that the organization of and transport around the Golgi
is strongly affected. Using specialized experiments, I next observed that the long form
of syntaxin-5 is trafficked differently through the cells than the short form and that,
ultimately, the short form is more important for transport within the Golgi. Taken
together these observations deliver an explanation for the observed disease in these
patients.
8.1.4 Conclusion
Inmy thesis I researched themolecular mechanisms that are the basis of two unique
disorders of glycosylation. By means of a novel microscopy method that I developed
I have shown that the loss of TMEM199 affects the acidity of the Golgi resulting in im-
paired glycosylation. Moreover, I have described a novel and rare disorder of glycosyla-
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tion caused by the loss of syntaxin-5, leading tomany separate symptoms and infant
mortality. I have discovered that this is due to defective Golgi organization and im-
paired transport processes around the Golgi.
In summary, this thesis describes how logistics within the cell are important for
glycosylation and how glycosylation is affected by impairments in these logistics. The
acquired knowledge from this thesis can now be applied to design fitting therapeutic
strategies, not only for patients with similar glycosylation disorders, but also for pa-
tients with different defects in cellular transportation.
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8.2 Nederlandse Samenvatting
8.2.1 Glycosylering
Elke cel in ons lichaam is een gespecialiseerde fabriek met duidelijke functies:
hersencellen scheiden stoffen uit die belangrijk zijn voor de hersenfunctie, immuun-
cellen scheiden signaleringsstoffen en antilichamen uit om ons te beschermen tegen
gevaren van buitenaf, en alvleeskliercellen scheiden onder andere insuline uit ten be-
hoeve van het reguleren van de suikerspiegel.
Binnen elke cel bestaat een netwerk van aaneengekoppelde machines, ook wel
organellen genoemd. Het organel dat centraal staat in het uitscheidingsproces is
het Golgicomplex, of de Golgi. De Golgi is een belangrijk distributiecentrum dat
nieuwgemaakte eiwittenontvangt vanhet endoplasmatisch reticulum, vervolgensde
kwaliteit controleert en nog laatste aanpassingen voor de stabiliteit en functie uitvo-
ert, en deze eiwitten naar de goede locatie binnen of buiten de cel stuurt. In de mens
heeft de Golgi een gelaagde structuur. Net als bij door demens vervaardigde distribu-
tiecentra is het van groot belang dat alle materialen en producten op het juiste mo-
ment op de juiste plaats zijn voor optimale werking van de Golgi.
Een belangrijke aanpassing die de Golgi uitvoert is het toevoegen van verschil-
lende suikers aan eiwitten; dit proces wordt glycosylering genoemd10. Deze toevoegde
suikers, die als structuur ook wel glycanen (Figuur 1) heten, zorgen ervoor dat deze ei-
witten de goede vorm, functie, stabiliteit, en vervoer hebben. De omgeving binnen de
Golgi is heel precies ingesteld, vande zuurgraad tot alle eiwitten die betrokken zijn bij
Golgiprocessen. Afwijkingen in de cel die effect hebben opde Golgi of op glycosylering
leiden tot verscheidene ziektebeelden die een of meerdere organen kunnen beïnvloe-
den.
8.2.2 Golgi transport
Vanuiterst belang voor alle transportstappen inmenselijke cellen is de aflevering van
eiwitten vanorganel naar organel. RonddeGolgiwordendeze transport stappenvoor-
namelijkuitgevoerdmetbehulpvanblaasjes. Dit zijnkleinemembraan-omgevenzak-
jes waarin eiwitten vervoerd kunnenworden. Afhankelijk van de inhoud krijgen deze
blaasjes ook hun bestemming toegewezen. Als deze blaasjes echter niet op tijd of op
de verkeerde bestemming aankomen, dan heeft dit hevige ziektebeelden als gevolg.
In hoofdstuk 2 heb ik in de literatuur gekeken naar alle bekende mutaties in genen
betrokken bij Golgi transport die ook bekend staan als mogelijke defecten in glyco-
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Figure 8.2: Enkele voorbeelden van glycanen. Glycanenworden op eiwitten op het aminozuur asparagine (N)
gezet en kunnen verschillende vertakte structuren vormen. De verschillende suikers worden één voor één in
de glycaanstructuur gebouwd.
sylering. Hieruit heb ik geleerd dat veel van dit soort mutaties uitmonden in ziektes
met beperkte uitscheiding; de communicatie in de hersenen wordt vaak verstoord of
er zijn problemen met de ontwikkeling van de huid of de functie van de lever. On-
twikkelingen in de diagnose van dit soort afwijkingen zijn de afgelopen jaren sterk
verbeterd en daardoor begrijpenwenu ook beter hoe het transport van de Golgi werkt
en ten grondslag ligt aan deze ziektebeelden.
Een belangrijke factor voor nauwkeurig Golgi transport is de zuurgraad binnende
Golgi zelf. Deze zuurgraad is strak gereguleerd en zorgt ervoor dat alle Golgi enzymen
zichopde juiste locatiebevindenendat zeoptimaalwerken. Inhoofdstuk2heb ikeen
aantal mutaties gevonden in eiwitten betrokken bij de regulering van de zuurgraad
van de Golgi die leiden tot defecten in glycosylering. Om het effect van deze mutaties
op de zuurgraad van de Golgi nauwkeurig te kunnen bestuderen, heb ik in hoofdstuk
3 een nieuwemethode ontwikkeld om de zuurgraad binnen organellen temetenmet
microscopie. Door middel van het labelen van specifieke eiwitten in organellen met
een zuurgraad-gevoelig fluorescerend label, kunnen wemet een speciale microscoop
de zuurgraad bepalen in de cel. Daarnaast laat ik in hoofdstuk 3 zien dat ik door
het synchroniseren van het transport van een bepaald cellulair communicatie-eiwit,
TNFα, de zuurgraad van alle structuren tijdens het uitscheidingsproces nauwkeuring
kanmeten.
Deze methode heb ik vervolgens toegepast in hoofdstuk 4 om de functie van de
mogelijke zuurgraadregulator TMEM199 te bestuderen. In hoofdstuk 2 heb ik mu-
taties gevonden in TMEM199 die leiden tot glycosyleringsdefecten en verminderde
leverfunctie, maar het precieze mechanisme hiervan bleek onduidelijk. Ik heb met
CRISPR/Cas9 cellulairemodellen ontworpen die TMEM199missen en vervolgens zowel
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de zuurgraad in de cel gemeten met de techniek van hoofdstuk 3 als analyses op de
glycosylering uitgevoerd. Hiervan leerde ik dat TMEM199 in ieder geval ten dele belan-
grijk is voor de regulatie van de zuurgraad en dit samen met het andere zuurgraad-
regulerende eiwit CCDC115 doet.
8.2.3 Syntaxin-5, het belangrijkste SNARE-eiwit voor Golgi transport
Voor elke transportstap in de cel is het van belang dat een blaasje samengaat met
een ander blaasje of het organel van bestemming. Voor Golgi transport houdt dit
in dat de membranen van het blaasje en de Golgi fuseren. Hiervoor zijn leden van
de SNARE-eiwitfamilie nodig, waarvan mensen er 36 verschillende hebben. Voor suc-
cesvollemembraanfusie is een complex van in totaal vier SNARE-eiwitten nodig; deze
zorgen ervoor dat het membraan van het blaasje en van het organel ineen ritsen.
Verschillende combinaties van deze SNARE-eiwitten zorgen ervoor dat unieke SNARE-
complexen gevormd worden voor elke transportstap. Dit geldt ook voor Golgi trans-
port. Zowel van en naar, als binnen de Golgi zelf bestaan unieke SNARE-complexen
met één constante factor: het SNARE-eiwit syntaxin-5.
Syntaxin-5 bestaat in demens als een lange vorm en een korte vorm, waarvan nog
niet duidelijk is waarom er twee vormen van bestaan. In hoofdstuk 5 heb ik in de lit-
eratuur gezocht naar verschillen en overeenkomsten in syntaxin-5 tussen demens en
gist, om zo te begrijpen hoe de functie van het eiwit veranderd is tijdens de evolutie.
Gist kent namelijk maar één vorm van syntaxin-5, waarvan we nu weten dat het het
meeste lijkt op de lange vorm bij de mens, maar dat het niet de gelaagde Golgi struc-
tuur bevat die demens wel heeft.
Vervolgens heb ik in samenwerking met collega’s in hoofdstuk 6 een nieuwe mu-
tatie in syntaxin-5 ontdekt die tot hevige afwijkingen van de glycosylering leidt, met
babysterfte als gevolg. Deze mutatie is zeer zeldzaam (er zijn in totaal drie patiënten
geïdentificeerd) enzorgt ervoordat alleende langevormvansyntaxin-5 geproduceerd
wordt. In huidcellen van patiëntenmet deze mutatie heb ik vastgesteld dat de organ-
isatie van en het transport rondom de Golgi sterk is aangedaan. Met gerichte exper-
imenten heb ik toen gevonden dat de lange vorm van syntaxin-5 anders door de cel
beweegt dan de korte vorm en dat de korte vorm belangrijker is voor transport bin-
nen de Golgi. Deze observaties bij elkaar geven een verklaring voor de ziektebeelden
van deze patiënten.
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8.2.4 Conclusie
In mijn proefschrift heb ik de moleculaire mechanismen onderzocht die ten grond-
slag liggen aan twee unieke glycosyleringsafwijkingen. Doormiddel van de ontwikke-
ling van een nieuwe microscopie methode heb ik laten zien dat het verlies van
TMEM199 zorgt voor een verstoring van de zuurgraad in de Golgi met defecte gly-
cosylering als gevolg. Ook heb ik een nieuwe en zeldzame glycosyleringsafwijking
beschrevendoorhet verlies vandekorte vormvan syntaxin-5, welke leidt tot eenbreed
ziektebeeld en overlijden op jonge leeftijd. Ik heb ontdekt dat dit komt door defecten
in de organisatie van de Golgi en transportprocessen rondom de Golgi.
Samenvattend beschrijft dit proefschrift hoe logistieke processen binnen de cel
van belang zijn voor glycosylering en hoe de glycosylering aangetast kanworden door
afwijkingen in deze logistieke processen. De opgedane kennis uit dit proefschrift kan
nuwordengebruikt ompassende therapeutische strategieën teontwerpen, niet alleen
voor patiëntenmet vergelijkbare glycosyleringsafwijkingen,maar ook voor patiënten
met andere afwijkingen in cellulair transport.
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8.7 Research DataManagement
All primary research data that were generated and presented in this thesis duringmy
PhD were archived according to the FAIR (Findable, Accessible, Interoperable and Re-
suable) principles. All dataare storeddigitally ona local server of the Tumor Immunol-
ogy department of the Radboud university medical center (Radboudumc) and experi-
ments are described in the online lab book system Labguru. All data and documents
stored on the local server are accessible to the supervisors and associated scientific
staff.
The studies involving human participants of Chapter 6 were performed in accor-
dancewith theprinciplesof theDeclarationofHelsinki, withapprovalby theResearch
Ethics Committee of the University of Tartu and Sanquin. All raw and processed data
of Chapters 3 and 6 are also available through the open-source repository Zenodo.
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- TIL Symposium on Computational Immunology 2017 0.25
- Protein Trafficking in Health and Disease, Hamburg, Germany^ 2017 1.25
- CHAINS, Veldhoven^ 2017 0.75
- FEBS Golgi Meeting, Sorrento, Italy^ 2018 1.75
- ASCB|EMBOMeeting, Washington DC, USA^ 2019 1.75
- EUROGLYCANomics Online Meeting^ 2020 0.75
d) Other
- Journal Clubs 2016-2021 6.0
- Tumor Immunology Meeting Presentations 2016-2021 5.0
- Manuscript Peer-review 2018 0.1
- eLife Community Ambassador 2019-2020 0.5
- Radboud Consortium for Glycoscience PhD Council Chair 2020-2021 3.0
TEACHINGACTIVITIES
e) Lecturing
- Biomedical Sciences / Medicine Imaging Minor 2017 0.3
- Biomedical Sciences / Medicine MIN04 2018 0.5
- Biomedical Sciences / Medicine Grant Proposals 2019-2020 1.0
f) Supervision of Internships / Other
- Supervision Master’s Students (4) 2017-2021 7.0
- Supervision Master’s Thesis (1) 2018-2019 1.5
TOTAL 45
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